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Introduction
The burden of malaria 
Over 3 billion people, close to half of the world’s population, are at risk of falling ill 
from malaria1. Over the course of the previous century, developed countries with 
temperate and sub-tropical climate in North America and Europe have eliminated 
malaria. Today mainly people living in poverty in tropical countries of Africa, Asia 
and South America suffer from the disease2 (Figure 1). In addition to 207 million 
cases and a death toll of approximately 627,000 (World Health Organization 
(WHO) estimate for 20123), most of which occur in children under 5 years of age in 
Sub-Saharan Africa, malaria also has enormous socio-economic consequences4. 
Poverty is concentrated in countries that are malaria-endemic and the extent of 
this correlation suggests they are intimately related. In Uganda malaria morbidity 
leads to an annual loss of 49.8 Million US$ of the countries gross domestic product 
thereby impairing long-term economic growth and efforts to eradicate poverty5. To 
combat this global scourge the stated 6th goal of the United Nations Millennium 
Declaration is therefore to eliminate malaria as a major cause of mortality and 
reduce its impact on socio-economic development by 20156. Efforts made by the 
Roll Back Malaria partnership and other research and public health coalitions have 
lead to a 25% decline in global cases, and deaths from malaria have fallen by 42% 
since 19987. A combination of interventions including timely diagnosis, treatment 
with effective drugs and vector-control by indoor spraying and bed net use have 
contributed to this decline in malaria incidence, but resistance of parasites and 
mosquitoes to drugs and insecticides is emerging. In addition, asymptomatic 
carriers are a constant source for ongoing transmission to the mosquito vector8. 
New strategies, including the development of an effective malaria vaccine, have 
hence to be pursued to continue reducing (and eventually eliminating) the global 
malaria burden.
The life-cycle of Plasmodium
The geographic distribution of malaria is restricted to areas where the mosquito 
vector Anopheles can thrive. Year-round high temperatures combined with rainfall 
and humidity provide ideal breeding-conditions for more than 400 Anopheles 
species, 25 of which are anthropophilic and thus effectively transmit malaria to 
humans9. The discovery of the apicomplexan malaria parasite Plasmodium in 
the salivary glands of tropical mosquitoes earned Ronald Ross a Nobel Prize 
Preface
The focus of this thesis is protective antimalarial immunity induced by 
chemoprophylaxis and sporozoite immunization. To appreciate why we need 
to understand immunity elicited by this experimental malaria immunization, 
the following introductory chapter elucidates the background of global malaria 
burden; the Plasmodium parasites causing it and the problems faced by efforts 
to eradicate malaria. The second part discusses the acquisition of antimalarial 
immunity, in particular humoral immunity. Different rodent malaria species and 
their contribution to our understanding of malaria are introduced. The need for an 
effective malaria vaccine to combat this global health scourge is highlighted and 
an overview of currently pursued approaches is given. The Plasmodium chabaudi 
mouse model and controlled human malaria infections are described in detail. 
Both approaches are used to study the objectives of this thesis i.e. to unravel 
the stage-specificity of protection and the contribution of humoral immunity after 
immunization with sporozoites and chloroquine.
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merozoites, which can in turn multiply leading to exponential growth in non-
immune individuals22,23.
By a poorly understood mechanism, some blood-stage parasites develop into 
gametocytes; the sexual form of the parasite, which can be taken up during a 
mosquito blood meal. Male and female gametes fuse and undergo meiosis 
forming a diploid zygote in the mosquito midgut. This zygote then differentiates 
into a motile ookinete that penetrates the gut-wall and resides on the exterior gut-
wall forming an oocyst24. This process is the most substantial bottleneck in the 
life-cycle with typically as few as 2 oocysts formed per mosquito. Inside the oocyst 
thousands of haploid sporozoites are produced that can then migrate actively to 
the salivary glands of the mosquito, starting the life-cycle again.
Figure 2  |  The life-cycle of Plasmodium
A) During natural mosquito bite infection in endemic areas a female Anopheles mosquito inoculates 
approximately 10 sporozoites into the dermis, some of which reach the liver to establish an infection 
of hepatocytes. B) Inside heapotcytes the parasite undergoes an immense asexual replication called 
schizogony for 2-10 days (dependent on Plasmodium species), multiplying so one infected liver cell can 
give rise to between 1x104 and 3x104 merozoites. C) After approximately 105 merozoites get release 
from hepatocytes, they invade erythrocytes and mature (becoming first rings, then trophozoites, then 
schizonts) and asexually replicate so each blood-stage schizont can give rise to 6-20 (dependent on 
Plasmodium species) new merozoites. This exponential blood-stage replication causes all malaria 
pathology. D) By a poorly understood mechanism some blood-stage parasites develop into male or 
female gametocytes, the stage that is transmissible to the mosquito. After being picked up by a feeding 
mosquito the gametes fuse, forming diploid zygotes, which become motile ookinetes traversing the 
midgut wall of the mosquito and residing just outside the gut as round oocysts. Despite there typically 
being only very few oocyts (2) they can give rise to 5x104 sporozoites after haploid replication. These 
sporozoites actively migrate to the salivary glands awaiting inoculation into a vertebrate host upon the 
next feed.
Reproduced with permission by the publisher from White et al., 201429
in 190210. Five years later Alphonse Laveran also received the Nobel Prize by 
confirming that the presence of the parasite in the blood causes the disease11.
Wild Anopheles mosquitoes typically harbour between 850 and 4000 sporozoites 
in their salivary glands12,13, but experimental models have shown that typically 
few (as little as 1 to 100) motile sporozoites are injected into the skin during one 
infectious bite14,15 (Figure 2). It appears that a substantial number of sporozoites 
remains in the dermis for up to 6h and about ⅓ of the inoculum enters lymphatic 
vessels16. Sporozoites that reach the blood circulation migrate to the liver where 
they traverse through several sinusoidal and Kupffer-cells as well as hepatocytes 
before settling on a final cell17-19. Over the next 2-10 days (dependent on the 
Plasmodium species) the uni-nucleated sporozoite undergoes an enormous 
asexual replication called schizogony to form 10,000 to 30,000 merozoites, that 
get released into the bloodstream as merosomes surrounded by a temporal 
membrane20,21. Some species of malaria can form hypnozoites, dormant stages 
of liver-stage parasites that can get re-activated to undergo schizogony at any 
time. Once in the blood stream each merozoite invades one erythrocyte that, 
upon maturation, can release 6 to 20 (dependent on Plasmodium species) new 
Figure 1  |  Global malaria endemicity between 1900 and 2002
Global malaria distribution maps from pre-intervention (circa 1900) over the course of the 20th century 
until 2002. High and low risk areas are merged for each time point to illustrate all-cause malaria 
transmission distribution.
Reproduced with permission by the publisher from Hay et al., 20041
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The complexity of the malaria life-cycle makes it difficult to find universal targets for 
intervention, and recombination in the mosquito intensifies genetic drift of parasite 
populations in the field25. On the other hand, the decrease in parasite numbers 
to single digits in certain life-cycle stages (infected hepatocytes, ookinetes and 
oocysts) could be exploited for better parasite control (Figure 2).
Plasmodium species causing malaria in humans and disease manifestations
The apicomplexan malaria parasite Plasmodium has co-evolved with the 
mosquito vector and its host for millions of years and can infect many vertebrates 
including birds, reptiles and mammals. Host specificity is very strict; for example 
P. reichenowi, which causes malaria in chimpanzees, fails to infect humans26. Five 
Plasmodium species with varying global distribution and infection characteristics 
cause malaria in humans; namely P. falciparum, P. vivax, P. ovale, P. malariae and 
P. knowlesi (Table 1). Infections with P. falciparum are of major concern, since 
this parasite is common all over the tropics, especially in Africa, causing severe 
disease and the greatest mortality of the five species. P. vivax was prevalent in 
temperate areas of Europe and North America until the second half of the 20th 
century and still occurs frequently in South America and Asia. It can cause febrile 
illness but leads to death less frequently than P. falciparum. P. vivax and P. ovale, 
which is very rare outside West-Africa, form hypnozoites (dormant stages of the 
parasite residing in the liver), which can lead to multiple relapse-infections for up 
to 1 year after the initial mosquito bite27,28. Infections with P. malariae occur all 
over the tropics, but are infrequent and usually mild, therefore having little impact 
on public health compared with P. falciparum and P. vivax29. P. falciparum can be 
cultured continuously in human blood under laboratory conditions since 1976, the 
importance of which for malaria research cannot be overestimated30 (Table 1).
P. knowlesi was first described in 1931 in a long-tail macaque (Maccaca 
fascicularis) and can infect other monkeys in the wild and experimentally31. After 
circumstantial reports that P. knowlesi can cause malaria in humans32, a startling 
study by Singh et al.33 demonstrated that over half of all malaria cases in the 
Malaysian part of Borneo could be attributed to P. knowlesi, which had been 
microscopically misdiagnosed as P. malariae. Infections with this parasite are 
concentrated in Malaysia and adjacent countries and can lead to severe disease 
and death. Reports about emerging resistance to chloroquine and mefloquine are 
a further source of concern34. P. knowlesi can now be successfully cultured and 
genetically modified in the laboratory in human blood35, which will greatly facilitate 
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even added to table salt in some countries47. Primaquine, the only drug that can 
eliminate dormant liver-stage parasites and mature P. falciparum gametocytes48, 
had just been introduced and was used to treat P. vivax and P. ovale infections 
and reduce transmission further. After initial success for example in India and Sri 
Lanka, resistance to DDT and chloroquine as well as organisational problems 
led to the failure of the WHO campaign, which was abandoned in 1969. 
Consequences were catastrophic. Because clinical immunity is only acquired 
and maintained after multiple previous exposures (Figure 3), India and Sri Lanka 
suffered a devastating malaria epidemic with over 6 million cases in 197649. This 
was facilitated by an abrupt increase in vector numbers as Anopheles mosquitoes 
became resistant to the insecticide DDT by a mutation in a sodium channel, which 
also mediates resistance to other insecticides, compromising vector control all 
over the world to this day50. Furthermore chloroquine-resistant P. falciparum (and 
to a smaller extend P. vivax) parasites emerged51, which was accelerated by 
mass administration of chloroquine monotherapy at often subcurative dosages52. 
Chloroquine resistance was first reported in 1960 in Thailand53 and Columbia54 
and reached Africa almost 20 years later in 197855, causing millions of deaths.
In the 1990s, resistance to most antimalarial drugs such as chloroquine and 
sulfadoxine-pyrimethamine had evolved and worsened the burden of malaria 
across the globe. With the imminent prospect of untreatable malaria infections 
in South-East Asia, the introduction Artemisinin, a compound that was identified 
in Chinese traditional medicine, saved control efforts by substantially lowering 
morbidity and mortality. Artemisinin-based combination therapies are the WHOs 
recommended therapy for all P. falciparum infections since 2005. Together with 
vector control, in particular widespread insecticide-treated bed net usage, this 
rapidly acting drug has contributed significantly to control malaria. Recently, 
however, resistance against Artemisinin has spread across South-East Asia56, 
originating from the same area as chloroquine resistance in previous decades. It 
was suggested that the unusual genetic structure of parasites in this region57 as well 
as Artemisinin monotherapy, poor drug quality, fake drugs as well as subcurative 
dosages have facilitated development of resistance, which is mediated by a single 
nucleotide polymorphism in kelch 1356. Spread of resistant P. falciparum parasites 
to Africa would reverse the gains made for malaria control in recent years, which 
makes some call for radical measures to confine Artemisinin resistance to Asia58.
The combination of vector control with surveillance (using rapid diagnostic tests and 
PCR) and drug-treatment (especially Artemisinin-based combination therapies) 
have already lead to a substantial decline in malaria cases and mortality in recent 
important research on this emerging human pathogen.
After mosquito bite the infection with malaria parasites remains asymptomatic 
during the liver-stage replication and the first erythrocytic cycles. P. falciparum 
and P. knowlesi non-selectively invade young and old erythrocytes and can thus 
reach high parasite densities. P. ovale only targets normocytes while P. vivax 
and P. malariae selectively invade reticulocytes36 (Table 1). The length of one 
erythrocytic replication cycle varies from 24h for P. knowlesi to 48h for P. falciparum, 
P. vivax and P. ovale to 72h for P. malariae (Table 1). Blood-stage infections can 
persist for months or years (decades for P. malariae) when untreated, as new 
antigenic variants escape control by the immune system37. Symptoms are caused 
directly by the parasite and by inflammatory host immune responses. Patients 
suffering from uncomplicated malaria have flu-like symptoms including head- 
and muscle-ache as well as fever29. Life-threatening manifestations of malaria 
include severe anaemia, which results from rupture of parasitized red blood 
cells and decreased erythropoiesis38 and acute respiratory distress syndrome39. 
P. falciparum parasitized erythrocytes are able to agglutinate40, rosette41 and 
adhere to endothelial cells to escape clearance by the spleen, causing severe 
complications by obstructing the microvasculature of vital organs, e.g. in the 
placenta42. Parasite accumulation in the brain combined with strong inflammatory 
responses can lead to the development of cerebral malaria, characterised by 
seizures, coma and death43.
Malaria eradication efforts and the emergence of drug and insecticide 
resistance
Control and elimination of malaria has been achieved in some parts of the world 
mainly by controlling the vector i.e. by using bed nets, insecticide spraying, and 
environmental control measures such as larvaciding and filling and draining of 
breeding sites44. These interventions contributed substantially to malaria elimination 
from the United States between 1947 and 1951. Encouraged by this success and 
armed with the effective, long-lasting insecticide dichlorodiphenyldichloroethane 
(DDT) and the antimalarial drug chloroquine, the WHO launched a global malaria 
eradication campaign in 195545. Eradication efforts initially focused on South-East 
Asia and South America with plans to include Sub-Saharan Africa later45. The 
campaign was driven by the Macdonald equation for vector control that predicts 
that reduction of mosquito population size below a critical threshold would disrupt 
transmission46. In addition, chloroquine was administered on a mass scale, and 
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inflammatory cytokine milieu75-77. For example severe malarial anaemia can be 
associated with an insufficient interleukin (IL)-10 response to high tumor necrosis 
factor (TNF) concentrations78,79, but the causal relationship remains unclear.
Figure 3  |  Naturally acquired immunity as relation between age and malaria severity
All infants are initially susceptible to severe malaria (red line), but with repeated exposure clinical 
immunity is acquired by children, which makes symptoms of malaria milder (blue line), while parasites 
are still present in the blood-stream of almost every child. Even in adulthood many people in endemic 
areas harbor microscopy-detectable blood-stage parasites (green line) as parasitological immunity 
is very slow to develop and incomplete. The here shown timings for the development of clinical and 
parasitological immunity are typical for areas of moderate transmission.
Reproduced with permission by the publisher from Marsh et al. 2006271 and Langhorne et al. 2008272
The role of humoral immunity for protection against malaria
Immunity against blood-stage malaria parasites is associated with a protective 
antibody response. Transfer of immunoglobulin (Ig) from clinically immune 
adults to children experiencing high-density parasitemias is able to reduce 
parasite numbers and clinical disease72. Furthermore immune IgG inhibits P. 
falciparum growth in vitro73. Antibodies can have a variety of antimalarial effects, 
the contribution of which to protection remains to be determined: i) inhibition of 
merozoite invasion80; ii) prevention of rosette formation and sequestration81; iii) 
antibody mediated cellular cytotoxicity82; iv) opsonisation for phagocytosis83; v) help 
for T cell effector response84. There are even reports suggesting that antibodies 
years3. It is however questionable that these tools will be sufficient to eradicate 
malaria. Since it is unlikely that we will be able to solve the problem of malaria 
before we understand it, research and the development of new tools, in particular 
a vaccine, are now the focus of a new malaria eradication campaign that was 
announced by the Bill and Melinda Gates Foundation and the Rollback Malaria 
Partnership in 20077,59.
Naturally acquired immunity to malaria
Malaria infections are most severe in the very young and in pregnant women, 
while older children and adults in endemic areas develop immunity after multiple 
infections with the parasite (Figure 3)60,61. An important study by Goncalves et 
al.62 recently showed that one episode of severe disease was sufficient to protect 
children against subsequent severe infections in most cases. Furthermore, while 
P. falciparum parasite densities were higher in children with severe malaria, mild 
high-density infections occurred before and after episodes of severe disease. The 
incidence of high-density infections in children remained stable across different 
age groups while the incidence of severe malaria decreased with age. Therefore 
immunity against severe disease is acquired very quickly (after one or very few 
episodes, Figure 3). Where transmission and risk of infection is high, the risk of 
severe disease is therefore limited to infants, young children, visitors and pregnant 
women, whereas in areas of low, unstable transmission almost all inhabitants are 
at risk of developing severe malaria63,64. It is hence possible that interventions that 
decrease the risk of infection actually increase the incidence of severe disease 
within a population with no previously acquired immunity65, although this remains 
controversial66,67. Immunity against malaria is generally not sterilizing68 and 
asymptomatic carrier status is the norm amongst adults in endemic areas (Figure 
3), which ensures continuous transmission to the mosquito vector61,69.
Naturally acquired immunity is mainly directed against blood-stage parasites and 
protection against pre-erythrocytic parasites does not appear to play a role in 
naturally exposed populations68. Despite decades of research there is still little 
direct evidence about precisly what constitutes protective immunity. It appears that 
early innate immune responses against blood-stage parasites shape the outcome 
of infection70,71. Naturally acquired immunity against blood-stage parasites 
depends to a large extent on antibodies72,73. Development of an effective antibody 
response is in turn dependent on an effective priming of the CD4 response74. A 
main risk factor for the development of severe disease appears to be an overly 
20  l  Chapter 1 Introduction  l  21
O
N
E
even in highly endemic areas where people receive an estimated 50-60 infectious 
bites per person per month during malaria season97. By contrast, a single small 
pox vaccination generates long-lived (>50 years) memory B cells in nearly all 
volunteers98.
Because of the relatively inefficient acquisition of long-lived plasma cells and 
memory B cells it was suggested that humoral immunity is dysregulated during 
malaria infection. The Ig binding cysteine-rich interdomain region (CIDR) α of P. 
falciparum erythrocyte membrane protein (PfEMP)-1 causes polyclonal B cell 
activation and thus hypergammaglobulinemia in a T cell-independent manner99. 
Excessive induction of B cell activating factor (BAFF) in the host may influence 
B cell function and change the composition of the entire B cell compartment 
systemically100,101. Atypical memory B cells, which were originally described 
as “exhausted” in HIV infection, are expanded in chronic malaria infection 
but it is unclear whether their role is protective or detrimental for the outcome 
of infection102. Furthermore pattern recognition receptors (PRRs), which are 
expressed on dendritic cells and B cells can become tolerant upon chronic malaria 
infection, thereby downregulating the antibody and memory B cell response103. 
Malaria-naïve volunteers given a MSP-1 or AMA-1 vaccine together with the toll-
like receptor (TLR) 9 agonist CpG, were shown to acquire memory B cell more 
rapidly, in greater numbers and maintain them for longer compared to vaccinees 
immunized without CpG104. This result did however not repeat in semi-immune 
adults in endemic areas105. All these observation could suggest a malaria-intrinsic 
dysregulation of the B cell response, but could equally just reflect that mounting 
an effective response against a pathogen with very diverse, polymorphic antigens 
is difficult and inefficient.
While humoral immunity is a central component of erythrocytic immunity, the 
contribution of antibodies to pre-erythrocytic protection (if at all observed)68 
remains controversial. However, antibodies in sera from exposed people do 
recognize sporozoites with a magnitude that reflects cumulative parasite exposure 
including transmission intensity and age106-108. Humans protected from malaria 
after immunization with infectious mosquito bites under chloroquine cover in the 
controlled human malaria infection model (see below) mount a functional antibody 
response that can inhibit sporozoite traversal in vitro and reduces P. falciparum 
liver parasite burden in humanized mice109.
inhibit parasite-induced inflammation, thereby controlling severe disease85. 
Despite the overwhelming evidence of the importance of antibodies for protection 
against blood-stage malaria infection, the identity and relative contribution of 
different antigenic targets remains unknown. It is likely that protection requires the 
induction of antibodies against multiple antigens. Kenyan children, for example, 
experienced no clinical disease if they had high antibody titres against 5 or more 
P. falciparum blood-stage antigens86.
In the absence of parasite exposure the number of short-lived plasma cells 
producing antibodies declines, leading to a drop in circulating antibody levels87. 
Low levels of antibodies are provided by long-lived plasma cells residing in 
the bone marrow. The breadth and magnitude of the malaria-specific antibody 
response increases with age and exposure in endemic areas88,89. In a seasonal 
high transmission setting antibody responses expand during the malarious wet-
season, but then contract during the 6-month malaria-free dry-season to levels 
just slightly higher than before transmission, leading to a gradual increase of 
antibody levels with cumulative parasite exposure which plateaus as adulthood is 
reached89. This is unlike antibody acquisition kinetics for other pathogens such as 
the measles virus, where one exposure (and the persistence of antigen) is sufficient 
to provide life-long levels of protective antibody90. It was therefore speculated that 
multiple infections are necessary to fill long-lived plasma cell niches with cells 
specific for any given malaria antigen in order to provide basal protective antibody 
levels against this complex parasite89. This extensive population of bone marrow 
niches with malaria specific long-lived plasma cells can dysregulate previously 
acquired long-lived plasma cell responses as shown for influenza in a rodent 
malaria model91.
Humoral immune memory is not only mediated by long-lived plasma cells, which 
continue to produce antibodies, but also by quiescent memory B cells that circulate 
and rapidly differentiate into antibody-secreting cells upon antigen re-encounter92. 
Therefore the presence of antigen-specific memory B cells in peripheral blood 
is a more reliable read-out for past exposure than plasma antibody93. Studies 
in areas of very low transmission in Madagascar94 and Thailand95 suggest that 
memory B cells are maintained even in the absence of exposure for many years. 
The magnitude of the malaria-specific memory B cell response is similar to that 
induced by childhood vaccinations like Tetanus in the same population96. However 
a substantial proportion (40-70%) of naturally immune adults in endemic areas 
still lack detectable numbers of memory B cells specific for malaria antigens like 
apical membrane antigen (AMA)-1 and merozoite surface protein (MSP)-188,89, 
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Rodent malaria models are especially valuable to study pre-erythrocytic parasite 
life-cycle stages, which are not accessible in humans due to obvious ethical 
constraints119. Genetic manipulation of the P. berghei genome120-122 and more 
recently P. yoelii123 and P. chabaudi124 allows labelling of parasites with fluorescent 
or other tags and to knock-out and over-express genes. Imaging of fluorescent 
or bioluminescent parasites has revealed that sporozoites are deposited into 
avascular parts of the dermis from where they have to actively migrate into 
blood vessels, which can be inhibited by antibodies125. Furthermore infection with 
bioluminescent parasites can be followed in real time through the liver- and blood-
stages in a non-invasive manner by using in vivo imaging126, thereby testing the 
effects of treatment or vaccination on parasite load.
Rodent malaria models are particularly valuable for studying immune responses to 
malaria in mechanistic detail. Genetically altered mice lacking key components of 
the immune system can contribute substantially to our understanding of antimalarial 
Figure 4  |  Origin of rodent malaria species
All rodent Plasmodium species were isolated from wild Grammomys surdaster (P. berghei) or 
Thamnomys rutilans (P. yoelii (y.), P. chabaudi (c.) and P. vinckei (v.)) in central West Africa between 
1943 and the mid 1960s. Diverse subspecies of all rodent Plasmodium parasites were found in 
different geographical locations, apart from P. berghei, which was only isolated once in the cool forests 
of Katanga (Democratic Republic of Kongo). The natural mosquito vector (A. dureni) is only known for 
P. berghei and P. v. vinckei.
Reproduced from The European Malaria Reagent Repository,
http://www.malariaresearch.eu/content/rodent-malaria-parasites
The contribution of rodent malaria models to our understanding of malaria
Research using Plasmodium species infecting rodents as models for human 
malaria has been indispensable for our understanding of parasite biology, 
genetics, evolution and ecology as well as for antimalarial immunity. The life-
cycle, morphology of the different stages, metabolomic pathways and genomic 
organisation110 are to a large extent conserved between human and most rodent 
malaria species. Four Plasmodium species were isolated from wild African rodents 
between 1943 and the 1960s (Figure 4, Table 2)111. P. berghei was discovered 
in the relatively cool gallery forest of Katanga (modern day Democratic Republic 
of Kongo) in A. dureni mosquitoes and in the African thicket rat Grammomys 
surdaster112. P. vinckei was originally also identified in Katanga but subspecies 
were later found in different parts of Africa in Thamnomys rutilans. The other two 
rodent species P. yoelii and P. chabaudi were also isolated from Thamnomys 
rutilans113, in a more tropical climate in the Central African Republic114, which is 
similar to the climate where human Plasmodium species thrive (Figure 4, Table 
2). Infection rate of thicket rats parasitized with P. yoelii and P. chabaudi was 
close to 100% in this area and parasitemia persists for a long time in these rats111. 
Apart from P. berghei, which after initial isolation was hardly found in wild animals, 
subspecies of all other rodent parasites were isolated across Cameroon, Congo 
and Nigeria (Figure 4).
All isolated rodent malaria parasites can infect laboratory mice and have a short 
liver-stage development of just over 2 days (Table 2). P. berghei and P. yoelii 
invade reticulocytes and their asexual blood-stage replication is asynchronous, 
whereas P. vinckei and P. chabaudi replicate synchronously in young and 
mature erythrocytes (Table 2). The distinct species and cloned strains exhibit 
different infection characteristics in different mice115,116, which can make data 
interpretation difficult117. Parasite factors together with host genetic background 
critically influence the pathology elicited by malaria infection. BALB/c mice are 
2000 times more susceptible to P. yoelii compared to P. berghei infection, which 
was attributed to more effective innate immune responses that eliminate pre-
erythrocytic P. berghei parasites118. Even the closely related P. y. nigeriensis 
strains 67 and 67C trigger fundamentally different innate immune responses71. 
Increased inflammation elicited by the more virulent 67C strain is responsible for 
severe disease and death caused by this parasite71. The same parasite can also 
have different pathogenesis in different inbred mouse strains: P. berghei ANKA 
causes lethal experimental cerebral malaria in C57BL/6 mice, severe anaemia in 
BALB/c mice and respiratory distress syndrome in DBA/2 mice119.
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gained from these models in humans. This can be done in field studies, which 
are however complex and therefore expensive to organize requiring a relatively 
large number of participants to allow for variables such as genetic heterogeneity, 
co-infections and (re)-infection rate. To test a growing number of new drugs and 
candidate vaccines in Phase IIa clinical trials and to study human antimalarial 
immune responses, controlled human malaria infection models have been 
established that mimic natural infections under strictly controlled clinical and 
laboratory conditions130. Facilitated by the in vitro production of gametocytes for 
mosquito infection131,132, over 2500 volunteers have been exposed to P. falciparum 
infected Anopheles spp. mosquito bites in three specialized centres- namely the 
Walter Reed Army Institute of Research, Silver Spring, Maryland (USA), the 
University of Oxford (UK) and the Radboud University Nijmegen Medical Center 
(RUMC, The Netherlands)- since the 1980s. Results are reproducible between 
the different locations, highlighting the robustness of this model133.
Exposure to 5 mosquitoes infected with the P. falciparum strain 3D7 or its parental 
strain NF54 ensures malaria infection in clinical trial participants of close to 100%, 
leading to detection of blood-stage parasites by thick blood film approximately 
9-11 days later, at which point the infection is treated with antimalarial drugs130. 
Most volunteers experience non-specific symptoms of uncomplicated malaria 
most frequently fever and headaches. Time to patency by thick blood film is 
used to estimate efficacy of a given intervention and is complemented by exact 
measurement of blood-stage parasite burden (up to three times daily) using 
quantitative RealTime (qRT) PCR134. Pooled data from clinical trials at RUMC 
show that between an estimated 23 and 5273 (mean 500) merozoites per ml 
are released within the first erythrocytic cycle from the liver (suggesting 2-1500 
infected hepatocytes) approximately 6.5 days after mosquito bite130. Thereafter P. 
falciparum erythrocytic replication follows a synchronous 48h pattern with blood-
stage multiplication rates of approximately 10.8130. Because these parameters are 
so consistent the number of participants in each trial can be small and still provide 
enough statistical power to evaluate the preliminary efficacy of pre-erythrocytic 
vaccine candidates130. Since treatment is necessary after only 2-3 erythrocytic 
replication cycles it has been questioned whether this system is appropriate to 
evaluate partially effective blood-stage vaccines, which could have effects only 
apparent after several erythrocytic replication cycles, reducing morbidity and 
mortality135.
Therefore a blood-stage challenge model was developed which utilizes 
cryopreserved parasitized blood from two volunteers experimentally infected with 
Rodent parasite 
species
Sporogony 
temperature
Length of liver-
stage
Erythrocyte 
preference
Synchronicity in 
blood-stage
P. berghei 19-21°C 50h Reticulocytes Asynchronous
P. y. yoelii 24°C 43-50h Reticulocytesb Asynchronous
P. y. killicki 22-24°C 46-50h Reticulocytes Asynchronous
P. y. nigeriensis 24°C 47-50h Reticulocytes Asynchronous
P. y. subsp ? ? ? ?
P. v. vinckei 20-21°C 53-61h Normocytes and 
reticulocytes
Synchronous
P. v. lentum 24-25°C <72h Normocytes and 
reticulocytes
Synchronous
P. v. brucechwatti 24-25°C 61-65h Normocytes and 
reticulocytes
Synchronous
P. v. petteri 24-26°C 53-61h Normocytes and 
reticulocytes
Synchronous
P. v. subsp. ? ? ? ?
P. c. chabaudi 26°C 52-53h Normocytes and 
reticulocytes
Synchronous
P. c. adami 24-26°C ? Normocytes and 
reticulocytes
Synchronous
P. c. subsp. ? ? ? ?
Table 2  |  Life-cycle characteristics of rodent Plasmodium speciesa
a Adapted from Stephens et al. 2012258
b P.y. yoelii 17XL and YM can invade normocytes
immunity. Basic characteristics of the humoral immune response against blood-
stage parasites are similar to humans e. g. passive transfer of hyperimmune serum 
can reduce parasitemia in P. b. yoelii infected mice127 suggesting that antibodies 
clear blood-stage parasitemia72. Infection of JHD mice
128, which are devoid of 
functional B cells, with P. c. adami, P. c. chabaudi CB and P. v. petteri resulted in 
clearance of the infection in the acute phase, while infecting of the same mice with 
P. y. yoelii 17X lead to death by hyper-parasitemia129.
Despite their usefulness for malaria research it is vital to design animal models 
carefully to mimic the right aspects of human infections in order to draw translatable 
conclusions.
Controlled human malaria infection
Rodent and other animal models offer a broad range of possibilities to gain insights 
into the biology of Plasmodium infection. However it is critical to test hypothesis 
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feasible to develop a malaria vaccine. A vaccine could either mimic naturally 
acquired immunity and target blood-stage parasites, reducing severe clinical 
disease, or target pre-erythrocytic stages, which, if 100% effective, would not only 
preclude all symptoms of malaria but also block transmission. Another advantage 
of targeting pre-erythrocytic parasite life-cycle stages is their small number 
(Figure 2) and that it takes several days for human Plasmodium parasites to 
complete liver-stage development143. If however even a single infected hepatocyte 
escapes the immune response, the resulting blood-stage infection (release of 
an estimated 10,000 merozoites from each infected liver-cell and exponential 
multiplication, Figure 2) would cause severe symptoms if no erythrocytic immunity 
was previously acquired. In fact mathematical modelling showed that even a 99% 
effective pre-erythrocytic vaccine leads only to a delay of two multiplication cycles 
until pathogenic blood-stage parasite densities are reached144 (Figure 5A). On 
the other hand even an only 40% effective blood-stage vaccine lets blood-stage 
parasitemia increase slower, while a 90% reduction of blood-stage parasitemia in 
each cycle actually overrides the blood-stage multiplication effect and leads to a 
decrease in parasitemia over time and eventual clearance144 (Figure 5B). Both 
blood-stage and pre-erythrocytic vaccine strategies utilizing individual parasite 
proteins or whole attenuated parasites are pursued, as summarized in the WHO 
rainbow table145,146. It is however likely that both strategies have to be combined in 
order to develop an effective multi-stage malaria vaccine. A 70% reduction in liver 
parasite burden combined with a 90% effective blood-stage vaccine would clear 
parasitemia eventually and keep parasite densities under 50 parasites per ml, 
which is 10-fold below pathogenic blood-stage parasite densities144 (Figure 5C). 
Additionally vaccines that block transmission, which have only delayed benefits for 
the vaccinee, could be incorporated147. Since a multi-stage vaccine is still lacking, 
blood-stage and pre-erythrocytic vaccination approaches using either individual 
proteins (subunit vaccines) or whole parasites are introduced separately below.
Blood-stage antigens as subunit vaccine
Using individual blood-stage malaria antigens for immunization was thought to be 
able to direct antimalarial immunity to few epitopes thereby maximising efficiency 
while minimizing unwanted side-effects148. As passive transfer of immunoglobulin 
from naturally immune adults was shown to protect vulnerable children72,149, 
antigens that were recognized by serum from clinically immune individuals were 
selected150,151. Therefore only few immunodominant, but also highly polymorphic, 
antigens were carried forward and assessed in Phase I and IIa clinical trials- with 
the 3D7 strain of P. falciparum by mosquito bite136. Injection of 1800 parasitized 
erythrocytes iv leads to blood-stage parasitemia that can be detected by qRT 
PCR after 3.5 days and reaches thick blood-film detectable levels after 8 days, 
thus allowing more time to detect effects targeting blood-stage parasites135. This 
approach may however miss potential cross-protective immune responses, which 
could enhance vaccine efficacy by protecting against pre-erythrocytic parasites.
As the company Sanaria Inc. can produce aseptically purified, cryopreserved 
sporozoites137, these can be used instead of mosquito bites to experimentally 
infect humans. Here, the number of sporozoites injected can be controlled thus 
minimizing inter-individual variations, and statistical power is improved, compared 
to infections initiated by mosquito bite. Furthermore cryopreserved sporozoites 
make it possible to conduct trials all over the globe as no access to highly 
specialized P. falciparum insectaries is required. It was shown in malaria naïve 
adults in the Netherlands138 as well as in adult Tanzanians from an endemic area139 
that intradermal (id) injection of 10,000 or 25,000 cryopreserved sporozoites is 
safe, well tolerated and infectious for a large proportion of individuals. Microscopic 
patency is substantially delayed by over 6 days compared to an infection with 5 
mosquito bites suggesting that id injection is very ineffective with few sporozoites 
actually reaching the liver to establish an infection140.
Together these controlled human malaria infection models are powerful tools to 
test drugs and candidate vaccines in small clinical trials before attempting large-
scale field trials.
Malaria vaccine development
Recent advances in malaria research have lead to a new enthusiasm to eradicate 
malaria59. It is now recognized that given the complexity of the problem no single 
strategy will suffice. However, the only successful eradication programme so far 
(smallpox) relied on a effective vaccine; something that is lacking for malaria to 
this date141. Successful vaccines have been developed for viral and bacterial 
diseases, against which immunity is acquired after a single infection by the 
induction of high levels of protective antibodies. It has proven to be much more 
challenging to develop a vaccine against diseases that do not naturally induce 
sterile immunity like HIV, Mycobacterium tuberculosis and complex eukaryotic 
pathogens including Plasmodium142. However clinical immunity against blood-
stage malaria parasites, which does not necessarily clear parasitemia, can be 
acquired naturally with repeated exposure (Figure 3), therefore it should be 
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against novel and little studied natively folded merozoites surface or secreted full-
length ectodomain proteins158. Protective efficacy of these antibody responses, as 
assessed by their correlation with absence of clinical episodes, showed that some 
of the new proteins had the same or higher efficacy than leading blood-stage 
vaccine candidates like MSP-2. Certain combinations of antibody responses were 
associated with high levels of protection and no clinical episodes were detected if 
at least 5 out of 10 leading proteins were recognized158. Thus the identification of 
new protective antigens and combination of these into a multi-component vaccine 
inducing high antibody titres could lead to an eventual success in subunit blood-
stage vaccine development.
Pre-erythrocytic antigens as subunit vaccine
Subunit vaccines based on proteins expressed during the pre-erythrocytic stages 
can elicit sterile immunity against sporozoites or liver-stage parasites thereby 
preventing generation of asexual blood-stage parasites responsible for morbidity 
and mortality as well as gametocytes responsible for transmission. The most 
advanced pre-erythrocytic subunit vaccine is RTS,S, which comprises of the 
C-terminal end of CSP fused to the hepatitis B virus antigen S and is administered 
with the adjuvant AS01 or AS02. CSP covers the entire surface of sporozoites 
and is an integral part of its membrane but is also found in the plasma membrane 
of liver-stage parasites159. In Phase IIa trials RTS,S was able to mediate over 
50% sterile protection against controlled human malaria infection in malaria-
naïve volunteers160. A large, multi-centre Phase III clinical trial in seven African 
countries with different transmission intensities (namely Burkina Faso, Gabon, 
Ghana, Kenya, Malawi, Mozambique, and the United Republic of Tanzania) 
involving 15,460 infants and young children RTS,S protected 30-50% of children 
against clinical and severe malaria161-163. Efficacy was lower in infants 6-14 weeks 
of age than in children aged 5-17 months and protection waned quickly within 
18 months163. Protection was associated with the induction of high CSP-specific 
antibody titres and CD4 T cell responses160,164,165. The benefits of this moderately 
effective vaccine for public health are disputed166-169. It is surprising that RTS,S, 
designed to protect against pre-erythrocytic parasites, actually reduces the risk of 
clinical disease associated with blood-stage parasites, instead of inducing sterile 
protection170. One explanation is that a profound reduction of infected hepatocyte 
numbers leads to low numbers of merozoites being released into the blood-
stream, which allows more time to activate adaptive immune responses before 
pathogenic erythrocytic parasite densities are reached. GlaxoSmithKline, who 
very limited success (reviewed148,152). One of the first malaria vaccines tested on a 
large scale was SPf66 which consisted of three merozoite-derived epitopes linked 
together with the repeat regions of the pre-erythrocytic antigen circumsporozoite 
protein (CSP). Following enthusiasm after field trials in South America where it 
showed over 80% efficacy153 SPf66 failed to induce any protection in Africa or 
Thailand. After a Cochrane review it was decided that there was no justification to 
continue clinical trials using this vaccine formulation154. Combination B, consisting 
of MSP-1 and -2 as well as ring-infected erythrocyte surface antigen (RESA), was 
reported to be safe, but only sub-optimally immunogenic155,156. Given that 5300 
genes are encoded in the P. falciparum genome157, it seems likely that there are 
many other proteins, which have not been investigated to date, that could mediate 
protection. In a recent study, Kenyan children mounted antibody responses 
Figure 5  |  Effect of pre-erythrocytic, blood-stage and multi-stage vaccines on blood-stage 
parasite densities
Simulated erythrocytic parasite densities (in parasitized erythrocytes (pE) per ml) after merozoites 
release from 200 infected hepatocytes 6.8 days after P. falciparum mosquito bite infection. Exponential 
replication within the first 3.5 erythrocytic cycles (Roman numerals) is shown with the black dotted line. 
A) Effect of a pre-erythrocytic vaccine that kills 70% (blue) or 99% (yellow) of all infected hepatocytes. 
B) Effect of 40% (red) and 90% (green) effective blood-stage vaccine. C) Combined effect of a multi-
stage malaria vaccine with 99% pre-erythrocytic efficacy plus 40% efficacy against blood-stage 
parasites (orange) or 70% pre-erythrocytic and 90% blood-stage vaccine effect (turquois).
Based on figure by Hermsen et al., 2004144, reproduced with permission by the publisher
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system to the attenuated parasites and therefore a broad range of antigens allows 
for the development of high levels of protection.
Whole blood-stage parasite immunization strategies
For malaria the first demonstration that live parasites can induce immunity came 
from immunization with killed Plasmodium blood-stage parasites and strong 
adjuvants, which partially protects birds, mice and non-human primates183-187. Low 
doses of 1000 P. chabaudi erythrocytic parasites killed by freeze/thawing combined 
with the adjuvant CpG-ODN, which induces potent Th1 responses, protects mice 
partially from challenge infection188. Since the need for strong adjuvants precludes 
the use of killed blood-stage parasites as an immunization strategy in humans, 
an alternative approach uses live, irradiated blood-stage parasites, which are 
incapable of further erythrocytic replication. Immunization with large numbers 
elicits partial protection against blood-stage challenge in chicken189,190, as well as 
in rats, mice191-193 and monkeys194. Blood-stage parasites can also be attenuated 
using centanamycin195, which leads to the persistence of parasite DNA for 110 
days and induces strong species-transcending protection in the mice196.
Moreover, targeted gene deletion can arrest P. falciparum blood-stage parasites 
in culture197-200 and immunization with genetically attenuated blood-stage 
parasites protects mice against infectious challenge201-204. Purine metabolism 
especially, which is unique to Plasmodium, is an attractive target for directed 
genetic manipulation203,204. It is important to note that gene knock-out needs to 
be conditional as parasites could otherwise not be manufactured for vaccine 
development.
Treatment of blood-stage infections before pathogenic parasite densities are 
reached also elicits protection against re-infection. P. yoelii blood-stage parasites 
combined with chloroquine treatment curtailing the infection can reduce liver 
parasite burden after challenge with 35,000 sporozoites iv, which is the first direct 
evidence of cross-stage immunity205. Immunization with P. yoelii blood-stage 
parasites under mefloquine cover did not lower liver parasite burden after sporozoite 
challenge but attenuated blood-stage parasite growth even after challenge with 
a different species (P. vinckei)206. Inoculation of 100,000 P. chabaudi parasitized 
erythrocytes followed by atovaquone/proguanil treatment protected mice against 
homologous and heterologous blood-stage challenge207. This vaccination 
strategy is also the only whole blood-stage parasite immunization strategy ever 
tested in humans: Volunteers were immunized with multiple ultra-low doses of 
approximately 30 infected erythrocytes, followed by treatment with atovaquone/
developed RTS,S in partnership with WRAIR and PATH Malaria Initiative (Bill and 
Melinda Gates Foundation) have announced in July 2014 to apply for licensure of 
the vaccine. If successful, RTS,S will be the first protozoan vaccine ever licensed 
for human use.
Another pre-erythrocytic antigen, Thrombospondin related anonymous protein 
(TRAP) fused to the T cell multiple epitope string (ME), formulated in a heterologous 
prime-boost regimen with replication-deficient viral vectors171, was shown to elicit 
very high protective CD8 T cell responses in malaria naïve volunteers and sterilely 
protects 21% against mosquito bite challenge infection, whilst delaying patency in 
36% of volunteers172. Delay in time to patency was attributed to a strong reduction 
of liver-parasite burden in these volunteers. Two recent Phase Ib studies in 
malaria-endemic areas of Kenya and The Gambia show that immunization with 
the chimpanzee adenovirus serotype 63 (ChAd63) and boost with modified 
vaccinia virus Ankara (MVA)- both encoding ME-TRAP- can induce cellular and 
humoral responses in previously exposed adults173 and will now be assessed for 
efficacy. A combination of RTS,S with TRAP did not improve protection or delay 
parasitemia174, compared to infection controls, while RTS,S alone was previously 
shown to induce 50% sterile protection in a similar experimental setting160. Thus 
the addition of TRAP to RTS,S has a detrimental rather than beneficial effect for 
the development of pre-erythrocytic immunity.
Liver-stage antigen (LSA) 1 and 3175 have been identified as key antigens of liver-
stage parasites. Formulated with AS01 and AS02, LSA 1 was safe and induced 
high antibody titres and CD4 T cell responses, but did not confer any protection in 
controlled human malaria infection trials176. LSA 3 can protect against P. falciparum 
challenge in chimpanzees177 and Aotus monkeys178 and was recently assessed for 
safety and immunogenicity in a human clinical trial (NCT00509158)179.
Rationale for whole parasite vaccination
Identification and selection of protective parasite antigens for subunit vaccine 
development is difficult and has so far not lead to the desired outcome- an effective 
malaria vaccine. There are however vaccines that induce sterile protection against 
veterinarian parasitic diseases like Theilaria, which are based on the inoculation 
of whole live-attenuated or drug-treated parasites180. Also it has been known for 
centuries that humans can be immunized by inoculation of infectious Leishmania 
parasites into the skin181. The resulting self-limiting lesion protects against 
subsequent infections, preventing disfiguring lesions and serious complications 
like visceral leishmaniasis182. It therefore appears that exposure of the immune 
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novel antigens that were recognized by protected volunteers immunized with 
irradiated sporozoites (and not unprotected controls), but at a lower magnitude 
than CSP or TRAP216. Despite the superior sterile immunity induced by this whole 
parasite immunization with irradiated sporozoites it was not deemed practically 
feasible to turn it into a commercial vaccine. However, Sanaria Inc. addressed 
some of these obstacles and can now produce aseptically dissected, purified 
and cryopreserved irradiated sporozoites. Immunization of volunteers with 
these irradiated sporozoites id and subcutaneously was safe but sub-optimally 
immunogenic217, while 5 immunizations with 135,000 sporozoites iv protected 
against mosquito bite challenge 5 months later218. Currently the efficacy of this 
vaccine is evaluated in adults in malaria-endemic areas of Mali. Sterile protection 
induced by immunization with irradiated sporozoites is strongly associated with 
the induction of high frequencies of CD8 T cells219,220 and persistence of parasite 
antigen in liver, draining lymphnodes and spleen221.
Similar to irradiation, treatment of sporozoites with centanamycin arrests parasite 
development in hepatocytes222 and repeated immunization with high doses elicits 
species-transcending protection against sporozoite challenge in mice223.Disruption 
of genes essential for the completion of liver-stage development224-230 equally halts 
progression through the life-cycle in pre-erythrocytic stages and can lead to the 
induction of pre-erythrocytic immunity, which is CD8 T cell-dependent231. This 
immunization strategy was also tested in a first trial in humans using p52- and 
p36-deficient P. falciparum infected mosquito bites232. Following exposure to 263 
bites one volunteer developed blood-stage parasitemia, which was confirmed to 
be caused by the transgenic parasite232. Blood break-through infections are thus 
a major concern when pursuing genetically attenuated parasites as a malaria 
vaccine233.
It was argued that arrest late in liver-stage development can induce more powerful 
protection234. This may be because antigenic targets become increasingly similar 
to blood-stage parasites235, which can allow for the development of cross-stage 
immunity.
Chemoprophylaxis and sporozoite immunization
Other than the stage-specific experimental vaccination approaches described 
above, chemoprophylaxis and sporozoite (CPS) immunization allows exposure to 
both pre-erythrocytic and blood-stage parasites. It was first described in rodents 
that injection of P. berghei sporozoites combined with prophylactic chloroquine 
proguanil. These people were protected against subsequent challenge with the 
same blood-stage inoculum208. Results may however have been confounded by 
persisting atovaquone-levels209. Immunity was associated with CD4 and CD8 T 
cells producing interferon (IFN) γ and nitric oxide, but not with antibodies binding 
parasitized erythrocytes. It therefore appears that induction of cellular immune 
responses is important for the generation of effective blood-stage immunity. Thus 
selection of antigens for blood-stage subunit vaccine development may have 
missed promising candidates, since it is based on antigens that are recognized 
by antibodies from immune individuals. Immunization with drug-, chemically- and 
genetically-attenuated blood-stage parasites hence has the potential to protect 
against malaria and should be investigated further: either as whole parasite 
vaccination strategy or to identify new protective antigens.
Pre-erythrocytic whole parasite immunization strategies
As for blood-stage parasites, irradiation (or UV-inactivation) of sporozoites 
causes such extensive DNA damage that they are incapable of further replication. 
However irradiated sporozoites can still invade hepatocytes and develop into 
uni-nucleated trophozoites, but never establish a blood-stage infection. Richards 
et al. demonstrated in 1966 that UV inactivation of P. gallinaceum sporozoites 
protects chickens against subsequent infections190. High numbers of irradiated 
P. berghei sporozoites were thereafter shown to sterilely protect susceptible A/J 
mice from lethal sporozoite challenge210, but not from direct blood-challenge211, 
which established the paradigm that immunity to malaria is stage-specific. These 
experiments were the first to validate that sterile protection against a parasitic 
disease is feasible and sparked much excitement. In 1973 one volunteer 
was immunized with over 1000 P. falciparum infected mosquito bites over the 
course of one year and challenged with infectious bites against which he was 
protected212. A direct transfer of blood-stage parasites however lead to patent 
blood-stage parasitemia that had to be treated, so again immunization with 
irradiated sporozoites did not seem to induce erythrocytic immunity, although 
blood-stage parasite growth rates and time to patency could not be compared 
to a naïve volunteer212. Immunity elicited by irradiated sporozoite immunization 
was strain-transcending212, but partially species-specific213. It was initially 
believed that the main mechanism of protection was the inhibition of sporozoite 
invasion by antibodies. CSP was identified as prominent antigen and used to 
formulate RTS,S214,215 (see above), but many antigens with potential protective 
properties remain to be investigated. A protein-microarray study identified three 
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of protective immunity following CPS immunization is dependent on the number 
or immunizing mosquito bites.
The complete absence of blood-stage parasites detectable by qRT PCR following 
mosquito bite challenge, led to the assumption that CPS-induced protection in 
humans is directed against pre-erythrocytic parasites. To address the question 
of stage-specificity, volunteers were immunized three times with 8 P. falciparum 
NF54 and 7 P. falciparum 3D7 infected mosquito bites and challenged with P. 
falciparum 3D7 infected erythrocytes136 by iv injection249. Patency and blood-
stage multiplication rates were not different between immunized volunteers and 
infection controls after direct blood challenge, suggesting that all immunity is 
directed against pre-erythrocytic parasites.
Since millions of travellers take chemoprophylaxis every year and intervention 
programmes using mass drug administration or intermittent preventive treatment 
of risk groups such as schoolchildren are employed in malaria endemic areas250, 
there should be evidence of protection induced by chemoprophylaxis and 
repeated exposure to infected mosquito bites. Despite worries that the incidence 
of disease and mortality after termination of drug treatment might rise (rebound 
effect), treatment with sulfadoxine-pyrimethamine was shown to protect infants 
and children against clinical malaria well beyond the pharmacological effects of 
the drug251, suggesting that chemoprophylaxis can positively enhance natural 
immunity. Unfortunately the massive methological differences between studies 
preclude unequivocal conclusions about the effect of chemoprophylaxis on 
naturally acquired immunity252.
CPS immunization is an invaluable tool to address fundamental questions about 
the contribution of each life-cycle stage to protection against malaria and the 
immune mechanisms involved. It can be used to identify new antigenic targets 
and immune-correlates of protection from both pre-erythrocytic and blood-stage 
parasites. Given its demonstrated potency, initiatives by Sanaria Inc. and partners 
are ongoing to explore its potential application as vaccine (PfSpzCVac) for special 
groups such as military personnel and/or tourists.
Rationale for choosing the P. chabaudi model to study the stage-specificity 
of protection and the role of humoral immunity after CPS immunization
An important question is which parasite life-cycle stages are the source and 
target of antimalarial immunity after CPS immunization. In this thesis we develop 
a novel mouse model of CPS immunization, resembling human clinical trials in 
treatment induces protection against sporozoite challenge236-238. Chloroquine 
inhibits the conversion of toxic free heme into hemozoin, which leads to the 
lysis of the parasitized erythrocyte239. Pre-erythrocytic immunity induced by CPS 
immunization, i.e. the reduction of liver parasite burden, was first confirmed after 
sporozoite challenge of mice immunized by iv injection of P. yoelii sporozoites, 
while receiving chloroquine240. Rodent studies have thereafter concentrated on 
substituting chloroquine for other antimalarial drugs206,241,242 and on delineating the 
mechanism of pre-erythrocytic immunity243-245, which appears to be dependent on 
the induction of large numbers of CD8 T cells producing IFNγ243. However immunity 
against blood-stage parasites can also be elicited by this immunization regimen, 
especially if exposure to erythrocytic parasites is prolonged e.g. when subcurative 
chloroquine regimens are used206,242,244. CPS-induced blood-stage immunity can 
be dependent on the induction of antibodies244. Immunization with P. yoelii and 
mefloquine can protect against P. vinckei sporozoite- and (to a lesser extend) 
blood-challenge206, thereby showing that protection following CPS immunization 
is species-transcending.
In humans 12 to 15 bites of mosquito infected with the NF54 strain of P. falciparum 
and prophylactic chloroquine treatment elicits sterile immunity against mosquito 
bite challenge246. Re-challenge of previously sterilely immune volunteers 2.5 
years after the last immunization revealed that protection is long lasting (although 
potentially dependent on boosting by first challenge infection), with four of 
six volunteers still sterilely protected247. The remaining two volunteers had a 
significantly delayed onset of patent parasitemia compared to infection controls247. 
All protected volunteers mounted pluripotent effector memory T cell responses 
producing IFNγ, TNF and IL-2246, which were stronger after re-stimulation in 
vitro with blood-stage parasites rather than sporozoites247. A dose de-escalation 
trial where immunization dose was reduced to 10 or 5 infective bites instead of 
15 given three times also showed a strong association between the magnitude 
of T cells expressing cytotoxic markers (CD4 T cells expressing CD107a and 
CD8 T cells expressing Granzyme B) and sterile protection from mosquito bite 
challenge infection248. In this thesis we address whether antibody and memory 
B cell responses against a set of immunodominant malarial antigens associate 
with protection from mosquito bite challenge infection. Only half of the volunteers 
immunized with three doses of 5 mosquito bites were sterilely protected, while 
the others developed thick blood film detectable parasitemia before day 21 and 
had to be treated. Patency was delayed by a median of 2.5 days compared to 
infection controls, but the delay was not significant248. Therefore the development 
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peak parasitemia in the ones that do259. Infections with serially blood-passaged 
P. chabaudi parasites seem to induce protection less efficiently than mosquito 
transmitted parasites, but can still elicit strain-specific immunity to re-infection, 
whereas only limited protection against challenge with a different parasite species 
was observed253,262.
Of course there are also inherent differences between P. chabaudi in mice and P. 
falciparum in humans. The liver-stage cycle is much shorter (52h for P. chabaudi 
instead of 158h for P. falciparum) and blood-stage parasitemia reaches higher 
levels before symptoms are observed, especially if serially blood-passaged P. 
chabaudi parasites are used258. Instead of fever mice develop hypothermia and 
the organs where P. chabaudi sequesters (liver and lungs) are more similar to P. 
vivax than P. falciparum infection255. However being aware of these limitations, 
P. chabaudi is in our eyes still the most appropriate model to study the stage-
specificity of CPS-induced protection.
We also use P. chabaudi to address if antimalarial antibodies are of functional 
relevance for protection after CPS. The humoral response to P. chabaudi blood-
stage infection is well characterised: Antibodies against P. chabaudi AS blood-
stage parasites increase over the course of blood stage infection and reach high 
levels 30 to 80 days after mosquito transmission (Figure 6A)259. A single infection 
with P. chabaudi can give rise to short-lived and long-lived plasma cells and 
memory B cells263. Memory B cells are in circulation at all times and thus peripheral 
blood frequencies, as sampled in humans, are representative of their frequency 
in lymphoid organs264. Mice lacking the transmembrane exon of the Ig μ chain, 
that cannot produce mature B cells and thus antibodies (so called μMT mice)265, 
infected with serially blood-passaged266-268 or mosquito transmitted P. chabaudi 
(Figure 6B) are able to control parasitemia in the acute phase, but importantly, 
do not clear blood-stage parasites in the chronic phase (Figure 6B). Therefore it 
seems antibody-independent immune responses (innate immune responses and 
T cells) can control blood-sage parasitemia during the acute phase129,269, while 
antibodies are crucial for complete parasite clearance in the chronic phase. The 
contribution of humoral immunity to pre-erythrocytic protection against P. chabaudi 
is unknown, since P. chabaudi could rarely be studied in the context of mosquito-
transmission and sensitive measurements for liver parasite burden were lacking.
Taken together the new P. chabaudi mouse model of CPS immunization described 
in this thesis, which uses immunization by mosquito bite, is perfectly suited to 
establish the functional contribution of humoral immunity to protection and to 
answer fundamental questions about the stage-specificity of immunity to malaria.
many aspects, to address the life-cycle stage specificity of protection. These 
studies have to be undertaken in rodent models since obvious ethical constraints 
preclude analysis of liver parasite burden in human volunteers, which is the only 
direct evidence for pre-erythrocytic immunity206,240,241,245. Furthermore blood-stage 
infection can be examined beyond patency, which may allow the detection of 
partial blood-stage immunity135. In humans only two erythrocytic cycles could be 
monitored by qRT PCR before thick blood film patency is reached (see above).
We CPS immunize C57BL/6 mice with two different clones of P. c. chabaudi 
(AS and CB, hereafter referred to as P. chabaudi) with different virulence 
phenotypes253. P. chabaudi was chosen since it has a synchronous life-cycle and 
is the only rodent parasite that mostly establishes chronic, recrudescing blood-
stage infections in mice. Furthermore, it exhibits many characteristics associated 
with the pathogenesis of human malaria, such as rosetting254, sequestration255 
and antigenic variation256,257. P. chabaudi is therefore an ideal model to study 
parasite-host interactions in an in vivo setting and has critically contributed to 
our understanding of antimalarial blood-stage immunity258. Distinct cloned lines 
of P. chabaudi have been extensively phenotypically characterised and genome 
sequencing revealed that they are also genetically very polymorphic, displaying 
distinct virulence phenotypes253,257 [Otto T. D. et al., BMC Biology in press.
Until recently most P. chabaudi parasites were maintained by serial blood 
passage of infected erythrocytes from one mouse to a naïve recipient, which 
was shown to enhance parasite virulence259. A recently described optimized 
protocol of laboratory mosquito transmission of P. chabaudi260 allows us now to 
study this parasite in the context of the full life-cycle and CPS immunization to be 
conducted by mosquito bite like in human volunteers. Infections with P. chabaudi 
by mosquito bite can persist for up to 100 days in mice259, but is even more 
chronic in its natural host Thamnomys rutilans113. Chronic infections are typical 
for untreated infections with human malaria parasites61. Of special importance 
to us are the similarities of protection against re-infection between P. chabaudi 
and P. falciparum. Neurosyphilis patients receiving malaria-therapy, which was 
considered standard medical care at the beginning of the 20th century, showed 
clinical and parasitological immunity after reinfection with a homologous (and 
to a lesser degree heterologous) P. falciparum strain, which was evident by 
few parasites in circulation and less, lower intensity fever episodes261. Equally 
one self-cured infection with P. chabaudi by mosquito bite elicits strong strain-
transcending immunity against homologous and heterologous re-challenge, 
reducing the number of mice developing patent infections and drastically reducing 
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Scope of this thesis
In order to design an effective malaria vaccine we have to understand what 
constitute protective antimalarial immunity. Immunity is thought to be Plasmodium 
life-cycle stage specific, but shared antigens between liver and blood-stage 
parasites235 may mediate cross-stage immunity. Cross-stage immunity could 
explain why chemoprophylaxis and sporozoite (CPS) immunization protects 
humans against malaria with unprecedented efficacy, since chloroquine treatment 
allows exposure to both pre-erythrocytic and blood-stage parasites. In this thesis 
we aim to characterise source and target of CPS-induced immunity. We therefore 
design a new experimental rodent P. chabaudi CPS immunization model to 
investigate liver parasite burden and patent blood-stage parasitemia, which is not 
possible in CPS immunized human volunteers. P. chabaudi shows many crucial 
similarities with P. falciparum infections in particular with regard to protection 
against re-infection. Immunization and challenge regimen in this rodent model 
were devised to mimic infection dynamics from human CPS clinical trials including 
immunization by mosquito bite, which is unique among all published rodent 
models of CPS immunization206,236-238,240-244 and was only recently made possible 
by an improved protocol for P. chabaudi mosquito transmission260.
Blood samples from CPS immunized volunteers offer the unique opportunity to 
study the development of immunity in a setting of complete protection against 
the malaria parasite. Antibodies are crucial for protection against blood-stage 
parasites72, but their contribution to sterile pre-erythrocytic immunity is less well 
defined109. The generation of a memory B cell response after CPS immunization 
of humans may also indicate whether humoral immune memory is really impaired 
following malaria infection, as previously suggested100. To analyze the generation 
of malaria antigen-specific memory B cells we use ELISpot analysis, which  relies 
on an unspecific, polyclonal activation step. It is unclear if the number of antigen-
specific memory B cell measured by ELISpot reflects memory B cell frequencies 
ex vivo96,270.
Our specific objectives are therefore:
• To identify evidence for cross-stage immunity following whole parasite 
vaccination approaches.
• To address under which conditions pre-erythrocytic, blood-stage or cross-
stage immunity are elicited following CPS immunization using a novel P. 
chabaudi mouse model.
Figure 6  |  A functional B cell response is indispensable for chronic parasite clearance
A) IgG plasma-antibody specific for P. c. chabaudi AS blood-stage parasite lysate as determined by 
enzyme-linked immunoabsorption assay after a primary infection of C57BL/6 mice with P. c. chabaudi 
AS by mosquito bite (n=8, displayed as arbitrary units (AU) relative to hyperimmune plasma). B) μMT 
mice (n=13), which cannot produce mature B cells and thus antibodies, and C57BL/6 (n=6) mice 
were infected with 105 P. c. chabaudi AS parasitized erythrocytes derived from a donor mouse that 
was infected by mosquito bite. The percentage of infected erythrocytes in the blood (parasitemia) was 
monitored for 96 days by thin blood films, which were examined by microscopy. Limit of detection was 
1 parasite in 104 erythrocytes (0.01% parasitemia).
A reproduced with permission by the publisher from Spence et al., 2013259
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address if humoral immunity contributes to protection following CPS immunization. 
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Background
Malaria remains a major global health scourge and there is a general consensus 
that elimination and eradication efforts will not be successful without an effective 
malaria vaccine. In malaria endemic areas, immunity against severe disease 
caused by blood-stage parasites can be acquired after only one or two infections, 
while infections with high parasite densities still occur1. Vaccines targeting blood-
stage parasites should equally induce control of (severe) disease but ultimately 
also clearance of blood-stage parasites. This is essential as gametocytes form 
during blood-stage infection and transmission to mosquitoes can thus continue. 
There is only very limited evidence for protection against pre-erythrocytic 
malaria parasites (sporozoites and liver-stage parasites) in naturally exposed 
populations2-4. Pre-erythrocytic vaccines aim to outperform naturally acquired 
immunity by targeting the clinically silent stages of infection thus precluding any 
parasites reaching the blood stream. This would abolish any symptoms of malaria 
and additionally block transmission. The risk of such an approach is however that 
breakthrough blood-stage infections can cause severe complications, if the pre-
erythrocytic vaccine is only partially effective. Therefore a blood-stage component 
should be included to minimize this risk5,6. This is especially important since it 
was suggested that declining transmission intensity and thus reduced boosting 
of clinically protective blood-stage immunity could in fact increase overall malaria 
morbidity7. The desired scenario would therefore be to develop a multi-stage 
malaria vaccine that minimizes both transmission and disease8.
Hypothesis: Shared antigenic targets between liver and blood-stage para-
sites can induce cross-stage immunity
Given that there are shared antigens between the different life-cycle stages of the 
malaria parasite9, it is possible that functional immunity to pre-erythrocytic and 
blood-stage parasites could enhance each other, offering an intriguing possibility 
for development of a multi-stage malaria vaccine. Evidence for cross-stage 
immunity comes from several studies10-13. For instance, apical membrane antigen 
(AMA)-1 and merozoite surface protein (MSP)-1 are highly abundant in blood-
stage parasites with roles in erythrocyte invasion14,15; however these antigens are 
also expressed by sporozoites and liver-stage parasites16,17. In human volunteers 
immunized with AMA-1 the number of parasitized erythrocytes during the first 
blood-stage cycle after mosquito bite challenge infection was about 7-times lower 
compared to non-immunized controls, suggesting that pre-erythrocytic immune 
responses may have eliminated sporozoites or infected hepatocytes13. Indeed an 
Abstract
A vaccine against malaria is urgently needed for control and eventual eradication. 
Different approaches are pursued to induce either sterile immunity directed against 
pre-erythrocytic parasites or to mimic naturally acquired immunity by controlling 
blood-stage parasite densities and disease severity. Pre-erythrocytic and blood-
stage malaria vaccines are often seen as opposing tactics, but it is likely that they 
have to be combined into a multi-stage malaria vaccine to be optimally safe and 
effective.
Since many antigenic targets are shared between liver- and blood-stage parasites, 
malaria vaccines have the potential to elicit cross-stage protection with immunity 
against both stages complementing and enhancing each other. Here we discuss 
evidence from pre-erythrocytic and blood-stage whole parasite immunization 
approaches that show that protection against malaria is not necessarily stage-
specific. Parasites arresting at late liver-stages especially, can induce powerful 
blood-stage immunity, and similarly exposure to blood-stage parasites can afford 
pre-erythrocytic immunity.
The incorporation of a blood-stage component into a multi-stage malaria vaccine 
would hence not only combat breakthrough infections in the blood should the pre-
erythrocytic component fail to induce sterile protection, but would also actively 
enhance the pre-erythrocytic potency of this vaccine. We therefore advocate that 
future studies should concentrate on the identification of cross-stage protective 
malaria antigens, which can empower multi-stage malaria vaccine development.
58  l  Chapter 2 Cross-stage immunity for malaria vaccine development  l  59
T
W
O
This suggests that blood-stage infection can enhance pre-erythrocytic vaccine 
efficacy. Furthermore in a P. berghei infection model in mice, multiple booster 
immunizations with high numbers of irradiated sporozoites resulted in delayed 
patency and reduced peak blood-stage parasitemia after sporozoite challenge 
(Nganou-Makamdop K, personal communication), suggesting that cross-stage 
protective responses targeting blood-stage parasites may have developed.
Targeted deletion of parasite genes important for liver-stage development is an 
alternative strategy to arrest parasite development in hepatocytes. Similar to 
irradiated and chemically attenuated26 sporozoites, immunization with knock-
out parasites that arrest during the early liver-stage (e.g. uis 327, uis 428, p36p29, 
sap-130, p52/p3631,32) results in pre-erythrocytic immunity. Late arrest during liver-
stage development33, however, appears to increase the chance of cross-stage 
immunity: Immunization with P. yoelii fabb/f knockout sporozoites can control and 
clear blood-stage parasitemia following challenge with parasitized erythrocytes34. 
This is the first direct evidence that immunization with an attenuated parasite, 
which does not develop beyond liver-stage, can elicit blood-stage immunity.
Cross-stage immunity therefore appears to be more efficient if liver-stage parasites 
arrest late in development as their antigenic profile becomes similar to blood-
stage parasites9 and the amount of antigen increases (Figure 1). Hence antigens 
expressed in late liver-stage parasites are, under certain conditions, capable of 
mediating not only pre-erythrocytic protection, but also reduce the risk of blood-
stage breakthrough infection by inducing effective blood-stage immunity.
Evidence for cross-stage immunity from whole blood-stage parasite 
vaccination approaches
Plasmodium replicates massively in the liver such that one infected hepatocyte can 
release up to up to 30,000 blood-stage parasites35. Also due to their subsequent 
exponential multiplication blood-stage parasites are hence much more numerous 
than pre-erythrocytic parasites, which increases their potential to present 
protective antigens successfully. The possibility that immune responses against 
these antigens might not be only specific for blood-stage parasites, but could also 
target pre-erythrocytic stages has however hardly been investigated (Figure 1).
Disruption of the purine nucleoside phoshphorylase gene (pnp)36 or nucleoside 
transporter 1 (nt1) gene37 in P. yoelii gives rise to severely attenuated blood-
stage infections, and mice that had undergone an infection with these knockout 
parasites did not develop detectable patent parasitemia after infectious mosquito 
bite or sporozoite challenge36,37. This could represent effective blood-stage or pre-
80% reduction of liver-stage parasite burden following sporozoite challenge was 
shown in mice immunized with AMA-110. After vaccination of humans with AMA-1 
and MSP-1, time to diagnosis, which was delayed in the vaccinees, significantly 
correlated with liver-to-blood parasite levels but not blood-stage multiplication 
rates. This suggests again that this vaccine may induce pre-erythrocytic rather 
than the originally intended blood-stage immunity12. These examples indicate that 
a vaccine formulation based on only one or two malarial antigens could induce 
cross-stage protective immunity. Whole organism vaccines that allow exposure to 
many parasite antigens should therefore provide greater potential for cross-stage 
immunity, which would enhance protection induced by pre-erythrocytic and blood-
stage parasites. We therefore discuss evidence for cross-stage immunity from 
different whole parasite vaccination approaches, which offer the opportunity to 
identify as yet unknown cross-protective antigens for multi-stage malaria vaccine 
development.
Evidence for cross-stage immunity from pre-erythrocytic whole parasite 
vaccination approaches
The proteome of liver-stage parasites becomes increasingly similar to blood-stage 
parasites as liver development proceeds9. Furthermore the amount of parasite 
antigen increases as the parasite matures in hepatocytes. Killed sporozoites that 
fail to invade hepatocytes are incapable of inducing protection18,19, suggesting 
that liver-stage development is indispensable for induction of protective immunity. 
Irradiation of sporozoites, which arrests their development early during the liver-
stage20,21, induces immunity to pre-erythrocytic stages only18,22. A very limited 
number of studies have, however, investigated whether there are significant 
immune responses, or any level of protection against blood-stage parasites. One 
report from Krzych et al.23 suggests a more in-depth study of cross-stage immune 
responses induced by irradiation attenuated sporozoites might be valuable, as T 
cells from human volunteers immunized with irradiated sporozoites responded to 
both pre-erythrocytic and blood-stage antigens, including MSP-1. This response 
was greater in immunized volunteers, who were protected from challenge 
infection, than in unprotected volunteers and comparable to malaria-experienced 
individuals23. Therefore, immunization of humans with irradiated sporozoites leads 
to the induction of immune responses recognizing blood-stage antigens. CD8 T 
cells, which were shown to be essential for pre-erythrocytic protection following 
irradiated sporozoites immunization24, proliferate more strongly in mice if in addition 
to P. berghei irradiated sporozoites they were exposed to parasitized erythrocytes25. 
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Is cross-stage immunity responsible for the unprecedented efficiency of 
chemoprophylaxis with sporozoites immunization?
The induction of cross-stage immunity should be facilitated by exposure 
to both pre-erythrocytic and blood-stage parasites during immunization. 
Chemoprophylaxis with sporozoites (CPS) immunization, which uses infectious 
wild-type sporozoites combined with prophylactic antimalarial drug treatment 
(often chloroquine), allows the immune system to experience all vertebrate 
Plasmodium life-cycle stages including sporozoites, infected hepatocytes and 
parasitized erythrocytes. CPS immunization was first described in rodents40,41 
and was later shown to induce long lasting sterile protection against homologous 
mosquito-bite challenge in human volunteers42-44. In humans CPS immunization 
is about 20 times more efficient than immunization with irradiated sporozoites22,45. 
We therefore hypothesize that the completion of liver-stage development and 
the exposure to blood-stage parasites38 during CPS immunization may enhance 
the protective efficacy by inducing protective cross-stage responses. CPS using 
primaquine, which primarily targets liver-stage parasites, substantially reduces 
the number of sterilely protected mice thereby strengthening this hypothesis19. In 
further support of this, mice that have experienced a self-cured infection with P. 
chabaudi blood-stage parasites derived from a donor mouse infected by mosquito 
bite have a substantially reduced liver-parasite burden following mosquito bite 
challenge46. Cross-stage immunity elicited by blood-stage parasites may hence 
contribute to the unprecedented efficiency of CPS immunization to induce sterile 
pre-erythrocytic protection in human volunteers42-44. Importantly exposure to 
blood-stage parasites during CPS immunization may significantly contribute to the 
observed pre-erythrocytic protection against mosquito bite challenge, but does 
not appear to protect against direct blood-challenge within the first four cycles of 
blood-stage replication43.
Conclusion: Importance of studying cross-stage immunity for malaria 
vaccine development
Cross-stage immunity would be a powerful means to improve protective efficacy 
of malaria vaccines, however data to support this hypothesis are sparse. During 
liver-stage development both the amount of antigen and the antigenic similarity to 
erythrocytic parasites increases (Figure 1). Thus as Plasmodium matures in the 
liver, it is potentially capable of inducing immunity not only against pre-erythrocytic 
but also against blood-stage parasites34. Equally, exposure to attenuated blood-
stage parasites could protect against sporozoite challenge38. 
erythrocytic immunity, since a reduction in liver parasite burden, which is the only 
direct evidence for pre-erythrocytic protection, was not shown. Direct evidence 
for pre-erythrocytic protection elicited by blood-stage parasites comes from mice 
that received a prophylactic treatment with chloroquine and were simultaneously 
infected with P. yoelii blood-stage parasites. Liver parasite burden is significantly 
reduced in these mice following sporozoite challenge38.
It is presumed that the main purpose of blood-stage components in a multi-stage 
vaccine is to protect against breakthrough blood-stage infection39, if the pre-
erythrocytic components are only partially effective. However, if whole parasite 
blood-stage immunizations have the potential to also induce cross-stage protective 
responses enhancing immunity against pre-erythrocytic stages, they would be 
even more valuable for multi-stage malaria vaccine development.
Figure 1  |  Shared antigens can mediate cross-stage immunity after whole parasite vaccination
Malaria infection is initiated by an infectious mosquito bite, which inoculates a few sporozoites into the 
skin. Sporozoites then migrate to the liver and invade hepatocytes. During pre-erythrocytic development 
parasite load slowly increases as Plasmodium matures in the liver. In addition, the antigenic repertoire 
becomes increasingly similar to blood-stage parasites9 and cross-stage antigens are expressed. Since 
up to 30,000 merozoites can be released from a single infected hepatocyte1 parasite load rises rapidly 
when blood-stage parasites are released from the liver. Blood-stage parasites mature from rings to 
trophozoites and schizonts and parasite load increases exponentially with each new replication cycle. 
Apart from typical blood-stage antigens infected erythrocytes also express cross-stage antigens, 
which are shared with pre-erythrocytic parasites. There is evidence from whole parasite immunization 
approaches that shared antigens between pre-erythrocytic and blood-stage parasites could induce 
cross-stage immunity. Characterization of these antigens would greatly facilitate multi-stage malaria 
vaccine development.
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Introduction
Protective immunity against microorganisms is developed after repeated infection 
and recovery1. Vaccines are usually successful if they mimic these naturally 
acquired immune responses2,3. While protection against viruses and bacteria can 
be induced by vaccination with killed (inactivated) or live-attenuated pathogens4, 
there is no licensed vaccine for human parasitic diseases like malaria that pose a 
major global health burden.
The apicomplexan malaria parasite Plasmodium is transmitted by bites of female 
anopheline mosquitoes. In the vertebrate host, sporozoites injected into the dermis 
migrate to the liver, where they establish a clinically silent infection of hepatocytes. 
Merozoites are then released from the liver and invade erythrocytes, leading to 
an exponential asexual replication cycle that is entirely responsible for the clinical 
signs and symptoms associated with malaria. Immunity against severe disease 
can be acquired following repeated infection, but sterile parasite clearance is 
rarely achieved5. Clinically immune adults in endemic areas still harbor parasites 
in their blood-stream6. These asymptomatic carriers also develop gametocytes, 
the form transmissible to mosquitoes, thereby allowing the parasite to complete 
its life-cycle.
To achieve malaria control and eventually eradication, transmission must be 
blocked7. A vaccine that protects against pre-erythrocytic parasites, and thus 
outperforms naturally acquired immunity, would greatly facilitate this aim. Parasites 
that arrest during the liver-stage, either because of irradiation8 or targeted gene 
deletion9, can provide immunity against challenge infection. Indeed, immunization 
of human volunteers with irradiated sporozoites can induce sterile protection in 
experimental settings10,11. However, in the absence of acquired immunity to the 
blood-stage parasite a pre-erythrocytic vaccine that is only partially effective, and 
therefore permits breakthrough erythrocytic infections, will provide no protection 
against severe malaria12. The inclusion of a blood-stage component together with 
an effective pre-erythrocytic vaccine is therefore preferred to provide a multi-stage 
malaria vaccine that minimizes both transmission and disease13,14.
A recently described experimental malaria immunization protocol using 
chemoprophylaxis and sporozoites (CPS)15 ensures exposure to pre-erythrocytic 
and blood-stage parasites, and hence has the unique potential to induce 
protection against all Plasmodium life-cycle stages in the vertebrate host. Three 
immunizations with bites of 10-15 P. falciparum-infected mosquitoes under 
chloroquine chemoprophylaxis are sufficient to elicit sterile protection against 
homologous challenge in human volunteers15-17. Although it is not possible 
Abstract
Protection against malaria in humans can be achieved by repeated exposure 
to infected mosquito bites during prophylactic chloroquine treatment 
(chemoprophylaxis and sporozoites (CPS)). We established a new mouse model 
of CPS immunization to investigate the stage- and strain-specificity of malaria 
immunity. Immunization with Plasmodium chabaudi by mosquito bite under 
chloroquine cover does not generate pre-erythrocytic immunity, which is acquired 
only after immunization with high sporozoite doses. Instead, CPS immunization 
by bite elicits long-lived protection against blood-stage parasites. Blood-stage 
immunity is effective against a virulent, genetically distinct strain of P. chabaudi. 
Importantly, if exposure to blood-stage parasitemia is extended, blood-stage 
parasites induce cross-stage immunity targeting pre-erythrocytic stages. We 
therefore show that CPS immunization can induce robust, long-lived heterologous 
blood-stage immunity, in addition to protection against pre-erythrocytic parasites 
following high dose sporozoite immunization. Cross-stage immunity elicited by 
blood-stage parasites may further enhance efficacy of this immunization regimen.
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Materials and Methods
Mice
Inbred C57BL/6 mice, originally obtained from Jackson Laboratories (Bar Harbor, 
USA), were bred under specific pathogen-free conditions at the MRC National 
Institute for Medical Research (NIMR) for over 30 years. All experiments were 
performed in accordance with UK Home Office regulations (PPL 80/2358) and 
approved by the ethical review panel at the MRC NIMR. Mice were housed under 
reverse light conditions (light 19.00-07.00, dark 07.00-19.00 GMT) at 20-22°C and 
50% relative humidity, with continuous access to mouse breeder diet and water. 
Parasites and Mosquitoes
Plasmodium chabaudi chabaudi (P. chabaudi) AS and CB were cloned at the 
University of Edinburgh and sent to the NIMR in 1978 and 1982 respectively. Both 
parasite lines were routinely serially blood-passaged through mice between 26-
32 times by intraperitoneal (ip) injection of parasitized erythrocytes or mosquito 
transmitted according to a recently published protocol19. In brief C57BL/6 mice 
were injected ip with 100,000 parasitized erythrocytes and 14 days post infection 
gametocytemia was assessed on Giemsa-stained (VWR, Lutterworth, UK) thin 
blood film. A. stephensi mosquitoes, pre-treated with 50μg/ml gentamicin (Sigma, 
Gillingham, UK) and starved for 24h before transmission, were fed on anaesthetised 
mice with >0.1% gametocytes of total erythrocytes at a ratio of >1 mouse per 100 
mosquitoes. Mosquitoes were kept at 26.0°C (+/− 0.5°C) in an ultrasonic humidity 
cabinet and provided with 8% Fructose and 0.05% 4-Aminobenzoic acid (both 
Sigma, Gillingham, UK) feeding solution. After 8 days a sample of 20 mosquitoes 
were dissected to assess development of P. chabaudi oocyts in the midgut. For 
infection of experimental mice 20-23 mosquitoes were transferred into 25cl paper 
cups after 14 days, starved for 24h and fed on anaesthetized mice for 20-25min at 
room temperature. Typically mice were exposed to 9.15 (Median, Range 6.9-13.6) 
P. chabaudi infected mosquito bites19.
Isolation of sporozoites
Sporozoites were isolated from P. chabaudi infected mosquito salivary glands 
15 or 16 days post gametocyte feed. Salivary glands were dissected under 
a stereomicroscope, transferred to a glass homogenizer and kept in RPMI 
supplemented with 0.2% Glucose, 0.2% Sodium bicarbonate (both Sigma, 
Gillingham, UK), 2mM L-Glutamine (Gibco, Paisley, UK) and 10% fetal bovine serum 
to measure liver parasite burden in human volunteers directly, it appears that 
immunity exclusively targets pre-erythrocytic parasite life-cycle stages, as there 
is no protection against direct blood challenge17. CPS immunization is thus 
substantially more effective than immunization with irradiated sporozoites, which 
requires 1,000 mosquito bites10 or 5 intravenous (iv) injections of more than 100,000 
sporozoites for sterile protection11. We therefore hypothesize that transient blood-
stage parasitemia, before abrogation by chloroquine, may contribute to immunity 
following CPS immunization.
Here we have investigated the stage- and strain-specificity of protection in a novel 
mouse model of CPS immunization using Plasmodium chabaudi. P. chabaudi 
establishes a chronic, non-lethal blood-stage infection, which has been used 
extensively to characterise the immune response to blood-stage parasites in 
vivo18. A recently optimized protocol for P. chabaudi mosquito transmission19 
allows us now to also study pre-erythrocytic stages of this rodent parasite. 
Heterologous protection can readily be assessed since many genetically distinct 
P. chabaudi isolates displaying a variety of virulence phenotypes are available20,21. 
We immunized C57BL/6 mice three times with bites of P. chabaudi infected 
mosquitoes under oral chloroquine chemoprophylaxis similar to human clinical 
trials15-17. This approach is unique amongst all published animal models of CPS 
immunization22-31, which have (without exception) used iv injection of high numbers 
of P. berghei or P. yoelii sporozoites for immunization. Furthermore rather than 
evaluating effector mechanisms by challenging shortly after immunization22,26,27, 
we performed the challenge 100 days after the final immunization to test the 
generation and maintenance of long-term immunological memory.
CPS immunization with P. chabaudi by mosquito bite does not generate pre-
erythrocytic immunity, which is acquired only after immunization with high doses 
of sporozoites. Instead, immunization by bite elicits blood-stage immunity that 
is effective against the immunizing strain and also a more virulent, genetically 
distinct P. chabaudi. Moreover, extended exposure to blood-stage parasitemia 
elicits robust pre-erythrocytic immunity, comparable to protection afforded by high 
dose sporozoite immunization. Exposure to blood-stage parasites thus elicits 
heterologous blood-stage immunity and can contribute to the pre-erythrocytic 
efficacy of this immunization regimen. Therefore these findings add significantly 
to advances from previous CPS immunization mouse models by evaluating the 
generation of immune memory after immunization with P. chabaudi by mosquito 
bite22-31. This is relevant for our understanding of acquired immunity in a malaria 
endemic setting, and can inform multi-stage malaria vaccine development.
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and immediately upon cessation of respiration their livers were perfused with 
5ml RNAse-free Phosphate buffered saline (PBS, Gibco, Paisley, UK). Using 
the Gentle MACS homogenizer (Miltenyi, Bisley, UK) the whole liver was 
homogenized in 4ml Guanidinium thiocyanate (Sigma, Gillingham, UK) solution32 
and 600μl aliquots were stored at -80°C. To assess blood-parasite burden during 
CPS immunization and in the first erythrocytic cycles following bite challenge 
10μl of blood were isolated from the tip of the mouse-tail and after 2 washes in 
RNAse-free PBS stored at -80°C in 100μl Guanidinium thiocyanate solution32. The 
first sample was taken either just before (erythrocytic cycle 0) or 20h after liver 
merozoite egress (erythrocytic cycle 1) and then every 24h for 4 days. Since P. 
chabaudi displays a synchronous infection18 all blood-stage parasites analyzed 
were therefore at the late trophozoite stage of development. RNA was extracted 
from liver- as well as blood-samples using the Guanidinium-thiocyanate-phenol-
chlorophorm method (all Sigma, Gillingham, UK)32. RNA was thereafter reverse 
transcribed by PCR (Temperature profile: 25°C for 10min, 42°C for 20min, 98°C 
for 5min) using 75U MuLV Reverse Transcriptase, 30U RNAse Inhibitor and 
2.5μM Random Hexamer primers (all Applied Biosystems, Paisley, UK) per 
sample. The amount of 18S rRNA copies was quantified by Real-Time PCR using 
TaqMan Universal PCR Master Mix (Applied Biosystems, Paisley, UK), 300ηM 
forward primer (5’-AAGCATTAAATAAAGCGAATACATCCTTAT-3’), 300ηM 
reverse primer (5’- GGGAGTTTGGTTTTGACGTTTATGCG-3’) and 50ηM probe 
([6FAM]CAATTGGTTTACCTTTTGCTCTTT[TAM]). All reactions were performed 
in the ABI 7900 HT Real Time PCR machine (Temperature profile: 50°C for 2min, 
95°C for 10min, 40 cycles of 95°C for 15sec and 60°C for 1min). The amount 
of parasite 18S rRNA in the liver was calculated based on a Standard curve of 
known copy numbers of 18S rRNA. For every experiment liver-parasite burden 
was normalized to the mean burden of controls infected in the same experiment. 
Blood-stage parasitemia was quantified based on a Standard curve of 10-fold 
dilutions of mosquito transmitted P. chabaudi AS late trophozoites prepared 
identically to the samples.
Statistical analysis 
Data were analyzed using GraphPad Prism v7. Unpaired data between two groups 
at a specific time point were analyzed by Mann-Whitney test (two-tailed, non-
parametric). Differences between more than two groups were analyzed by non-
parametric Kruskal-Wallis test with Dunn’s multiple comparisons test. Significant 
differences are indicated by asterisks with *≤p0.05, **p≤0.01, ***p≤0.001.
(GE Healthcare Life Sciences, Pittsburgh, Pennsylvania), on ice for maximum 2h. 
Sporozoites were released from the glands by gentle homogenization and washed 
3 times before enumeration. The number of sporozoites per infected mosquito 
was enumerated for each mosquito transmission experiment. For iv injection P. 
chabaudi CB sporozoites were used, since mosquitoes infected with this parasite 
strain harbor an increased number of sporozoites per infected mosquito in their 
salivary glands (Median 1638, Range 175-2576) compared to P. chabaudi AS 
(Median 438, Range 43-956)19.
Attenuation of sporozoites by irradiation
To arrest parasite development in the early stages of liver development P. 
chabaudi CB infected A. stephensi were exposed to 16 Gray (=16,000 rad)25 
of Caesium-137 γ-irradiation 15 or 16 days post gametocyte feed just prior to 
sporozoite dissection.
Chemoprophylaxis and sporozoite (CPS) immunization and challenge 
regimen
Female age-matched 8-10 week old C57BL/6 mice were infected three times in 
two-week intervals with P. chabaudi: either by P. chabaudi AS infected mosquito 
bites or iv injection of P. chabaudi CB sporozoites. Mice were treated after each 
immunization with 100mg/kg chloroquine diphosphate salt (chloroquine, Sigma, 
Gillingham, UK) by gavage daily for 10 days, starting from the day of mosquito 
transmission. Mock immunized mice received uninfected mosquito bites and 
chloroquine treatment. 100 days after the last CPS immunization mice were 
challenged with P. chabaudi AS or P. chabaudi CB infected mosquito bites, or 
via ip injection of 100,000 parasitized erythrocytes (direct blood-challenge) that 
were obtained from either a donor mouse infected by mosquito bite or after serial 
blood passage. Since each erythrocytic cycle of P. chabaudi is approximately 
24h long18 development of blood-stage parasitemia was monitored daily by 
microscopy of Giemsa-stained thin blood films, from erythrocytic cycle 3 to 14 and 
every other day thereafter. The limit of detection was 0.01% parasitemia, which 
equals 1 parasitized red blood cell in 10,000 erythrocytes or 1,000,000 parasitized 
erythrocytes per ml of blood. 
Quantification of liver- and blood-stage parasitemia by quantitative Real 
Time PCR
Liver and blood-parasitemia was assessed by quantifying 18S rRNA using qRT 
PCR. 42h after mosquito bite challenge mice were terminally anaesthetized 
74  l  Chapter 3 Blood-stage immunity after whole sporozoite immunization  l  75
T
H
R
E
E
Figure 1  |  Overview experimental procedures (see previous page)
To quantify transient blood-stage exposure during chemoprophylaxis and sporozoite (CPS) 
immunization female C57BL/6 were immunized three times at 2-week intervals with P. chabaudi AS 
infected mosquito bites (typically 9.15 (Median, Range 6.9-13.6) [19]). Following each immunization 
mice received 100 mg per kg chloroquine (CQ) per os daily for 10 days, starting from the day of 
infection. A small blood sample was taken 48h after each mosquito transmission (before merozoite 
egress from the liver, P. chabaudi develops in the liver for 52h [18]; erythrocytic cycle 0), and then every 
24h until erythrocytic replication cycle 4. Blood parasitemia was analyzed by sensitive quantitative 
RealTime (qRT) PCR (Figure 2).
Pre-erythrocytic immunity was evaluated in mice immunized three times with either P. chabaudi AS 
infected mosquito bites (Figure 3A) or by intravenous (iv) injection of defined numbers of P. chabaudi 
CB sporozoites (Figure 3B). P. chabaudi CB was used since mosquitoes infected with this parasite 
harbor an increased number of sporozoites in their salivary glands [19], which made injections of high 
numbers of sporozoites technically feasible. Mice were challenged 100 days after the last immunization 
by mosquitoes infected with the respective homologous strain. Liver parasitemia was examined 42h 
after challenge by qRT PCR.
Blood-stage immunity was assessed in mice immunized with P. chabaudi AS infected mosquito bites 
by qRT PCR and thin blood film following homologous challenge with either infected mosquito bites 
(Figure 4A and 5C/D) or intraperitoneal (ip) injection of parasitized erythrocytes, which were either 
derived from a donor mouse infected by mosquito bite (recently mosquito transmitted, Figure 4B) 
or after 26-32 serial blood-passages (Figure 4C). Heterologous protection was assessed using P. 
chabaudi CB infected mosquito bites (Figure 5A/B).
To evaluate cross-stage protection mice received a first infection with P. chabaudi AS either by 
mosquito bite or by ip injection of recently mosquito transmitted parasitized erythrocytes. The resulting 
blood-stage infection was eventually self-cured without intervention. Mice were re-challenged 100 
days after their first infection with P. chabaudi AS infected mosquito bites and liver parasitemia was 
evaluated by qRT PCR (Figure 6).
blood were detected within the first erythrocytic cycle (Figure 2). The amount of 
blood-stage parasites within the first erythrocytic cycle varied extensively (Median 
47,596, Range 67 to 222,699), reflecting the stochastic inoculation of sporozoites 
during mosquito bite33-35. Thereafter, chloroquine reduced parasitemia by 86-96% 
every 24h. After the 4th cycle the majority of erythrocytic parasites were cleared. 
Similarly, after the second and third immunization mice experienced a substantial 
number of circulating blood-stage parasites for 48-72 hours. However, although 
blood-stage parasites were detected in all but one mouse, parasitemia in the 
first erythrocytic cycle was reduced by 5- and 13-fold after the second and third 
immunizations, respectively, when compared to infection controls (Figure 2). 
Consequently, one CPS immunization is sufficient to reduce blood-stage parasite 
burden within the first erythrocytic cycle, which indicates either pre-erythrocytic or 
blood-stage immunity.
Pre-erythrocytic immunity requires high doses of sporozoites during CPS 
immunization
In order to assess directly whether pre-erythrocytic immunity was generated by 
this CPS immunization protocol, liver parasite burden was analysed after mosquito 
bite challenge. Surprisingly, there was no difference in the liver parasite burden 
Results
We investigated the stage- and strain-specificity of protection in a novel mouse 
model of CPS immunization (Figure 1). C57BL/6 mice were immunized three 
times at 2-week intervals with P. chabaudi AS infected mosquito bites. For 
certain experimental questions it was necessary to deviate from the natural 
route of infection and inject sporozoites iv to control the dose. Starting on the 
day of infection, mice were then treated orally with 100 mg per kg chloroquine 
for 10 days following each immunization. To assess the long-term efficacy of 
acquired immunity, mice were challenged approximately 100 days after the last 
immunization. Protection against pre-erythrocytic or blood-stage parasites was 
evaluated after mosquito bite or direct blood challenge. 
CPS immunization leads to a transient blood-stage infection
Transient blood-stage parasitemia is a key feature of CPS immunization. We used 
quantitative RealTime (qRT) PCR to measure erythrocytic parasite burden after 
each immunization with P. chabaudi AS infected mosquito bites under chloroquine 
cover. After the first immunization, approximately 50,000 parasites per ml whole 
Figure 1  |  Overview experimental procedures (for legend see next page)
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Figure 3  |  Pre-erythrocytic immunity following CPS immunization requires high doses of 
sporozoites
Liver parasite burden was determined 42h after mosquito bite challenge as copy number of P. 
chabaudi-specific 18S rRNA. A) Mice were CPS immunized three times (i1, i2, i3) with P. chabaudi AS 
infected mosquito bites under chloroquine (CQ) cover (CPS (Bite)) and challenged (C) 96-104 days 
after immunization by bites of P. chabaudi AS infected mosquitoes (Pooled data from 3 independent 
experiments; naïve infection controls (-) n=25, CPS (Bite) n=35). B) 100 or 10,000 untreated 
or irradiated (Irr.) P. chabaudi CB sporozoites (spz) were injected iv three times under CQ cover. 
Mice were challenged 96 days after immunization by bites of P. chabaudi CB infected mosquitoes 
(naïve infection controls (-) n=12, all other groups n=20). All data are displayed relative to the mean 
of corresponding liver parasite burden of naïve infection controls and presented as Mean ± SEM, 
A) Mann-Whitney test: no significant difference between the groups; B) Kruskal Wallis with Dunn’s 
multiple comparisons test *p≤0.05, ***p≤0.001.
to 90%) after mosquito bite challenge, compared to infection controls (Figure 3B). 
Conversely, mice immunized iv three times with a low dose of 100 P. chabaudi CB 
sporozoites (representative of the estimated number of P. chabaudi sporozoites 
that initiate infection via mosquito bite19) do not acquire pre-erythrocytic immunity 
(Figure 3B). It also appears that CPS immunization with 10,000 live sporozoites 
was more effective at inducing pre-erythrocytic immunity than immunization 
with 10,000 irradiated P. chabaudi CB sporozoites, which arrest during hepatic 
development36 and do not establish a blood-stage infection (Figure 3B). This 
suggests that complete liver-stage maturation and the increased blood-stage 
parasitemia that accompanies immunization with 10,000 sporozoites (as 
compared to 100 sporozoites or mosquito bite) could contribute to pre-erythrocytic 
protection.
between mice given three CPS immunizations with P. chabaudi AS infected 
mosquito bites and infection controls (Figure 3A). Therefore, immunization by 
mosquito bite under chloroquine cover according to this protocol failed to elicit 
pre-erythrocytic immunity. This is in contrast to results from other animal models 
of CPS immunization where pre-erythrocytic immunity is induced after high 
numbers of sporozoites are injected iv25-29,31. To test if pre-erythrocytic immunity 
can be induced after CPS immunization with large numbers of sporozoites we 
used P. chabaudi CB, since mosquitoes infected with this parasite strain harbor 
an increased number of sporozoites in their salivary glands compared to P. 
chabaudi AS19, making these experiments technically feasible. In agreement with 
previous studies25-29,31, mice immunized iv three times with 10,000 P. chabaudi CB 
sporozoites under chloroquine cover did show reduced liver parasite burden (up 
Figure 2  |  Chloroquine permits transient blood-stage parasitemia during each immunization
The number of parasitized erythrocytes (pE) per ml of whole blood was enumerated by quantitative 
RealTime PCR after each CPS immunization (i1, i2, i3) with P. chabaudi AS infected mosquito bites 
under chloroquine (CQ) cover. The number of pE (at the late trophozoite stage) was quantified 
immediately before merozoite egress from the liver, at 48h post mosquito transmission (erythrocytic 
cycle 0), and then every 24h until erythrocytic replication cycle 4. Daily parasitemia of ten CPS 
immunized mice (each color represents an individual mouse) are shown. Blood-stage parasites were 
detected within the first erythrocytic cycle after every immunization in all but one mouse after the final 
immunization. Grey bars represent the mean parasitemia in the first erythrocytic cycle of naïve mice 
infected as controls for mosquito transmission efficiency separate with each immunization (n=3-5). 
Significant differences in the number of blood-stage parasites in the first erythrocytic cycle between 
naïve and CPS immunized mice are indicated (Mann Whitney test, ** p≤0.01).
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CPS immunization by mosquito bite elicits blood-stage immunity
To test whether the transient blood-stage infection resulting from CPS immunization 
by mosquito bite (Figure 2) is sufficient to induce protection against erythrocytic 
parasites, we challenged mice approximately 100 days after the last immunization 
and measured blood-stage parasitemia (Figure 4). Mice that were CPS immunized 
with P. chabaudi AS had similar numbers of parasitized erythrocytes as compared to 
mock immunized controls within the first five erythrocytic cycles following mosquito 
bite challenge (Figure 4A). However, from erythrocytic cycle six parasitemia was 
significantly reduced and blood-stage parasites were cleared more rapidly in 
immunized mice. This was reflected in a 6-fold reduction of total area under the 
curve (AUC) (right inset, Figure 4A). Protection against erythrocytic parasites was 
also evaluated by direct blood challenge, using blood-stage parasites obtained 
from a donor mouse infected by mosquito bite. Similar to the results of mosquito 
bite challenge, blood-stage parasitemia was significantly reduced (Figure 4B), 
but the infection was still chronic in some mice (Supplementary Figure 1). 
However, blood-stage protection was abrogated when CPS immunized mice were 
challenged with serially blood passaged P. chabaudi; blood-stage parasites with 
increased virulence following multiple passages through naïve mice37 (Figure 
4C). In this case, CPS immunization reduced blood-stage parasite burden only 
between erythrocytic cycle 6 and 8, as compared to mock immunized controls. 
This was reflected in only a 1.2-fold reduction in total AUC (right inset, Figure 4C). 
Therefore, CPS immunization by mosquito bite elicits homologous blood-stage 
immunity, which is most effective in the context of mosquito transmission.
Figure 4  |  CPS immunization elicits blood-stage immunity (see previous page)
Mice were CPS immunized three times (i1, i2, i3) using chloroquine (CQ) and P. chabaudi AS 
infected or uninfected mosquito bites (mock immunized). Approximately 100 days after the final CPS 
immunization, mice were challenged (C) with P. chabaudi AS. Erythrocytic parasitemia was evaluated 
daily by quantitative RealTime PCR (cycle 1-3, displayed as parasitized erythrocytes (pE) per ml 
whole blood; left) and from cycle 3-14 by thin blood-film (expressed as % parasitized erythrocytes 
(parasitemia) 0.01% parasitemia corresponds to 1,000,000 pE per ml; middle). The total area under 
the curve (AUC) was calculated for each mouse between erythrocytic cycle 3 and 14 (right). A) 
Mosquito bite challenge: parasitemia from 1st to 3rd (n=10) and between 3rd and 14th erythrocytic cycle 
(representative of 3 independent experiments, n=12-19), total AUC between cycle 3 and 14 (n=19). 
B) Direct blood challenge using 10,000 erythrocytic parasites obtained from a donor mouse infected 
by mosquito bite; injected ip: parasitemia between 1st and 3rd (n=10) and 3rd and 14th erythrocytic cycle 
(representative of 3 independent experiments, n=10), total AUC between cycle 3 and 14 (n=10). C) 
Blood challenge using 10,000 serially blood passaged parasites; injected ip: parasitemia from 1st to 3rd 
(n=10) and between 3rd and 14th erythrocytic cycle (representative of 2 independent experiments, n=8-
10), total AUC between cycle 3 and 14 (n=10). All data are presented as Mean ± SEM, Mann-Whitney 
test per time point *p≤0.05, **p≤0.01, ***p≤0.001.
Figure 4  |  CPS immunization elicits blood-stage immunity (for legend see next page)
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Figure 5  |  CPS immunization elicits heterologous blood-stage immunity (see previous page)
Mice were CPS immunized three times (i1, i2, i3) under chloroquine (CQ) cover by P. chabaudi AS 
infected mosquito bites or mock immunized with uninfected mosquito bites, and challenged (C) 96 to 
107 days later by mosquito bite. Erythrocytic parasitemia was evaluated daily by quantitative RealTime 
PCR for blood-stage parasites (cycle 1-3, displayed as parasitized erythrocytes (pE) per ml whole 
blood) and from cycle 3-20 by thin blood-film (expressed as % parasitized erythrocytes (parasitemia), 
0.01% parasitemia corresponds to 1,000,000  pE per ml). A/B Heterologous challenge with P. chabaudi 
CB infected mosquitoes A) Parasitemia between 1st and 3rd (n=10) and B) from 3rd to 20th erythrocytic 
cycle (n=20). C/D Homologous challenge with P. chabaudi AS infected mosquitoes C) Parasitemia 
between 1st and 3rd (n=10) and D) from 3rd to 20th erythrocytic cycle (CPS immunized n=20, mock 
immunized n=19). E) Total AUC comparing mock and CPS immunized mice receiving heterologous 
or homologous mosquito bite challenge. Data are presented as Mean ± SEM, A-D Mann-Whitney test 
per time point E) Kruskal Wallis with Dunn’s multiple comparisons test *p≤0.05, **p≤0.01, ***p≤0.001.
than heterologous immunity. In this experiment, CPS immunization reduced 
total AUC by 25-fold following homologous challenge, as compared to 6-fold 
following heterologous challenge (Figure 5E). Nevertheless, CPS immunization 
elicits blood-stage protection against a robust heterologous challenge with the 
genetically distinct, and more virulent, CB strain of P. chabaudi.
Extended exposure to blood-stage parasites elicits robust pre-erythrocytic 
immunity
Blood-stage parasites appear to be both the source and target of protection 
following CPS immunization with P. chabaudi AS infected mosquito bites. It was 
shown that immunization with serially blood passaged P. yoelii parasites and 
prophylactic chloroquine treatment can elicit pre-erythrocytic immunity38. We 
wanted to assess whether blood-stage parasites have the potential to induce 
pre-erythrocytic protection also in the context of mosquito transmission. We 
therefore asked whether a fulminant blood-stage infection could elicit cross-stage 
immunity against pre-erythrocytic parasites. We infected mice with P. chabaudi 
AS by mosquito bite or ip injection of recently mosquito transmitted blood-
stage parasites. The two groups of mice were not drug-treated, and therefore 
experienced a low-grade chronic, recrudescing blood-stage infection for up to 90 
days37. After mosquito bite challenge, both groups of mice demonstrated reduced 
liver parasite burden (up to 85%), compared to infection controls (Figure 6). 
Cross-stage immunity is therefore a powerful mechanism for protection against 
pre-erythrocytic parasites, which may be absent during CPS immunization with 
small sporozoite numbers as the blood-stage infection is curtailed by the use of 
chloroquine.
CPS immunization elicits heterologous blood-stage immunity
CPS immunization has so far not been shown to induce protection against 
challenge with genetically distinct strains of Plasmodium; a situation that would 
be encountered in human malaria-endemic areas. The genetic diversity amongst 
strains of P. chabaudi20,21 allows us to investigate heterologous immunity in this 
model of CPS immunization. Mice that were CPS immunized with P. chabaudi AS 
infected mosquito bites had reduced peak parasitemia, and blood-stage parasites 
were cleared faster, when compared to mock immunized mice after homologous 
(P. chabaudi AS) and heterologous (P. chabaudi CB) mosquito-bite challenge 
(Figure 5A-D). A direct comparison between P. chabaudi AS and CB challenge 
revealed nonetheless that homologous blood-stage immunity is more effective 
Figure 5  |  CPS immunization elicits heterologous blood-stage immunity 
(for legend see next page)
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Discussion 
Timing, route of infection and antigen dose play major roles in determining the 
initial priming of the antimalarial immune response38-42. We incorporated many of 
these aspects from human clinical trials15-17 in a new P. chabaudi mouse model of 
CPS immunization to investigate the stage- and strain-specificity of CPS-induced 
protection against malaria. Our results highlight the complexity of immunity against 
the different life-cycle stages of the malaria parasite (Table 1). Pre-erythrocytic 
immunity appears to depend on the number of immunizing sporozoites. Here 
we find no evidence of pre-erythrocytic immunity after CPS immunization with P. 
chabaudi infected mosquito bites, which inoculate an estimated maximum of 100 
sporozoites per immunization19,37. Sterile pre-erythrocytic protection was however 
reported in human CPS immunization trials15-17. Anopheles stephensi mosquitoes 
experimentally infected with P. falciparum 3D7 or NF54 habor 50-200 times more 
sporozoites in their salivary glands17 compared to P. chabaudi AS19. However, 
only few sporozoites are injected into the skin during mosquito bite and this 
number is independent of salivary gland sporozoites load33-35. Since the number 
of sporozoites establishing a liver-stage infection can further be influenced by 
inherent sporozoite infectivity43, our best estimate of immunizing sporozoite dose 
is the number of infected erythrocytes observed directly after egress from the liver. 
Assuming that 10,000 merozoites are released from one infected liver cell44 we 
estimate approximately 400 infected hepatocytes (95% CI 137-1250) in human 
volunteers17 compared to 5 in P. chabaudi AS immunized mice (95% CI 1-31). 
Therefore the number of infected hepatocytes after CPS immunization by mosquito 
bite in the P. chabaudi mouse model is approximately 100-fold lower than in CPS 
immunized humans. We show that this differences in infected hepatocyte numbers 
by a factor of 100 can be significant for the development of pre-erythrocytic 
immunity: Three immunizations with 10,000 P. chabaudi sporozoites iv induces 
long-lasting protection against mosquito bite challenge, while three immunizations 
with 100 P. chabaudi sporozoites fails to do so. This is in general agreement with 
other rodent malaria studies using P. berghei22-26,31 or P. yoelii27-30, in which sterile 
pre-erythrocytic immunity is observed after immunization with high sporozoite 
doses (typically 10,000-50,000 sporozoites per immunization), while a reduction 
in sporozoite dose or the number of immunizations leads to breakthrough blood-
stage infections upon challenge27,29. Reduction of the number of P. falciparum 
infected mosquitoes also reduces the frequency of sterilely protected volunteers16, 
indicating that the number of sporozoites establishing a liver-stage infection fails 
to surpass the protective threshold to elicit sterile pre-erythrocytic immunity. 
Figure 6  |  Extended blood-stage parasitemia 
elicits pre-erythrocytic immunity
Mice received a first infection with P. chabaudi 
AS either by mosquito bite (Bite) or ip injection 
of 10,000 parasitized erythrocytes obtained 
from a donor mouse infected by mosquito 
bite (Blood (MT)). Blood-stage parasitemia 
was self-cured before challenge (C; 98 days 
post-infection) using P. chabaudi AS infected 
mosquito bites. Liver parasite burden was 
determined 42h after mosquito bite challenge 
as copy number of P. chabaudi-specific 18S 
rRNA. Data are displayed relative to the mean 
of corresponding liver parasite burden of 
naïve infection controls (-). Pooled data from 
2 independent experiments (Naïve (-) and Bite 
n=30, Blood (MT) n=20) are presented as Mean 
± SEM, Kruskal Wallis with Dunn’s multiple 
comparisons test *p≤0.05, ***p≤0.001.
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immunized volunteers compared to infection controls after direct blood challenge17. 
It will be of value to investigate whether the observed blood-stage protection in 
this mouse model is also detected in CPS immunized primates, where a longer 
blood-stage infection than that allowed in human clinical trials is possible.
Despite the reduced peak parasitemia and faster clearance of blood-stage 
parasites during the acute phase of infection in CPS immunized mice, recrudescent 
parasitemia could still be observed in the chronic phase of infection after challenge, 
suggesting a parasite variant escapes the protective immune response52. There 
are very few reports on protective efficacy of CPS immunization (or indeed 
any sporozoite-based vaccine) against direct blood-challenge27-29. Doll et al.30 
reported that sustained, subpatent blood-stage infection after treatment with a 
commonly used dose of chloroquine can induce partial blood-stage protection. 
Low-grade transient blood-stage parasitemia, achieved by attenuation of blood-
stage parasites using an antimalarial drug40,49, a DNA alkylating agent53 or genetic 
tools54,55 similarly provides protection against homologous and heterologous 
blood-stage challenge.
We could show that CPS-induced blood-stage immunity is effective against 
heterologous mosquito bite challenge with a more virulent and genetically distinct 
strain of P. chabaudi20,56. In agreement with the observed cross-species protection 
after CPS immunization with mefloquine29, and one study using chemically 
attenuated sporozoites for immunization57, heterologous protection is less effective 
than homologous immunity. Nevertheless, CPS immunization can elicit long-lived 
protection against both homologous and heterologous blood-stage parasites, 
which will be important to minimize disease severity in the case of breakthrough 
blood-stage infections. This is essential for the development of an effective multi-
stage malaria vaccine12,14.
In stark contrast to the observed heterologous blood-stage protection after 
mosquito bite challenge infection, protection was almost completely abrogated 
following direct blood-challenge with virulent parasites obtained after continuous 
serial blood passage. This suggests that blood-stage parasites immediately after 
mosquito transmission express antigens not present on serially blood passaged 
parasites and that these antigens may be the target of protective immunity following 
CPS immunization. Serially blood passaged parasites can hence escape from 
CPS-induced blood-stage immunity. One group of Plasmodium genes, whose 
expression is altered by mosquito transmission during blood-stage infection is 
the Plasmodium interspersed repeat gene family (pir); termed cir in P. chabaudi58. 
Transcription of more than half of all cir genes is increased in blood-stage parasites 
This may also explain why in malaria-endemic areas pre-erythrocytic immunity 
is thought to be absent45. In addition to maximizing specific responses against 
immunodominant antigens, CPS immunization with high numbers of sporozoites 
may broaden the immune repertoire by including protective responses against 
subdominant antigens, which could enhance heterologous pre-erythrocytic 
protection46. This may further be enhanced by the longer liver-stage development 
of P. falciparum (egress 6.8 days after mosquito bite47) compared to P. chabaudi 
(egress after 52h18). Longer liver stage development may positively influence the 
generation of pre-erythrocytic immunity by allowing time for protective immune 
responses to develop.
A key feature of CPS immunization is that it permits exposure to all Plasmodium 
life-cycle stages in the vertebrate host, including parasitized erythrocytes. It is well 
known that repeated exposure to blood-stage parasites, for example in rodent 
models39,40,48, in humans exposed to ultra-low doses of parasitized erythrocytes 
while receiving drug treatment49, during malaria-therapy of neurosyphilis patients50, 
and in people living in malaria-endemic areas51, induces blood-stage immunity. Our 
results also clearly show that during CPS immunization repeated transient blood-
stage infection (less than 0.01% parasitemia for 48-72 hours) elicits long-lasting 
blood-stage immunity. Protection against challenge infection was only apparent 
after multiple erythrocytic replication cycles and patent blood-stage parasite 
densities, which could indicate that blood-stage protection was not observed in 
CPS immunized human volunteers after direct blood-challenge because drug 
treatment is required at low parasite densities as soon as patency is reached 
(typically between the 3rd and 4th erythrocytic cycle17). Blood-stage parasites are 
however recognized in human volunteers, which was demonstrated by an earlier 
increase of IFNγ and monokines induced by IFNγ (MIG) concentrations in CPS 
Table 1  |  Relationship between the dose of immunizing pre-erythrocytic and blood-stage 
parasites and the acquisition of immunity
Low dose High dose
Sporozoites 
(Liver-stage parasites)
Mosquito bite or 100 sporozoites iv:
→ No pre-erythrocytic immunity 
Figure 3A/B
10,000 sporozoites iv:
→ Pre-erythrocytic immunity 
Figure 3B
Blood-stage parasites Blood-stage infection curtailed by 
chloroquine:
→ Partial blood-stage immunity 
Figure 4
Fulminant, self-cured blood-stage 
infection:
→ Blood-stage immunity [37]
→ Pre-erythrocytic immunity
Figure 6
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after mosquito transmission compared with their transcription after serial blood 
passage. This diversification of cir transcription is associated with a more effective 
host immune response, which in turn attenuates parasite virulence37. The cir 
genes could also be candidate targets for cross-stage immunity, as P. berghei 
pir genes are also transcribed during the liver stages (personal communication 
B.M. Franke-Fayard and C.J. Janse, Leiden University Medical Center, The 
Netherlands). An investigation into shared PIR proteins between liver and blood-
stage parasites may hence provide valuable information for multi-stage malaria 
vaccine development. Furthermore absence of blood-stage protection in previous 
CPS models may have been due to challenge with serially blood passaged rather 
then recently mosquito transmitted blood-stage parasites. It is therefore always 
essential to evaluate blood-stage immunity in the context of mosquito transmission.
As shared antigenic targets between liver- and blood-stage parasites have been 
described59, the exciting possibility of cross-stage protection has been considered 
but only rarely assessed. Genetically modified fabb/f- sporozoites that arrest late 
in liver-stage development protect against iv challenge with 100 blood-stage 
parasites60. On the other hand, a blood-stage infection with serially blood passaged 
P. yoelii, drug-treated with chloroquine after 4-5 days, reduces liver parasite load 
upon iv challenge with 35,000 sporozoites38. In our model of CPS immunization 
by mosquito bite it is likely that repeated transient blood-stage infection during 
immunization elicits the observed blood-stage protection, although we cannot 
yet exclude that responses acquired against pre-erythrocytic antigens, which are 
shared with blood-stage parasites59, contribute as well. Because of the low number 
of infected hepatocytes after CPS immunization with P. chabaudi infected mosquito 
bites this seems however unlikely. Nevertheless, we demonstrate unequivocally 
that extended exposure to blood-stage parasites is an effective stimulator of pre-
erythrocytic immunity. Exposure to blood-stage parasites during CPS immunization 
may thus significantly contribute to the observed pre-erythrocytic protection in 
human volunteers15-17. Indeed, cross-stage immunity could be responsible for the 
unprecedented efficacy of CPS immunization compared to immunization with 
irradiated sporozoites10,11, which arrest early during liver-stage development and 
never establish a blood-stage infection. While extending exposure to replicating 
blood-stage parasites by delayed drug administration is not possible in humans, 
the incorporation of chemically53 or genetically54,55 attenuated blood-stage parasites 
should be considered to further enhance the generation and maintenance of both 
pre-erythrocytic and blood-stage immunity. This makes CPS immunization a 
powerful tool for the development of an effective multi-stage malaria vaccine.
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Supplementary Figure 1  |  Chronic blood-stage infection in CPS immunized mice
Naïve infection controls or mice that were CPS immunized three times (i1, i2, i3) using chloroquine 
(CQ) and P. chabaudi AS infected mosquito bites were challenged (C) by ip injection of 100,000 
parasitized erythrocytes derived from a mosquito bite initiated infection 100 days later. Parasitemia 
was evaluated by thin blood film for 96 erythrocytic cycles. Different colors represent individual CPS 
immunized mice (n=8), naïve infection controls are presented in grey with dashed lines (n=6). The limit 
of detection by thin blood film is 0.01% parasitemia (1 parasite in 10,000 erythrocytes or 1,000,000 
parasites per ml blood).
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Introduction
Malaria remains a major global-health burden leading to widespread morbidity 
and mortality, which is mainly caused by Plasmodium falciparum1. Apicomplexan 
Plasmodium parasites have a complex multi-stage life-cycle, initiated by 
anopheline mosquitoes depositing sporozoites into the skin of the vertebrate host, 
which then migrate to the liver where they establish a clinically silent infection 
of hepatocytes. After maturation, merozoites egress from hepatocytes into the 
blood stream where they invade and cyclically replicate within erythrocytes. 
During blood-stage infection, clinical pathology becomes apparent and can be 
severe. A safe, affordable and effective vaccine to supplement other intervention 
strategies would dramatically benefit public health2, but remains elusive in spite of 
immense time and money investment3, also due to our incomplete understanding 
of protective immunity4.
Malaria subunit vaccine development has thus far yielded disappointing 
results; RTS,S being the only one ever tested in Phase III clinical trials. This 
circumsporozoite protein (CSP)-based vaccine showed an encouraging 50% 
sterile protection in malaria-naive adult volunteers5, but only reduced clinical and 
severe disease by 30-45% in children in malaria endemic areas6,7. In contrast, 
using whole sporozoites as immunogens has the potential to 100% sterilely protect 
humans against malaria in experimental settings. These regimens often use 
irradiation-attenuated sporozoites, that cannot complete liver-stage development8. 
Twenty times more efficient than immunization with irradiated sporozoites, which 
requires bites by 1,000 mosquitoes9 or at least 5 intravenous (iv) injections of 
135,000 sporozoites for sterile protection10, is immunization with fully infectious 
wild-type sporozoites delivered by mosquito bites combined with chloroquine 
chemoprophylaxis (Chemoprophylaxis and sporozoites, CPS). CPS immunization 
provides sterile and long-lasting protection 11,12 against pre-erythrocytic parasites 
(sporozoites and liver-stages)13. One potential reason for this unprecedented 
efficiency is the fact that in contrast to irradiation, chloroquine does not affect 
pre-erythrocytic parasite development14, but only kills the pathogenic erythrocytic 
stage. CPS immunization is therefore an invaluable tool to systematically delineate 
mechanisms of protective immunity to malaria.
Antibodies play a critical role in preventing infection by a large range of 
pathogens15. Immediately after antigen encounter, antibodies are produced by 
short-lived plasma cells16. Long-term humoral immune memory, however, is 
only acquired if in addition both long-lived antibody-producing plasma cells and 
memory B cells (MBC) are generated16-18. MBC are activated upon antigen re-
Abstract
Background
Immunization of healthy volunteers under chemoprophylaxis with Plasmodium 
falciparum sporozoites (CPS immunization) induces sterile protection from malaria. 
Antibody responses are long known to contribute to naturally acquired immunity 
against malaria, but their association with sterile protection after whole sporozoite 
immunization is not well established. We therefore studied the induction and 
kinetics of malaria antigen-specific antibodies and memory B cells (MBC) during 
CPS immunization and their correlation with protection from challenge infection.
Methods
We assessed humoral reactivity to nine antigens representing different life-cycle 
stages of the malaria parasite by performing standardized MBC ELISpot and 
ELISA on peripheral blood mononuclear cells and plasma samples from 38 Dutch 
volunteers enrolled in two randomized controlled clinical trials (NCT01236612, 
NCT01218893).
Results
MBC and antibodies recognizing pre-erythrocytic and cross-stage antigens were 
gradually acquired during CPS immunization. The magnitude of these humoral 
responses did not correlate with protection, but directly reflected parasite exposure 
in CPS immunization and challenge. 
Conclusions
Humoral responses to the malarial antigens circumsporozoite protein, liver-stage 
antigen-1, apical membrane antigen-1 and merozoite surface protein-1 do not to 
predict protection from challenge infection, but can be used as sensitive marker 
of recent parasite exposure.
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Materials and Methods
Human ethics statement
Both clinical trials, from which samples for this study were obtained, received 
approval by the Central Committee for Research Involving Human Subjects of 
The Netherlands (Study A, NL34273.091.10, Study B, NL33904.091.10) and 
were registered at ClinicalTrials.gov, number NCT01236612 (Study A) and 
NCT01218893 (Study B). The study team complied with the Declaration of Helsinki 
and Good Clinical Practice including monitoring of data. Volunteers enrolled in 
both studies provided written informed consent.
Clinical trial design
To determine the generation of malaria-specific MBC and antibody responses 
in CPS immunized and in primary infected individuals, we utilized peripheral 
blood mononuclear cell (PBMC) and plasma samples from two single-center 
randomized controlled clinical trials (Figure 1). In Study A13, volunteers received 
bites from 15 P. falciparum-infected mosquitoes on three occasions, which was 
previously shown to sterilely protect from mosquito challenge11,12, and were 
subjected to challenge with mosquito bites or parasitized erythrocytes injected iv. 
Study B20 was a CPS immunization dose de-escalation study where volunteers 
were immunized thrice with bites from either 15 (3x15), ten (3x10) or five (3x5) 
P. falciparum-infected mosquitoes. All immunized and control subjects in this 
study were subjected to mosquito challenge. This study set-up allowed us to 
longitudinally assess humoral responses in healthy, previously malaria-naïve, 
adult volunteers before and after exposure to different P. falciparum life-cycle 
stages in the context of CPS immunization, in the presence of prophylactic drug 
levels, as well as after challenge infection. After challenge, sterile protection was 
defined as the absence of thick smear-detectable parasitized erythrocytes until 
21 days post challenge. Volunteers who did show parasites by thick smear were 
immediately treated with antimalarial drugs, and all remaining volunteers received 
a presumptive drug-treatment 21 days after challenge. Importantly, the amount of 
exposure to blood-stage parasites during both immunization and challenge was 
characterized for each volunteer retrospectively by quantitative RealTime (qRT) 
PCR. For further details about study groups, outcomes and sample collection see 
supporting information.
encounter and rapidly develop into new antibody-producing cells that replenish 
the plasma cell pool17. In malaria, antibodies are mainly known for their ability 
to control erythrocytic parasites, thereby contributing to clinical immunity19. Their 
possible contribution to sterile, pre-erythrocytic immunity is less well established. 
In the present study, we therefore investigated the generation of malaria-specific 
MBC and antibody responses in CPS immunized volunteers, and assessed their 
association with sterile protection from challenge infection. We found that the 
magnitude of these responses, predominantly directed against pre-erythrocytic 
and cross-stage antigens, does not predict sterile protection from challenge 
infection, but is a sensitive read-out for the degree and nature of antigen exposure 
during immunization.
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and recombinant human IL-10 to promote development of MBC into antibody 
secreting cells22. Antibody-secreting cells were then quantified by ELISpot 
analysis. Levels of malaria antigen-specific antibodies were determined in plasma 
as arbitrary units (AU) in relation to a pool of 100 sera from adults living in a highly 
endemic area in Tanzania by standardized enzyme-linked immunosorbent assay 
(ELISA)11. For a detailed description of both methods see supporting information.
Statistical Analysis
Data were analyzed using GraphPad Prism v6. Differences between two time 
points were analyzed by Wilcoxon matched-pairs signed rank test (two-tailed, 
non-parametric, paired). Unmatched data between two groups were analyzed by 
Mann-Whitney U test (two-tailed, non-parametric). Differences between more than 
two times points were analyzed by Friedman test with Dunn’s multiple comparison 
post-hoc test (two-tailed, non-parametric, paired). Differences between two or 
more different groups over time were analyzed by repeated measures, mixed 
model two-way ANOVA with Bonferroni post-hoc test. Correlations were analyzed 
by Spearman correlation (non-parametric). Significant differences are indicated 
by asterices; * (p<0.05), ** (p<0.01), *** (p<0.001), ns (not significant).
PBMC and plasma samples
PBMC were isolated by density centrifugation, cryopreserved at 107 cells/ml in 
fetal calf serum (FCS; Gibco)/10% DMSO (Merck) using Mr. Frosty freezing 
containers (Nalgene) and stored in vapor-phase nitrogen. Plasma samples were 
stored in aliquots at -20°C and re-thawed no more than twice.
Analysis of Memory B cell and antibody responses 
The generation of malaria-specific MBC was assessed by MBC ELISpot assay21. 
Cryopreserved PBMC were thawed and stimulated for five days with the lectin 
Pokeweed Mitogen, Staphylococcus aureus Protein A, TLR9 ligand ODN 2006, 
Figure 1  |  Study design
Samples from two clinical chemoprophylaxis and sporozoites (CPS) immunization trials were 
analyzed. In Study A, volunteers were immunized three times with bites of 15 Plasmodium falciparum-
infected mosquitoes every 4 weeks, while receiving a prophylactic regimen of the antimalarial drug 
chloroquine (grey box). For challenge infection 21 weeks after the last immunization (17 weeks 
after final chloroquine dose), immunized volunteers were split into two groups receiving either P. 
falciparum-parasitized erythrocytes or bites from 5 infective mosquitoes. Plasma and peripheral blood 
mononuclear cells (PBMC) were sampled prior to immunization (D0), one day before challenge (C-1) 
and 35 days after challenge (C+35). In Study B, three different immunization groups were exposed 
to bites from 3 times 15 (3x15), 10 (3x10) or 5 (3x5) P. falciparum-infected mosquitoes in 4-week 
intervals whilst receiving chloroquine prophylaxis. All groups were challenged 19 weeks after the last 
immunization (15 weeks after the last chloroquine dose) with 5 P. falciparum-infected mosquito bites. 
Plasma and PBMC samples were collected prior to immunization (D0), 28 days after the first (i1), 
second (i2) and third (i3) immunization, one day before challenge (C-1) and 35 days after challenge 
(C+35). 
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Figure 2  |  Antibody 
responses against 
antigens representing 
different life-cycle stages 
of the malaria parasite
Antibody responses 
were determined before 
immunization (D0) and 19 
to 21 weeks after the last 
CPS immunization (C-1) for 
volunteers immunized three 
times with bites from 15 
infected mosquitoes (n=14 
from Study A and n=5 from 
Study B). Responses are 
expressed as arbitrary units 
(AU) for malaria antigens 
representing different 
life-cycle stages of P. 
falciparum in the human host 
(schematically represented 
by illustration on the left): 
A) CSP and LSA-1 are 
expressed in pre-erythrocytic 
stages, B) while EXP-1, 
TRAP, MSP-1 and -2 and 
GLURP are present in liver 
and blood-stage parasites 
and C) EBA175 is exclusively 
expressed in P. falciparum 
infected erythrocytes. For 
Study B, responses were 
assessed for CSP, LSA-1, 
AMA-1 and MSP-1 only. 
Data are presented as 
ladder plots, with each dot 
representing an individual 
volunteer and dotted lines 
connecting values before 
and after immunization 
for each volunteer. The 
black line represents assay 
background levels (upper 
99% Confidence interval of 
the mean of >40 malaria-
naive samples tested). 
Differences between D0 and 
C-1 were analysed using 
Wilcoxon matched-pairs 
signed rank test. Significant 
differences are indicated 
by asterices * (p<0.05), ** 
(p<0.01), *** (p<0.001), ns 
(not significant).
Results
Humoral responses against pre-erythrocytic and cross-stage malaria 
antigens are induced by CPS immunization
Malaria-specific antibody and MBC responses induced by the highest dose 
regimen of CPS immunization (bites from 3x15 infected mosquitoes, Study A and 
Study B, Figure 1) were analyzed for nine P. falciparum antigens representing 
either the pre-erythrocytic or the erythrocytic part of the Plasmodium life-cycle. 
circumsporozoite protein (CSP) and liver-stage antigen (LSA)-1 are exclusively 
expressed by sporozoites and liver-stage parasites, whereas most proteins 
including exported protein (EXP)-1, thrombospondin related anonymous protein 
(TRAP), the merozoite surface proteins (MSP)-1 and -2, apical membrane antigen 
(AMA)-1 and glutamate rich protein (GLURP), are most highly abundant in blood-
stage parasites but are also expressed in late liver-stages (cross-stage antigens). 
Erythrocyte binding protein (EBA)-175 on the other hand is only expressed in 
blood-stage parasites. Nineteen to 21 weeks after the last CPS immunization 
(day before challenge: C-1, Figure 1) high antibody titers to the pre-erythrocytic 
antigens CSP and LSA-1, but no antibodies to the erythrocytic antigen EBA175 
were detectable (Figure 2A and C). Antibodies for the cross-stage antigens EXP-
1, MSP-1 and MSP-2 were induced, whereas no significant induction of AMA-1, 
GLURP and TRAP antibodies was observed (Figure 2B). All immunized volunteers 
developed CSP-specific antibodies (above group-background), and antibodies 
were detectable in 74% of volunteers for LSA-1. Over half (53%) of the volunteers 
had MSP-1-specific antibodies above background after CPS immunization, while 
42% developed antibodies against EXP-1 and 37% against MSP-2. Immunization 
also gave rise to CSP-specific MBC in 95% of volunteers, and 42% of volunteers 
also developed MSP-1-specific MBC, while no MBC specific for any other selected 
antigen were observed (data not shown). 
In the absence of parasite exposure antimalarial antibody responses 
contract, but memory B cells are maintained
We next studied the kinetics of acquisition of antibody and MBC responses to 
the strongest recognized antigens, CSP and MSP-1 over the course of CPS 
immunization (Study B, Figure 1). CSP- and MSP-1-specific antibody responses 
increased step-wise after the first, second and third immunization (Figure 3A). 
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The magnitude of CPS-induced humoral responses is a sensitive read-out 
of parasite exposure, but does not predict sterile protection
An important question is whether the magnitude of CPS-induced humoral 
responses to the antigens investigated reflects the degree of parasite exposure 
and whether they are predictive of sterile protection from challenge infection. 
We therefore compared immune responses in volunteers who received different 
immunization doses (Study B, Figure 1), and were subsequently either sterilely 
protected or not from mosquito challenge.
In volunteers protected from mosquito bite challenge, there was a trend for higher 
antibody responses to CSP with increasing amounts of immunizing infectious 
mosquito bites, consistent with the different doses of pre-erythrocytic parasites 
experienced (Figure 4A). CPS immunization with different numbers of infectious 
mosquito bites also lead to a different amount of blood-stage exposure measured 
by qRT PCR after the first immunization (Figure 4B). This is consistent with the 
dose-response relation for completed pre-erythrocytic and early erythrocytic 
development, which is in turn reflected in the induction of MSP-1 antibodies 
(Figure 4A). Blood-stage parasitemia was reduced after the second and 
completely absent after the third CPS immunization in volunteers subsequently 
sterilely protected from mosquito challenge (Figure 4B).
In the group receiving the lowest immunization dose (bites of 3x5 mosquitoes), 
half of the volunteers were unprotected from mosquito challenge. Unprotected 
volunteers had significantly higher antibody responses after the third immunization 
against both CSP and MSP-1 compared to protected volunteers receiving the 
same number of immunizing mosquito bites (Figure 4C). This was probably the 
result of the greater parasite exposure during the second and third immunization, 
reflected by the significantly higher blood-stage parasitemia compared to protected 
volunteers (Figure 4D).
Across all immunized volunteers in this dose de-escalation trial (Study B, Figure 
1), magnitudes of CSP and MSP-1 antibody responses after the third immunization 
correlated with the cumulative blood-stage parasitemia to which volunteers were 
exposed over the course of the three immunizations (Figure 4E).
These data clearly demonstrate that the magnitude of the humoral response 
against CSP, LSA-1, AMA-1 and MSP-1 after CPS immunization does not predict 
protection from challenge infection, but accurately reflects parasite exposure (both 
the number of infectious mosquito bites and amount of blood-stage parasitemia) 
during CPS immunization.
Antibody responses peaked after the third immunization, but then contracted in 
the following 15 weeks until C-1 (Figure 3A). Importantly, a different pattern was 
observed for the acquisition of MBC (Figure 3B): CSP- and MSP-1-specific MBC 
were also acquired in a stepwise fashion during CPS immunization, but for the 
majority of volunteers did not contract after the third immunization in the absence 
of parasite exposure, but instead remained stable or even increased over the more 
than 4 months until C-1. These patterns of CSP- and MSP-1-specific antibody and 
MBC acquisition were seen irrespective of immunization dose (Figure 4A and 
data not shown).
Figure 3  |  Acquisition kinetics of antimalarial antibody and memory B cell responses
Antibody (A; in arbitrary units (AU)) and MBC responses (B; presented as % antigen-specific MBC of 
total IgG+ MBC) for CSP and MSP-1 were analyzed 28 days after the first (i1), second (i2) and third (i3) 
immunization and 19 weeks after i3 (C-1) for all CPS immunized volunteers of Study B (n=24). Data 
were corrected for the volunteers own background response at D0 and are presented as ladder plots, 
each dot representing an individual volunteer, and dotted lines connecting the different time points 
for each volunteer. Differences between the time points were analyzed by Friedman test with Dunn’s 
multiple comparison post-hoc test. Significant differences are indicated by asterices: * (p<0.05), ** 
(p<0.01), *** (p<0.001).
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Boosting of humoral responses by challenge infection reflects exposure to 
different P. falciparum life-cycle stages.
Humoral immune responses acquired during CPS immunization were boosted 
dependent on parasite exposure by different challenge regimens and protection 
status (Figure 5 and Table S1). A total of 22 immunized volunteers across both 
clinical trials were protected from mosquito challenge (Study A and B, Figure 
1). Since they did not develop blood-stage parasitemia, these volunteers were 
only exposed to pre-erythrocytic parasites13. In line with this, antibody and 
MBC responses specific for CSP were boosted in these volunteers (Figure 5A 
and Table S1), but not responses specific for cross-and blood-stage antigens 
analyzed (Table S1). One volunteer, however, who was classified as protected 
from mosquito challenge by absence of thick smear-detectable parasites, was 
retrospectively found to have developed qRT PCR-detectable parasitemia (457 
parasites/ml) at day 21 post-challenge just prior to presumptive drug-treatment13. 
This small exposure to blood-stage parasites was sufficient to induce a strong 
boost of MSP-1-specific antibody responses (white triangle in Figure 5A).
Seven CPS immunized volunteers were unprotected and thus experienced blood-
stage parasitemia (as well as pre-erythrocytic parasites) after mosquito bite 
challenge infection (Study B, Figure 1). In line with exposure to a broad array of 
antigens, we found that antibody responses to the pre-erythrocytic antigens CSP 
and LSA-1 and the cross-stage antigens AMA-1 and MSP-1, as well as MBC 
responses to CSP, AMA-1 and MSP-1 were boosted in these volunteers (Figure 
5B and Table S1).
Furthermore a group of nine CPS immunized volunteers was subjected to and 
Figure 4  |  Influence of parasite exposure during immunization on magnitude of the antibody 
response and protection status (see previous page)
A/B CPS immunized volunteers of Study B protected from mosquito challenge (MC), receiving either 
3x5 (white, n=5), 3x10 (yellow, n=8) or 3x15 (orange, n=4) bites from infectious mosquitoes during 
immunization. A) CSP and MSP-1-specific antibody levels (in arbitrary units (AU)) and B) blood-stage 
parasitemia (expressed as number of parasitized erythrocytes per ml blood (pE/ml, determined by 
quantitative RealTime PCR) were analyzed 28 days after first (i1), second (i2) and third (i3) CPS 
immunization. C/D 3x5 CPS immunization resulted in either protection from subsequent MC (white, 
n=5) or not (purple, n=5). C) CSP and MSP-1-specific antibody (in AU) and D) erythrocytic parasitemia 
(in pE/ml) 28 days after i1, i2 and i3 are displayed. E) Correlation between CSP and MSP-1 antibody 
responses (in AU) 28 days after immunization 3 and cumulative parasitemia (in pE/ml) over the course 
of all CPS immunizations for all Study B volunteers. All antibody-responses were corrected for the 
volunteers own background response at D0 and are presented as individual values (dots) and whisker 
box plots (box: median with 10-90 percentile; whiskers: min to max) and individual values (dots). 
Differences between groups over time were analyzed by repeated measures, mixed model two-way 
ANOVA with Bonferroni post-hoc test. Significant differences are indicated by asterices: * (p<0.05), ** 
(p<0.01), *** (p<0.001). Correlation was analysed by Spearman coefficient (r).
Figure 4  |  Influence of parasite exposure during immunization on magnitude of the antibody 
response and protection status (for legend see next page)
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Discussion
In this study we provide the first comprehensive and side-by-side analysis of the 
kinetics and specificity of antibody and MBC responses generated in humans by 
CPS immunization and their association with sterile protection. We demonstrate 
that humoral responses, predominantly against pre-erythrocytic P. falciparum 
antigens, are efficiently generated in a stepwise fashion. The magnitude of these 
responses does not predict sterile protection from challenge infection, but is a 
sensitive marker of parasite exposure.
We show that CPS immunization induces strong humoral reactivity to pre-
erythrocytic (CSP and LSA-1) and cross-stage (MSP-1) antigens, which is 
consistent with exposure mainly to pre-erythrocytic parasite antigens during CPS 
immunization. Exposure to erythrocytic-stage parasites is limited by chloroquine 
in this immunization regime; hence no humoral responses against AMA-1, 
GLURP and EBA175, which are mainly expressed during the erythrocytic stages 
of the parasite, were detectable. This recognition profile is in line with data from a 
previous CPS immunization study, where antibody reactivity towards CSP, but not 
schizont lysate or GLURP was observed in most volunteers11. Furthermore CSP 
and LSA-1 were also identified as the two predominantly recognized antigens by 
P. falciparum protein-microarray of CPS immunized volunteers23.
The abundance of P. falciparum-specific antibodies and MBC after CPS 
immunization was associated with cumulative parasite exposure i.e. number of 
immunizations, immunization dose and blood-stage parasitemia experienced. 
Curiously, correlation of CPS-induced humoral responses with cumulative blood-
stage exposure during immunization was not only observed for MSP-1, which is 
expressed in erythrocytic parasites, but also for CSP, which is often considered 
a sporozoite-specific antigen. However, it was shown that CSP-expression is 
not confined to the sporozoite stage, but continues until the late stages of liver-
infection for P. falciparum24 as well as for the rodent parasites P. berghei and P. 
yoelii25,26. Since antibody responses are a sensitive reflection of parasite exposure, 
this indicates that in protected volunteers CPS-induced protective immunity is 
targeting early pre-erythrocytic stages (sporozoites or early liver-stage parasites), 
thus reducing the liver-parasite load. Hence there is shorter/less exposure to the 
pre-erythrocytic antigen CSP, leading to lower anti-CSP responses in protected 
compared to unprotected volunteers.
Antibody and MBC levels expanded gradually after the first, second and third 
CPS immunization, a kinetic seen independently of the level of parasite exposure 
during immunization. Antibody titers declined in the absence of parasite exposure 
not protected from injection of parasitized erythrocytes (Study A, Figure 1), and 
thus did not experience sporozoites and liver-stage parasites. Antibody responses 
specific for the cross-stage antigens AMA-1, EXP-1, GLURP, MSP-1, MSP-2 and 
TRAP were boosted, but no boosting effect was observed for pre-erythrocytic 
antigens (Figure 5C and Table S1).
Interestingly, a single MC of malaria-naïve controls from Study A and B also 
induced CSP- and MSP-1-reactive antibodies in 80 and 90% of volunteers, 
respectively (Table S2), albeit at lower levels than after MC of primed CPS 
immunized volunteers. In the majority of volunteers a single infection was not 
sufficient to induce a detectable MBC response.
Figure 5  |  Boosting of antibody levels in CPS immunized volunteers by challenge infection 
Antibody levels (in arbitrary units (AU)), corrected for volunteers own background at D0) for CSP 
and MSP-1 in immunized volunteers were determined prior to (C-1) and 35 days following challenge 
infection (C+35). Each dot represents an individual volunteer for which values before and after 
challenge are connected by a dotted line. CPS immunized volunteers were grouped for analysis in: 
A) mosquito challenge (MC), protected (exposure to pre-erythrocytic parasites only), n=5 volunteers 
from Study A and n=17 volunteers from Study B; NOTE: White triangle: volunteer with qRT PCR 
detectable blood-stage parasitemia on day 21 post challenge. B) MC, unprotected (exposure to both 
pre-erythrocytic and blood-stage parasites), n=7 volunteers from Study B; C) blood-stage challenge 
(BC; exposure to erythrocytic parasites only), n=9 volunteers from Study A. Differences between time 
points were analyzed by Wilcoxon matched-pairs signed rank test. Significant differences are indicated 
by asterices with * (p<0.05), ** (p<0.01), *** (p<0.001).
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after challenge were not boosted. In turn, a lack of boosting of MSP-1-specific 
antibody responses after challenge infection may be used as an indicator of 
sterile pre-erythrocytic protection. Taken together, antibody and MBC responses 
observed in our study depended directly on the amount and life-cycle stage of 
parasite exposure during both CPS immunization and challenge. 
The immunodominant antigens in our study, CSP and MSP-1, induced antibodies 
in the majority of volunteers already after a single CPS immunization or mosquito 
bite infection, and can thus be used as markers of recent parasite exposure. 
Indeed, CSP antibodies can be used to assess P. falciparum transmission 
dynamics in a naturally exposed population36. However, although humoral 
immune responses during CPS immunization are efficiently generated, there 
was no association between the magnitude of humoral responses to CSP, LSA-
1, AMA-1 or MSP-1 or any combination of those antigens with protection from 
challenge infection. CSP-specific antibodies37,38 were originally suggested as the 
mechanism of protection following immunization with irradiated sporozoites and 
have driven the development of CSP-based malaria vaccine candidate RTS,S. 
However, despite inducing high CSP-specific antibody responses, that can 
protect human liver-chimeric mice against P. falciparum sporozoite challenge39, 
RTS,S only confers moderate protection against clinical and severe disease in 
children and infants in endemic areas6,7. The association of humoral responses 
against CSP with sterile protection therefore remains controversial40-43. Our results 
suggest that after whole sporozoite immunization under chemoprophylaxis, 
sterile pre-erythrocytic protection may be associated with recognition of novel, 
less immunodominant antigens. Encouragingly, a pilot protein-microarray study 
identified three novel antigens that were recognized exclusively by protected 
volunteers immunized with irradiated sporozoites42. Analysis of CPS immunization 
samples using an extended version of this protein-microarray will help to identify 
potential new protective antigens. Moreover, protection against malaria may not 
be associated with humoral responses to one antigen in isolation, but instead 
a panel of antigens44. In irradiated sporozoites-immunized volunteers, the 
cumulative response to 19 pre-erythrocytic antigens, rather than reactivity to an 
individual antigen, differentiated protected from unprotected volunteers42.
Finally, while the magnitude of individual or combined humoral responses does not 
predict protection, the actual functional capacity of the resulting antibodies could 
do so. We have recently shown that antibodies induced by CPS immunization can 
reduce sporozoites traversal through hepatocytes in vitro as well as liver-stage 
infection and development in vivo in human liver-chimeric mice45. However, even 
between immunization and challenge, likely due to the physiological contraction 
of short-lived plasma cell responses, whereas MBC levels were largely stably 
maintained or even increased further. That MBC are much more long-lived than 
quickly waning serological responses, was recently also reported in African 
children no longer exposed to malaria27. Furthermore, multigravid Ghanaian 
women showed a much stronger and faster MBC response to a pregnancy-
restricted P. falciparum erythrocyte membrane protein-1 than women in their first 
pregnancy, also indicating a successful generation and maintenance of humoral 
immune memory28. An intrinsic impairment in the generation of B cell memory as 
suggested previously in naturally malaria-exposed individuals29,30, is not apparent 
in our study.
Challenge infection strongly boosted antibody responses acquired during 
immunization. This suggests an efficient differentiation of MBC into antibody 
secreting cells upon antigen-re encounter, even in volunteers experiencing patent 
blood-stage parasitemia during challenge infection. Therefore, low-grade blood-
stage exposure during challenge infection in humans does not lead to an ablation 
of previously generated MBC or impaired survival of resulting antibody secreting 
cells, unlike previously shown for high erythrocytic parasitemias in rodent malaria 
models31,32.
Boosting of humoral responses to the different P. falciparum antigens was 
dependent on exposure to different parasite life-cycle stages during challenge. 
MC boosted pre-erythrocytic and cross-stage responses, while exposure to blood-
stage parasites boosted responses to cross-stage and erythrocytic antigens. Of 
note, the subunit vaccine candidate TRAP33, often classified as a pre-erythrocytic 
P. falciparum protein, was also increased by blood-stage exposure during 
challenge, strengthening reports of TRAP or TRAP-like proteins being expressed 
in erythrocytic parasites34,35. We consistently found that MSP-1 antibody responses 
were strongly boosted in every single immunized volunteer experiencing both full 
liver-stage and patent erythrocytic parasitemia during challenge infection. That 
an increase in MSP-1 antibody levels is a reliable read-out even for low-level 
blood-stage exposure following B cell priming, in this case by CPS immunization, 
was illustrated strikingly in our study: One volunteer (classified as protected by 
the absence of parasitized erythrocytes on thick smear), was retrospectively 
shown by qRT PCR to have had sub-patent blood-stage parasitemia13. This small 
exposure to few P. falciparum infected erythrocytes for one day only lead to a 
strong boosting of the MSP-1 antibody response. By contrast, MSP-1 antibody 
levels in volunteers with qRT PCR-confirmed absence of blood-stage parasitemia 
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antibodies from sterilely protected volunteers were not able to fully prevent liver-
stage infection45. In the dose de-escalation CPS immunization cohort, we have 
recently shown that sterile protection from challenge infection was associated with 
induction of higher levels of CD4 T cells with a cytotoxic phenotype (CD107a+)20. 
An integrated analysis of cellular and humoral responses both on antigen-
recognition and functional level in the same group of volunteers will be crucial to 
solve the question of a potential immune correlate of sterile protection.
In conclusion, CPS immunization induced antibody and MBC responses mainly 
against pre-erythrocytic and cross-stage antigens of P. falciparum. Despite their 
efficient acquisition, the magnitude of acquired humoral immune responses to the 
set of immunodominant malarial antigens analyzed in this study did not predict 
sterile protection from challenge infection. Instead it proved to be a sensitive 
read-out for the degree and nature of parasite-antigen exposure during both 
immunization and challenge. The magnitude of acquired antigen-specific humoral 
responses alone can therefore not be used as a surrogate marker of protective 
efficacy. Other readouts and assessing responses to novel antigens are hence 
necessary to predict protection.
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Supporting information
Materials and Methods
Clinical trial: study design and sample collection
Study A1
Fourteen CPS immunized volunteers were assigned to receive a challenge with 
P. falciparum-parasitized erythrocytes (blood-challenge BC; n=9) or a sporozoite 
challenge by infected mosquito bites (MC; n=5). Ten additional volunteers were 
assigned to two control groups for either BC (n=5) or MC (n=5) (Figure 1, Study 
A). CPS immunization was conducted with three times 15 mosquitoes (eight 
mosquitoes infected with P. falciparum strain NF54 and seven mosquitoes infected 
with P. falciparum 3D7 (clone of NF54)). Twenty-one weeks following immunization 
(17 weeks after discontinuation of chloroquine prophylaxis), all volunteers were 
subjected to a challenge infection. MC was performed by exposure to bites of 
five P. falciparum 3D7-infected mosquitoes. BC was conducted by intravenous 
administration of 1962 viable 3D7 P. falciparum-infected erythrocytes. All ten 
control subjects (MC and BC) and all nine immunized BC volunteers showed 
parasitized erythrocytes on thick smear and qRT PCR, whilst the five immunized 
MC volunteers remained thick smear negative until 21 days after challenge and 
were then presumptively drug-treated. 
Study B2
Twenty-nine volunteers were randomly assigned to four groups, three CPS 
immunization groups and one control group (Figure 1, Study B). CPS immunization 
was carried out using three different numbers of NF54-infected mosquitoes: Study 
subjects were subjected three times to bites of 15 infected mosquitoes (3x15; 
n=5), ten infected (and five uninfected) mosquitoes (3x10; n=9) or five infected 
(and ten uninfected) mosquitoes (3x5; n=10). Control subjects received bites from 
15 uninfected mosquitoes (n=5). Therefore, data from 29 challenged subjects 
were available for analysis. Nineteen weeks following immunization (15 weeks 
after discontinuation of chloroquine prophylaxis), all volunteers were subjected to 
a MC challenge infection by bites of five P. falciparum NF54-infected mosquitoes. 
All five control subjects developed blood-stage parasitemia, as detected by thick 
smear and qRT PCR. Of the 24 immunized subjects, sterile protection from MC 
challenge (defined as blood-stage parasite negative by thick smear until day 21 
after challenge) was observed in 4/5 volunteers in the 3x15 group, 8/9 in the 3x10 
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2.5µg/ml ODN 2006 (Type B CpG nucleotide-human TLR9 ligand; InvivoGen tlrl-
2006 5’-TCGTCGTTTTGTCGTTTTGTCGTT-3’) and 25ng/ml recombinant human 
IL-10 (PeproTech).
ELISpot assay
MultiScreen Filter PVDF Immobilon plates (MSIPS4510, Millipore) pre-treated with 
35% Ethanol were coated overnight at 4°C with 10µg/ml monoclonal antibodies to 
human IgG (clones MT91/145; Mabtech) or 4µg/ml of one of the malaria antigens 
(all dilutions in PBS). Plates were washed thoroughly and blocked with 1% bovine 
serum albumin (BSA; Sigma-Aldrich) in RPMI for 2h at 37°C. 4x105 mitogen-
stimulated PBMCs per well were seeded in quadruplicates into the malaria 
antigen-coated filter plates. Anti-IgG coated wells were seeded with 1200 or 4000 
cells/well. All time points for one volunteer were measured on the same plate. 
Filter plates were incubated for 6h at 37°C, 5% CO2. After washing, immobilized 
IgG antibody in the proximity of ASCs was detected using polyclonal goat anti-
human IgG (Fcg) alkaline phosphatase (1:1000 in PBST/0.5% FCS; Mabtech) 
overnight at 4°C. Plates were developed in the dark using alkaline phosphatase 
substrate BCIP/NBT (Mabtech), rinsed with water, left to dry and stored protected 
from light until reading using the CTL ImmunoSpot Reader (Cellular Technology 
Ltd.).
Background correction 
Since pre-culture B cell proportions (percentage of total PBMCs) and post-culture 
ASCs (per million PBMCs) were highly variable between donors (median with range 
5.97 % (1.12-18.32 %) and 31,792 (6625-138,125), respectively), we corrected for 
inter-individual differences by expressing malaria-specific MBCs as the percentage 
of total IgG+ MBCs. Group-background levels of MBCs were defined by upper 
99% confidence interval of the mean of all time points pre-malaria exposure of 
all involved volunteers (CSP=0.0054, LSA-1=0.01, TRAP=0.0084, AMA-1=0.01, 
EXP-1=0.008, MSP1=0.01, MSP-2=0.01, EBA175=0.007, GLURP=0.009). If 
indicated, MBC responses are presented after individual background correction 
for each volunteer by subtraction of the average number of spots counted for 
the specific antigen prior to malaria exposure (immunized individuals D0, control 
volunteers C-1).
group and 5/10 of the 3x5 group. The remaining seven CPS immunized subjects 
were not protected, but did show a mean delay of 2.5 days in prepatent period 
of blood-stage parasitemia by both thick smear and qRT PCR compared to the 
control subjects. Twenty-one days after challenge, all volunteers remaining thick 
smear negative were presumptively drug-treated.
Sample collection
Sampling of citrate anti-coagulated peripheral blood for immunological analysis 
was performed at different time points in Study A and Study B using CPT 
vacutainers (Becton Dickinson). In Study A, samples were available from D0 (pre-
immunization, before onset of chloroquine prophylaxis), day before challenge 
(C-1) and 35 days after challenge (C+35). In Study B, additional sampling was 
performed one month (28 days) after each of the three immunizations (Figure 1).
Malaria antigens
As representative for pre-erythrocytic antigens we assessed P. falciparum 
circumsporozoite protein (CSP) and liver-stage antigen 1 (LSA-1)3. Erythrocyte 
binding protein 175 (EBA175, purchased from Protein Potential, LLC (9800 
Medical Center Drive, Suite A209 Rockville, MD 20852)) on the other hand is only 
expressed in erythrocytic parasites. Most proteins, however, despite being most 
highly abundant in blood-stage parasites, are also are expressed in late liver-
stages (cross-stage antigen). The investigated cross-stage antigens were apical 
membrane antigen 1 (AMA-1)4,5, exported protein 1 (EXP-1)6, thrombospondin 
related anonymous protein (TRAP)7 and the 19 kDa C-terminal region of merozoite 
surface protein 1 (MSP-1)8 and 2 (MSP-2)9 as well as glutamate rich protein 
(GLURP)10.
Malaria antigen-specific memory B cell ELISpot assay 
Mitogen stimulation
The generation of malaria-specific memory B cells (MBCs) was assessed by MBC 
ELISpot assay11,12. Cryopreserved PBMCs were thawed and 1x106cells/ml in RPMI 
containing 10% FCS, 100U/ml penicillin/streptomycin, 100mM HEPES, 50mM 
2-β-Mercaptoethanol and 2mM L-Glutamine (all Invitrogen) were added to 25cm2 
cell culture flasks (Greiner). To promote development of MBCs into antibody-
secreting cells (ASCs), PBMC were stimulated for five days at 37°C and 5% CO2 
with 50ng/ml Pokeweed Mitogen derived from Phytolacca americana (Sigma-
Aldrich), 1:5000 Staphylococcus aureus Protein A, Cowan Strain (Sigma-Aldrich), 
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Measurement of malaria-specific plasma antibodies responses
ELISA
Concentrations of malaria antigen-specific antibodies were determined in citrate 
anti-coagulated plasma in relation to a pool of 100 sera from adults living in a 
highly endemic area in Tanzania (HIT serum13) by standardized enzyme-linked 
immunosorbent assay (ELISA). Polystyrene flat-bottom plates (NUNC™ Maxisorp, 
Thermo Scientific) were coated overnight at 4°C with 1µg/ml malaria antigen in 
PBS. After washing, plates were blocked with 3% BSA in PBS. Plasma samples 
were diluted in PBST/1% FCS and analyzed in duplicates. A four-point 1:2 dilution 
series was carried out for each sample. As a standard, duplicates of pooled HIT 
serum were included on every plate in a seven-point dilution series. The optimal 
dilution range was determined prior to the study for every antigen. All time points 
for one volunteer were measured on the same plate. Two-step detection was 
performed using biotinylated polyclonal goat anti-human IgG (Fcg) (Mabtech; 
1:1250) and streptavidin-conjugated horseradish peroxidase (HRP, Mabtech, 
1:2000). All incubation steps from blocking to detection were carried out for 1h at 
37°C in a humidified chamber. Plates were developed at room temperature using 
HRP substrate (Tetra-methyl-benzidine; tebu-bio); the reaction was stopped using 
0.2M H2SO4. Spectrophotometrical absorbance at 450nm was measured using 
the Anthos 2001 ELISA plate reader.
Analysis
The standard curve of HIT serum was plotted on a logarithmic scale and fitted to a 
power trend line (R2> 0.99), optical density (OD) measurements for each sample 
(average of duplicates that were no more than 15% different) were converted to 
arbitrary units (AU) in relation to HIT serum. For each antigen, undiluted HIT serum 
was defined to contain 100 AU of IgG directed against this antigen. Dilutions of 
test samples that did not fall within the linear part of the optical density range of 
the standard curve were excluded. Group-background levels (in AU) were defined 
by upper 99% confidence interval of the mean of all time points pre-malaria 
exposure of all involved volunteers (CSP=4.18, LSA-1=3.0, TRAP=5.25, AMA-
1=0.27, EXP-1=0.72, MSP1=1.6, MSP-2=0.45, EBA175=4.16, GLURP=2.42). If 
indicated, values for malaria antigen-specific antibody responses are presented 
after individual background correction by subtraction of the average number of AUs 
for each volunteer for the specific antigen prior to malaria exposure (immunized 
individuals D0, control volunteers C-1). 
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Introduction
Humoral immunity is crucial to combat many infections and to provide protection 
against re-infection and after vaccination. Primarily, antibodies are used as 
readouts for humoral immunity since they can be easily measured by enzyme-
linked immunoabsorbance assay (ELISA). Long-term humoral immune memory 
is, however, not only conveyed by antibody-producing long-lived plasma cells, but 
also relies on the efficient acquisition and maintenance of memory B cells (MBCs), 
who, upon antigen reencounter, can rapidly develop into antibody secreting cells 
(ASCs) to mount a strong secondary antibody response1. Circulating MBCs 
have low frequencies and are quiescent, i.e. do not secrete antibody. Two main 
methods addressing these challenges have been developed to quantify the 
magnitude of the circulating MBC response: Direct ex vivo quantification can 
be performed using flow cytometry upon labelling of MBCs with fluorescently 
labelled monomeric or tetrameric antigens2-4. Alternatively, MBC-secreted 
antibodies can be quantified (by Enzyme-linked ImmunoSpot assay (ELISpot) 
or ELISA) following a pre-activation step using mitogens to differentiate MBCs 
into ASCs5. This method is readily applicable to large numbers of samples and 
antigens (provided sufficient cells are available from each sample), without the 
need for fluorescent labelling, which can be challenging for individual antigens6. 
It has thus become the main readout used to measure antigen-specific MBCs 
in the context of infections, vaccinations or allergy6-12. A necessary underlying, 
but yet untested, assumption made when using the MBC ELISpot to quantify 
antigen-specific responses is that MBCs are differentiated into ASCs at a fixed 
ratio13. Antigen-specific MBC responses measured using this technique are 
either reported as the number of ASC per million post-culture peripheral blood 
mononuclear cells (PBMC), or as percentage of total ASCs. Expressing antigen-
specific cells as a proportion of ASC-differentiated MBC corrects for variation 
in both total MBC precursor frequencies and potential differences in expansion 
during mitogen-culture between donors. Reporting antigen-specific ASCs as 
per million post-culture PBMCs is mostly used to get insights into the absolute 
frequency of antigen-specific MBCs. This is done to also take into account inter-
individual variations in total MBC frequencies particularly when comparing across 
age groups12,13 that differ not just in their antigen-experience but also the size 
and composition of the (memory) B cell compartment12,14. This readout, however, 
does not correct for expansion and potential skewing of the MBC compartment 
during mitogen-culture. It is therefore important to know (i) whether B cells are 
indeed consistently expanded during mitogen-culture, (ii) which factors influence 
Abstract
The memory B cell (MBC) ELISpot assay is the main technique used to measure 
antigen-specific MBCs as a readout of humoral immune memory. This assay relies 
on the ability of MBCs to differentiate into antibody-secreting cells (ASCs) upon 
polyclonal stimulation. The total number of IgG+ ASCs generated by mitogen-
stimulation is often used as a reference point; alternatively antigen-specific MBCs 
are expressed as a frequency of post-culture peripheral blood mononuclear cells 
(PBMC) as a surrogate for absolute frequencies. Therefore, it is important to know 
whether IgG+ B cells are uniformly expanded during the preceding mitogen-culture 
as a true reflection of MBC frequencies ex vivo. We systematically compared B cell 
phenotype and proportions before and after mitogen-stimulation in cultures of 269 
peripheral blood mononuclear cell samples from 62 volunteers by flow cytometry 
and analyzed the number of resulting ASCs. Our data show that the number of 
total IgG+ ASCs detected by ELISpot after mitogen-stimulation correlates with 
the proportion of IgG+ MBCs ex vivo, highlighting its general robustness for 
comparisons of study cohorts at group level. The expansion of total and IgG+ 
B cells during mitogen-stimulation, however, was not identical in all cultures, 
but influenced by size and composition of the ex vivo B cell compartment. The 
uncorrected readout of antigen-specific MBCs per million post-culture PBMCs 
therefore only preserves the quality, but not the magnitude of differences in the ex 
vivo MBC response between groups or time points, particularly when comparing 
samples where the B cell compartment substantially differs between cohorts 
or over time. Therefore, expressing antigen-specific cells per total IgG+ ASCs 
is currently the best measure to correct for mitogen-culture effects. Additionally, 
baseline information on the size and composition of the ex vivo B cell compartment 
should be supplied to additionally inform about differences or changes in the size 
and composition of the ex vivo MBC compartment.
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Materials and Methods
Peripheral blood mononuclear cells
To enable systemic analysis of B cell expansion and ASC generation in a large 
number of mitogen-stimulated cultures, we took advantage of 269 individual 
PBMC samples that were collected longitudinally from 62 healthy adult volunteers 
(age range 18–32 years) enrolled in two clinical trials conducted at the Radboud 
university medical center (Nijmegen, The Netherlands) and the Leiden University 
Medical Centre (Leiden, The Netherlands) between March 2011 and April 
2012. Both studies received approval by the Central Committee for Research 
Involving Human Subjects of The Netherlands (CCMO; NL34273.091.10 
and NL33904.091.10) and volunteers enrolled in the studies provided written 
informed consent. The study team complied with the Declaration of Helsinki and 
Good Clinical Practice including monitoring of data. The trials are registered at 
ClinicalTrials.gov, number NCT01236612 and NCT01218893.
In Study A15, volunteers received a prophylactic dose of chloroquine for three 
months and bites from 3x15 Plasmodium falciparum-infected mosquitoes 
(Chemoprophylaxis and sporozoites, CPS), and were subjected to challenge with 
P. falciparum-infected red blood cells (n= 9) or infective mosquito bites (n= 5). Ten 
volunteers received only chloroquine prophylaxis and then a single P. falciparum 
challenge either with P. falciparum-infected red blood cells (n= 5) or mosquito-
bites (n= 5). In Study B16 volunteers undergoing chloroquine chemoprophylaxis 
were immunized with bites from either three times 15 (n= 5), ten (n= 9) or 
five (n= 10) P. falciparum-infected mosquitoes, or not-immunized (n= 5). All 
immunized and control subjects in this study were subjected to mosquito-bite 
challenge. Sampling of citrate anti-coagulated peripheral blood for immunological 
analysis was performed at different time points using CPT vacutainers (Becton 
Dickinson). In Study A and B, samples were available for each volunteer from D0 
(preimmunization, before onset of chloroquine prophylaxis), day before challenge 
(C-1) and 35 days after challenge (C+35). In Study B, additional samples were 
available from one month (28 days) after each of the three immunizations (for 
CPS immunized volunteers only) as well as 140 days after challenge (C+140). 
Additionally, we included single samples from 9 healthy, Dutch adult malaria-naıve 
volunteers. At none of the blood collection time points for this study was any of the 
volunteers infected with P. falciparum. 
PBMCs were isolated by density centrifugation. Following four washes in 
phosphate buffered saline (PBS), PBMCs were cryopreserved at 2x107 cells/ml 
this expansion, and (iii) whether the total number of Ig-secreting cells generated 
truly reflects MBC frequencies ex vivo. One study has addressed this last point 
for antigen-specific MBCs4, but the readout by ELISA did not allow comparisons 
of ASCs following mitogen-stimulation and ex vivo MBCs on the single-cell level. 
A follow-up study demonstrated that the two possible readouts after culture with 
mitogens, limiting dilution ELISpot/ELISA and bulk culture ELISpot, correlated for 
two out of the three antigens analyzed6, supporting the use of the cheaper and 
less time consuming bulk ELISpot. However, none of these studies investigated 
the effect of mitogen-culture on B cell expansion, which would have affected both 
post-culture read-outs equally.
In this study, we therefore investigated both the consistency of B cell expansion 
during mitogen-culture as well as the robustness of this assay to detect total 
IgG+ ASCs that correspond to ex vivo IgG+ MBC frequencies, by systematically 
comparing B cell phenotype and proportions before and after mitogen-stimulation 
in a large number of human PBMC cultures.
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PBMCs and averaged between the two cell concentrations. To check for assay 
background some wells on every plate received only medium instead of cells (no 
background detected) or 4x105 cells were added to wells coated with 5 μg/ml the 
irrelevant antigen Bovine Serum Albumin (BSA; background: 0.33 spots/well).
Flow cytometry analysis
IgG+ B cells and B cell proportions were analyzed prior to (ex vivo; stain 1; Figure 
S1) and after mitogen-culture (stain 2; Figure S2). B cell subsets ex vivo were 
distinguished as described previously17. For post-mitogen-culture phenotyping we 
chose a different staining panel for the following reasons: (i) mitogen-stimulation 
results in a down-regulation of CD19 expression, necessitating the inclusion of 
CD20 to identify B cells. (ii) we aimed to assess proliferation after stimulation, thus 
including Ki67. (iii) in previous experiments we found that CD21 as well as IgD 
expression are down-regulated during culture of B cells, while CD38 expression 
is strongly up-regulated in the majority of B cells by mitogen-stimulation (Figure 
S3), thus preventing us to use the same gating strategy to distinguish different B 
cells subsets after 5 days of culture.
5x105 to 1x106 cells per stain were transferred to 96 wells V-bottom plate (Sarstedt), 
washed with PBS and incubated for 30 min on ice with 50μl viability dye diluted 
in PBS (fixable viability dye eFluor 450, eBioscience (stain 1); aqua LIVE/DEAD 
fixable dead cell stain, Invitrogen (stain 2)). Cells were washed twice with staining 
buffer (PBS/0.5% BSA), and stained with 50μl antibody cocktail diluted in staining 
buffer for 30min at room temperature (RT). Antibodies used for surface staining 
are listed in Table 1 and Table 2. After another wash, cells were resuspended in 
50μl fixation/permeabilization buffer (eBioscience), incubated for 30min at 4°C, 
and washed with 150μl permeabilization buffer (eBioscience). For intracellular 
staining, cells were incubated for 30min at RT with 50μl antibody cocktail (stain 
2; Ki67 AlexaFluor 647 (B56); BD Biosciences) diluted in permeabilization buffer 
(eBioscience). Cells were washed with permeabilization buffer and re-suspended 
in 200μl PBS/1% paraformaldehyde. 1 to 2x105 events per sample were acquired 
on a Cyan ADP 9-colour flow cytometer (Dako/Beckman Coulter) and analysis 
performed using FlowJo v9.2 software.
Statistical analysis
Data were analyzed using GraphPad Prism v5. B cell proportions ex vivo versus 
post-culture were compared by Wilcoxon matched pairs signed rank test. Skewing 
of distributions was tested by D’Agostino and Pearson omnibus normality test. 
Relationships between B cell proportions, expansion (fold change; calculated 
in ice-cold fetal calf serum (FCS; Gibco)/10% DMSO (Merck) using Mr. Frosty 
freezing containers (Nalgene). PBMC samples were stored in vapour phase 
nitrogen.
Mitogen-stimulation
Differentiation of MBCs into ASCs was initiated in bulk PBMC cultures based 
on a previously established protocol5, using a stimulation cocktail composed of 
pokeweed mitogen (PWM), Staphylococcus.aureus Cowan I protein A (SAC) and 
CpG. IL-10 was added to the stimulation mix since a previous study showed that 
this enhanced the efficiency of MBC into ASC differentiation by more than 9-fold6. 
Briefly, PBMCs were thawed for 30sec in a 37°C water bath and cold RPMI medium 
was immediately added drop wise. After washing, the cells were re-suspended 
in RPMI containing 10% FCS, 100U/ml penicillin/streptomycin, 100mM HEPES, 
50mM 2-β-Mercaptoethanol and 2mM L-Glutamine (all Invitrogen) and counted. 
1x106 cells/ml were added to 25cm2 cell culture flasks (Greiner). Culture medium 
was supplemented with 50ng/ml PWM lectin derived from Phytolacca americana 
(Sigma-Aldrich), 1:5000 Protein A from Staphylococcus aureus, Cowan Strain 
(Sigma-Aldrich), 2.5μg/ml ODN 2006 (Type B CpG nucleotide-human TLR9 
ligand; InvivoGen tlrl-2006) and 25ng/ml recombinant human IL-10 (PeproTech) 
and incubated at 37°C, 5% CO2 for 5 days.
Memory B cell ELISpot
MultiScreen Filter PVDF Immobilon plates (MSIPS4510, Millipore) were pre-
wetted with 35% Ethanol, rinsed twice with PBS and coated with 10μg/ml 
monoclonal antibodies to human IgG (clones MT91/145; Mabtech) diluted in PBS. 
After overnight incubation at 4°C, plates were washed (1x PBS/0.05% Tween 
20 (Sigma-Aldrich, PBST), 3x PBS) and blocked with 1% bovine serum albumin 
(BSA; Sigma-Aldrich) in RPMI for 2 h at 37°C. Cells were harvested from the 
flasks, counted and seeded in quadruplicates at both 1200 and 4000 cells per 
well. Filter plates were incubated for 6h at 37°C, 5% CO2 with minimized ambient 
vibration. After washing (4x PBS, 4x PBST), immobilized IgG was labeled using 
polyclonal goat anti-human IgG (Fcγ) alkaline phosphatase (1:1000 in PBST 
containing 0.5% FCS; Mabtech) overnight at 4°C. Following thorough washing 
(4x PBST, 4x PBS, 3x distilled water), alkaline phosphatase substrate BCIP/NBT 
(Mabtech) was added and the filter plates were kept in the dark until fully developed. 
Developed plates were rinsed with water, left to dry and stored protected from light 
until reading using the CTL ImmunoSpot Reader (Cellular Technology Ltd.). The 
mean number of IgG+ ASCs in quadruplicate wells was calculated per million 
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Results
Applying both flow cytometry and ELISpot, we conducted a systematic large-scale 
analysis of 269 PBMC samples (derived from 62 donors sampled over 1–7 time 
points) before and after mitogen-stimulation (Figure 1A). We firstly determined 
the ex vivo composition of the B cell compartment (for subset definitions see 
Table 3 and Figure S1), and particularly of IgG+ MBCs, from which IgG+ ASCs 
originate. Upon thawing of cryopreserved PBMCs, B cells made up 5.97% 
(median, interquartile range (IQR) 4.26–8.25%) of PBMCs, and 7.86% (median; 
IQR 5.69– 11.5%) of these B cells were IgG+. The IgG+ B cell compartment 
was largely composed of CD38lowIgD-CD102 MBCs (Figure 1B), dominated by 
CD21+CD27+ classical MBCs (cMBC; median 63.4%, IQR 55.9–67.8%), followed 
by CD21+ CD27- MBCs (median 20.3%, IQR 15.4–24.6%). Three other MBC 
populations constituted 3.3–5% each of the IgG+ B cell compartment, i.e. CD21-
CD27- atypical MBCs (atypMBC), CD21-CD27+ activated MBC (actMBC) and 
IgD+CD21+CD27+ non-switched MBCs (nsMBC). With the exception of a slight 
dip in total B cells four weeks after the last immunization, both the size of the total 
and IgG+ circulating B cell compartment, and the proportions of the different MBC 
subsets remained constant over time in the 53 donors from which multiple samples 
were available (Table S1 and Table S2), highlighting that the interventions the 
volunteers underwent in the clinical trials had no biasing effect on the samples 
analyzed. Recovery of total seeded PBMC after 5 days of culture in the presence 
of mitogens was 95.45% (median, IQR 82.9–112.1%). Consistent with 90.4% 
(median; IQR 87.5–92.1%) of B cells proliferating at day 5 (based on Ki67 staining, 
Figure S3), mitogen-stimulation successfully increased the proportion of total 
B cells (Figure 1C, p<0.0001) and IgG+ B cells within recovered PBMCs in all 
cultures (Figure 1D, p<0.0001). While the absolute number of both total and IgG+ 
B cells prior to culture correlated with their number after culture, this relationship 
was stronger for total B cells (Spearman r= 0.87, p<0.0001; Figure 2A), than for 
IgG+ B cells (r= 0.67, p<0.0001; Figure 2B). For total B cells, the median fold 
increase in absolute numbers over 5 days of culture was 6.04 (IQR 5.0–7.74; 
p<0.001), and this increase in total B cell numbers during mitogen-culture was not 
normally distributed (D’Agostino and Pearson omnibus normality test; skewness 
1.06, kurtosis 2.04). Since all mitogen-cultures were performed under identical 
conditions, the most likely confounding factor was the variation in the starting 
proportion of total B cells (median 5.97%, range 1.1–18.3%). Indeed, we found 
that expansion of B cells during mitogen-culture was variable and dependent of 
B cell proportions before stimulation with an inverse and non-linear (exponential 
by dividing for each sample the absolute number of total (or IgG+) B cells post 
mitogen-culture by the absolute number of total (or IgG+) B cells ex vivo) and 
ASCs were analyzed by non-parametric Spearman correlation. Correlation 
coefficients listed are for PBMC samples of the 62 volunteers at baseline, i.e. a 
time point when all of them where malaria-naıve and none of them was undergoing 
chloroquine prophylaxis. Correlation coefficients obtained for baseline samples 
only were comparable to those obtained when analyzing all 269 cultures from all 
collected time points.
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decay) relationship between the ex vivo proportion and the fold increase in both 
their percentage (r= 20.69, p<0.0001, data not shown) and absolute number (r= 
20.38, p= 0.023; Figure 2C) during culture. The largest expansion was found in 
cultures with the lowest starting proportions of total B cells. We next addressed 
whether mitogen-culture affected the composition of the B cell compartment. 
Overall, proportions of IgG+ cells within the B cell pool only increased slightly 
(pre- versus post-culture: median with IQR 7.68% (5.7–11.5%) and 10.3% (7.7–
12.8%), respectively). However, as for B cells within total PBMCs, we also found 
that the ex vivo percentage of IgG+ cells strongly influenced their expansion 
within the B cell pool, with a strong inverse and skewed correlation (Figure 2D, 
r= 20.65, p<0.0001) between their starting proportions and fold increase during 
culture (median fold change post-culture/ex vivo 1.22, IQR 0.88–1.6; skewness 
7.1; kurtosis 58.1). These effects of pre-culture size and composition of the B cell 
pool on the efficiency of mitogen-driven expansion also affected the increase in 
IgG+ B cells, with a strong inverse correlation between starting proportions and 
the increase in their percentage (r= 20.76, p<0.0001, data not shown) or absolute 
numbers (r= 20.70, p<0.0001; Figure 2E): This was particularly evident in cultures 
with a low proportion of starting IgG+ B cells (<0.5% of PBMCs; 155/269), where 
expansion was higher (median fold increase 9.3), more variable (IQR 6.7–13.4) 
and skewed (skewness 5.6, kurtosis 34.7) than in cultures with higher pre-culture 
proportions of IgG+ B cells (≤0.5% of PBMC; 114/269; median fold increase 
5.3; IQR 4.4–6.7; skewness 2.2, kurtosis 7.8). Finally, expansion of IgG+ B cells 
was higher than that of IgG- B cells (Figure 2E, F; median fold increase 7.16 vs 
5.86; p<0,0001), and expansion of IgG+ B cells more strongly influenced by their 
starting proportion (skewness 6.9, kurtosis 55.9; Spearman r= -0.70) than IgG- B 
cells (skewness 0.99, kurtosis 1.7; Spearman r= -0.29). 
Taken together, differences in both size and composition of the ex vivo B cell 
compartment do directly influence the outcome of mitogen-stimulation cultures. 
When comparing the number of IgG+ B cells determined by flow cytometry to 
the number of IgG+ ACSs detected by ELISpot, both per million PBMCs post-
culture, we found that the number of IgG+ B cells, although in a similar range, was 
slightly but significantly higher than that of IgG+ ASCs (Figure 3A; p= 0.003). This 
suggests that the majority of IgG+ B cells expanded during mitogen-culture also 
differentiate into ASCs. There was, however, only a relatively weak correlation 
between the proportion of IgG+ B cells and IgG+ ASCs after mitogen-culture 
(Spearman r= 0.48, p<0.0001; Figure 3B), showing that for a large number of 
cultures, staining of post-culture PBMCs for surface IgG will overestimate the 
Figure 1  |  Expansion of total and IgG+ B cells following mitogen-stimulation
Panel A) schematically illustrates the cellular composition of PBMCs directly ex vivo and after mitogen- 
culture. The grey circle represents total PBMCs, the blue circle all CD19+ B cells and the orange 
triangle IgG+ B cells. B) The composition of the IgG+ B cell compartment ex vivo was analyzed by flow 
cytometry and is depicted as median proportions of individual B cell subsets within total CD19+ B cells 
for baseline samples of 62 donors. The individual B cell subsets were subdivided based on IgD, CD38, 
CD10, CD21 and CD27 expression and include five memory B cell subsets: classical MBCs (cMBCs, 
red), CD27- MBCs (yellow), activated MBCs (actMBC, black), atypical MBCs (atypMBC, green) and 
non-switched MBCs (nsMBC, white). Depicted in shades of grey are plasma blasts (PB), activated 
naive B cells (actN), classical naive B cells (cN) and double-negative naive B cells (dnN). Panels C–D 
show ex vivo and post-culture proportions of total CD19+ B cells (C, blue dots) and IgG+CD19+ B cells 
(D, orange dots) within viable PBMCs. Black lines indicate the median. Dots show all 269 cultures. 
Differences between ex vivo and post-culture samples were compared by Wilcoxon matched pairs 
signed rank test.
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Figure 2  |  Size and composition of the B cell compartment ex vivo influences B cell expansion 
during culture (see previous page)
Flow cytometry analysis was performed to determine proportions and subsequently calculate absolute 
numbers of A) total CD19+ B cells (blue dots) and B) IgG+CD19+ B cells (orange dots) ex vivo and 
post-culture. Ex vivo proportions of C) total CD19+ B cells (blue dots) within viable PBMCs were 
plotted against the fold change in their absolute numbers, and D) IgG+ B cells (orange dots) within total 
CD19+ B cells were plotted against the fold change in their proportion within the B cell compartment. 
E) Proportions of IgG+CD19+ B cells (orange dots) and F) IgG-CD19+ B cells (green dots) within 
viable PBMCs were plotted against the fold increase in their respective absolute numbers post-culture 
compared to ex vivo. Colored dots show cultures from all 269 stimulated samples (3–7 time points per 
volunteer), while black dots show the cultures from only the 62 baseline samples (1 for each individual 
volunteer). The black dashed line indicates the median fold change (with value), grey dotted lines 
represent the upper and lower limit of the interquartile range. Spearman r and p values are shown for 
analysis of baseline samples (black dots) from the 62 donors assessed.
potential of these cells to secrete IgG, as detected by ELISpot. When IgG+ ASC 
numbers (per million PBMCs) were compared instead to the ex vivo proportion 
of IgG+ cells within PBMCs prior to culture, this correlation improved (r= 0.55, 
p<0.0001; Figure 3C), showing that IgG+ ASCs detected by MBC ELISpot are 
overall a good estimate of ex vivo MBC frequencies. Moreover, when taking out 
variations in the size of the B cell pool by analyzing ex vivo IgG+ proportions within 
the B cell compartment, the correlation with IgG+ ASC numbers post-mitogen-
culture improved further (r= 0.65, p<0.0001; Figure 3D). This correlation was the 
same for IgG+ cMBCs, which constitute the largest proportion of the IgG+ B cell 
pool (r= 0.65, p<0.0001). IgG+ ASC numbers post-culture further correlated with 
the ex vivo proportions of IgG+ CD27- MBCs (r= 0.51, p<0.0001), the second 
largest population within IgG+ MBCs, but not for IgG+ atypMBCs (r= 0.24, p= 
0.06). Of note, across all baseline samples of 62 volunteers, the ratio of atypMBCs/
cMBCs correlated inversely with the proportion of IgG+ cMBCs ex vivo (r= -0.54, 
p<0.0001), but correlated positively with the expansion of IgG+ B cell numbers 
during mitogen-culture (r= 0.49, p<0.0001, data not shown).
Figure 2  |  Size and composition of the B cell compartment ex vivo influences B cell expansion 
during culture (for legend see next page)
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Discussion
The MBC ELISpot assay is the most widely used method to quantify MBC 
responses in addition to plasma antibodies as an independent readout of humoral 
immune memory6-12,18. A basic assumption when using the MBC ELISpot assay to 
estimate the frequency of antigen-specific MBCs is that in the preceding mitogen-
culture, all MBCs are expanded and differentiate into ASCs in a constant manner or 
at a fixed ratio, although this has not been examined to date13. We show here that 
the expansion of total and IgG+ B cells during culture is not constant, but instead 
influenced by both the size and composition of the ex vivo B cell compartment, 
which vary widely between individuals. At group level, the number of IgG+ ASCs 
detected by ELISpot after mitogen-stimulation indeed reflects the proportion of 
IgG+ MBCs ex vivo, in particular for the two major populations of IgG+ MBCs, i.e. 
cMBCs and CD27- MBCs. This good correlation between total input (ex vivo IgG+ 
MBC) and output (IgG+ ASC) is in line with a previous small-scale study on TTX-
specific MBCs4 and highlights the general robustness of this assay to compare 
antigen-specific MBC frequencies on group level (e.g. between different cohorts). 
This relationship was found across cultures from 62 volunteers with a wide range 
of ex vivo IgG+ MBC frequencies. We also observed, however, that the expansion 
of both B cells and IgG+ B cells during culture showed an inverse correlation 
with the size and composition of the pre-culture B cell compartment. This was 
particularly evident for IgG+ MBCs. As a result, when total or antigen-specific 
MBCs are expressed as a proportion of total post mitogen-culture PBMCs to 
estimate their frequency, this introduced bias into the readout, rather than allowing 
to take into account inter-individual variations in total ex vivo MBC frequencies13.
The reason underlying this inverse relation between the ex vivo proportion of total 
or IgG+ B cells with their respective increase in absolute numbers during culture 
remains unknown. One possibility is that the T cell compartment is relatively larger 
in cultures with lower B cell proportions, and thus more T cells are available for 
cytokine production upon PWM-stimulation, providing more favorable expansion 
conditions than in cultures with higher B cell and lower T cell numbers. This factor 
would influence total B cell expansion whenever mitogen-stimulation is performed 
in bulk PBMC cultures. It does not, however, explain the skewing for IgG+ B 
cells within the B cell compartment, since cultures with the lowest total B cell 
proportion where not those with the lowest proportion of IgG+ B cells within the 
B cell compartment and vise versa. Alternatively, assuming the same expansion 
efficiency in all samples, IgG+ B cells in samples with a high starting proportion 
might die in culture due to crowding, limited nutrients or toxin build up, whereas 
Figure 3  |  Relationship between post-culture IgG+ ASC numbers and ex vivo or post-culture 
IgG+ B cell proportions
After 5 days of mitogen-culture, proportions of IgG+ B cells were analyzed by flow cytometry (orange 
dots) and IgG+ ASCs were quantified by ELISpot (red dots) and expressed as per million post-culture 
PBMCs A). Black lines indicate the median. Post-culture B) and ex vivo proportions C) of IgG+ cells 
within PBMCs, and ex vivo proportions of IgG+ cells within CD19+ B cells D) were plotted against the 
number of IgG+ ASCs per million PBMCs. Red dots show cultures from all 269 stimulated samples 
(3–7 time points per volunteer), while black dots show the cultures from only the 62 baseline samples 
(1 for each individual volunteer).
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number of post-culture surface IgG+ B cells, however, did not fully predict the 
number of IgG+ ASCs. One potential reason could be the down-regulation of 
surface IgG expression on differentiating ASCs in mitogen-culture. This would 
lead to an underestimation of IgG+ ASCs, which could be rectified by performing 
intracellular IgG staining post culture. However, after mitogen-culture the number 
of surface IgG+ B cells slightly but significantly exceeds, and thus over- rather 
under-estimates the number of IgG+ ASCs. While we can further not formally 
show that all expanded IgG+ B cells are indeed plasma blasts (since staining 
for CD27 was not performed in addition to CD38), we find that the number of 
post-culture IgG+ cells and IgG+ ASCs correlates (Spearman r= 0.48, p<0.0001), 
indicating that at least a major proportion of those cell populations does overlap. 
Moreover, these data indicate that not all IgG+ B cells (ex vivo and post culture) 
actually acquire ASC function, as previously shown on single-cell level for isotype-
switched MBCs after stimulation with CpG and cytokines20,21. A marker identifying 
MBC subsets with the capacity to become ASCs is unfortunately still lacking20, 
and this may further differ depending on the combination of stimuli chosen: Since 
the description of the MBC ELISpot by Crotty et al.5, many different polyclonal 
stimulation protocols relying on the activation of Toll-like receptors as well as 
cytokine receptor signaling have been tested to effectively differentiate MBCs into 
ASCs. Here we choose a stimulation cocktail containing PWM, SAC, CpG and 
IL-10, which was previously shown to be the most efficient out of 12 different 
stimulation protocols tested6. Based on the data we provide, future studies using 
other effective stimulation protocols (e.g. IL-2 and R8489,11, or IL-15 and CpG8) 
or purified B cells18 should determine whether the size and composition of the ex 
vivo B cell pool influences the expansion of total and IgG+ B cells during culture.
Most IgG+ B cells ex vivo are cMBCs, and their proportion correlated as strongly 
with IgG+ ASCs detected by ELISpot as the proportion of total ex vivo IgG+ B 
cells. Curiously, low proportions of IgG+ cMBCs within the B cell compartment 
ex vivo (and thus low numbers of IgG+ ASCs after mitogen-culture) were 
predominantly found in volunteers with high ex vivo ratios of atypMBC to cMBC. 
This was particularly evident for one volunteer, who at all three time points, at 
which PBMCs were sampled, showed the highest number of IgG+ B cells after 
mitogen-stimulation but only very low IgG+ ASC numbers, suggesting that only a 
small fraction of the efficiently expanded IgG+ B cells actually secreted IgG: this 
volunteer had a very low proportion of cMBCs and CD27- MBCs within IgG+ B 
cells, but a particularly large proportion of atypMBCs prior to mitogen-culture. This 
observation would be consistent with previous studies that reported atypMBCs 
IgG+ B cells in samples with a low starting proportion can continue to proliferate 
and differentiate until the end of the 5 day culture. While this again may be true for 
the B cell compartment as a whole, we consider it unlikely to be the sole reasons 
for the strong inverse relationship between starting proportion and expansion of 
IgG+ B cells: Firstly, the strong skewing effect was also observed within the B cell 
compartment for IgG+ B cells. Secondly, albeit 10 times more numerous, starting 
proportion of IgG- B cells (containing mostly naive B cells and a few IgA+ or IgM+ 
MBCs) had only a very weak influence on their expansion in culture. This suggests 
that other reasons underlie these differences in expansion efficiency of IgG+ B 
cells. The skewing effect of B cell frequency and composition particularly affected 
cultures with a low proportion of ex vivo IgG+ MBCs, which were expanded 
with a greater magnitude and variation than those in culture with high starting 
proportions. One potential explanation for this observation is that expansion of 
IgG+ MBCs might also be enhanced by direct cell-cell contact of IgG+ B cells with 
PWM-activated T cells (for instance via CD40- CD40L19): when the IgG+ B cell 
population is smaller to begin with, the likelihood for direct cell-cell contact may 
be lower, and interactions thus more random, than when IgG+ B cells are more 
frequent. In line with a greater variation in expansion, when ex vivo IgG+ MBC 
proportions were plotted against post-culture IgG+ ASCs, the spread was wider 
and the correlation coefficient weaker for cultures with lower starting proportions 
of IgG+ MBCs (less than 0.5% of starting PBMCs). Thus, special care should be 
taken when comparing absolute IgG+ MBC numbers between subjects particularly 
with low starting frequencies of IgG+ MBCs, such as young children12,14. In such 
a case, expressing antigen-specific MBCs as a proportion of post-culture PBMCs 
gives even less insight into their actual ex vivo frequencies than when comparing 
across samples with a wide range of starting IgG+ MBC proportions. Expressing 
antigen-specific IgG+ MBCs as a proportion of IgG+ ASCs is therefore necessary 
to correct for this great variation in expansion. Prior knowledge of the starting 
concentration of IgG+ MBCs (e.g. by whole blood staining in a small volume prior 
to cryopreservation) might provide valuable additional information to accurately 
estimate differences in antigen-specific IgG+ MBC precursor frequencies: This 
information may be used to determine whether an actual difference in IgG+ 
MBC frequencies or MBC subsets exists between two groups, or whether they 
are comparable and differences in antigen-specific cells per total ASCs thus also 
reflect a different magnitude of the antigen-specific MBC response.
Another basic assumption of the MBC ELISpot assay is that all antigen-specific 
cell subsets have an equal ability to differentiate into ASCs. In our hands the 
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the methods of choice.
An immediate practical implication of our finding is thus the way that results 
from bulk-culture MBC ELISpot should be reported: Specifically, we recommend 
not to express antigen-specific MBCs as a proportion of post-culture PBMCs in 
an attempt to compare their frequencies- particularly between clearly different 
cohorts, since this actually introduces bias. Instead, to allow interpretation of MBC 
ELISpot data in a meaningful manner, we propose to always include total IgG+ 
ASCs as a reference point to correct for variations in MBC precursor frequencies 
and hence expansion during mitogen-culture between donors. Between relatively 
homogenous groups (in regards to their B cell compartment), expressing antigen-
specific cells per total ASCs is currently the best measure to correct for mitogen-
culture effects. The same is true for longitudinal studies where the size and 
composition of the (memory) B cell compartment does not alter over time (as in 
the samples analyzed herein). In settings, however, where groups differ in the size 
and makeup of their (IgG+ memory) B cell compartment (or these parameters vary 
over time in longitudinal studies) due to age or pathogen exposure, we propose 
that this information about the B cell compartment should be additionally provided 
as a separate measure. This will also inform the reader appropriately whether it is 
simply the size of the MBC compartment that differs between (age) groups or alters 
over time, or the proportion of antigen-specific cells within the MBC compartment, 
or both- information that is lost when only providing the mitogen-culture biased 
readout of antigen-specific MBCs per post-culture PBMCs.
from HIV-infected individuals to be less efficient in differentiating into IgG+ ASCs 
in vitro, and similar data are available for a very limited number of atypMBCs from 
malaria-exposed subjects10,22. On the other hand, there is evidence that atypMBCs 
from malaria-exposed individuals may contribute to antibody production, since 
as for cMBCs, their BCR sequences can be matched to circulating plasma 
antibodies23. Additionally, bulk-sorted atypMBCs in this study contained both the 
membrane-bound and secreted form of IgG, however, a contamination of this 
population with non-atypMBC antibody secreting cells cannot be fully excluded, 
since CD38hi cells were not depleted23. It therefore remains to be conclusively 
established whether atypMBCs indeed actively secrete antibodies in vivo, or 
simply differentiate into ASCs like cMBCs (just potentially less efficiently) and 
then contribute to IgG-secretion upon antigenic stimulation. The extent to which 
atypMBCs and cMBCs in both malaria-exposed and healthy, malaria-naïve 
individuals vary in their ability to differentiate into ASCs to different stimuli also 
remains to be established. Should this indeed be the case, then data not only on 
the size, but also the detailed composition of the ex vivo IgG+ MBC pool might 
be helpful for data interpretation, especially when comparing populations with 
a broad range of proportions of atypMBC, such as individuals of different age 
groups in malaria-endemic areas or in different transmission settings12,22.
Antigen-specific ASCs are often reported per million postculture PBMCs to get 
insights into the frequency of circulating antigen-specific MBCs. This readout, 
however, does not correct for differential expansion and thus skewing of the MBC 
compartment during mitogen-culture. Therefore only qualitative (higher or lower ex 
vivo frequencies of antigen-specific cells) but not quantitative differences between 
groups (which one aims to examine when using this readout) are preserved. This 
is specifically relevant for comparing antigen-specific MBCs between groups that 
markedly differ in size and composition of the B cell compartment, such as between 
different age groups12,14. A correction factor to accurately quantify antigen-specific 
MBC responses (taking into account both the size of the B cell compartment and 
the proportion of IgG+ MBCs ex vivo), would simplify analysis, but its determination 
is complicated by two main aspects: (i) different IgG+ MBC subsets may have 
varying abilities to differentiate into ASCs and (ii) other stimulation protocols may 
introduce different degrees of skewing during culture, for instance since receptor 
expression varies between MBC subsets24. In the absence of such a correction 
factor, we conclude that it is not possible to accurately estimate MBC frequencies 
by MBC ELISpot on an individual level. For this question, limiting dilution assay or 
ex vivo staining with fluorescently-labeled antigens3,4 or B cell tetramers2 remain 
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Conclusions
The number of total IgG+ ASCs detected by ELISpot after mitogen-stimulation 
correlates with the proportion of IgG+ MBCs ex vivo, highlighting the general 
robustness of this assay to compare MBC responses between different cohorts, 
i.e. at group level. The expansion of total and IgG+ B cells during mitogen-
stimulation, however, was not identical in all cultures, but influenced by both 
the size and composition of the ex vivo B cell compartment, which vary widely 
between individuals. The uncorrected readout of antigen-specific MBCs per million 
post-culture PBMCs therefore only preserves the quality, but not the quantity of 
differences in the ex vivo MBC response between samples and thus groups or 
time points. Expressing antigen-specific cells per IgG+ ASCs is currently the 
best measure to correct for differences in the ex vivo B cell compartment and 
resulting mitogen-culture effects. To be able to evaluate not only changes within 
the MBC compartment, but their actual magnitude within the circulation, additional 
information on the size and composition of the ex vivo B cell compartment should 
be supplied as a separate measure, particularly under circumstances when the 
proportions IgG+ MBC are highly variable or proportions of B cell subsets are 
altered by environmental factors either between groups or over time.
144  l  Chapter 5 Expansion of B cells during mitogen-stimulation for MBC ELISpot assay  l  145
F
I
V
E
18 Hendrikx, L. H. et al. Identifying long-term memory B cells in vaccinated children despite 
waning antibody levels specific for Bordetella pertussis proteins. Vaccine 29, 1431-1437, 
doi:10.1016/j.vaccine.2010.12.033 (2011).
19 Morimoto, S. et al. CD134L engagement enhances human B cell Ig production: CD154/
CD40, CD70/CD27, and CD134/CD134L interactions coordinately regulate T cell-dependent 
B cell responses. Journal of Immunology 164, 4097-4104 (2000).
20 Henn, A. D. et al. Functionally Distinct Subpopulations of CpG-Activated Memory B Cells. 
Scientific Reports 2, 345, doi:10.1038/srep00345 (2012).
21 Henn, A. D. et al. Modulation of single-cell IgG secretion frequency and rates in human 
memory B cells by CpG DNA, CD40L, IL-21, and cell division. Journal of Immunology 183, 
3177-3187, doi:10.4049/jimmunol.0804233 (2009).
22 Weiss, G. E. et al. Atypical memory B cells are greatly expanded in individuals living 
in a malaria-endemic area. Journal of Immunology 183, 2176-2182, doi:10.4049/
jimmunol.0901297 (2009).
23 Muellenbeck, M. F. et al. Atypical and classical memory B cells produce Plasmodium 
falciparum neutralizing antibodies. The Journal of Experimental Medicine 210, 389-399, 
doi:10.1084/jem.20121970 (2013).
24 Sanz, I., Wei, C., Lee, F. E. & Anolik, J. Phenotypic and functional heterogeneity of human 
memory B cells. Seminars in Immunology 20, 67-82, doi:10.1016/j.smim.2007.12.006 
(2008).
References
1 McHeyzer-Williams, M., Okitsu, S., Wang, N. & McHeyzer-Williams, L. Molecular 
programming of B cell memory. Nature Reviews. Immunology 12, 24-34, doi:10.1038/
nri3128 (2012).
2 Franz, B., May, K. F., Jr., Dranoff, G. & Wucherpfennig, K. Ex vivo characterization and 
isolation of rare memory B cells with antigen tetramers. Blood 118, 348-357, doi:10.1182/
blood-2011-03-341917 (2011).
3 Moody, M. A. & Haynes, B. F. Antigen-specific B cell detection reagents: use and quality 
control. Cytometry. Part A : The Journal of the International Society for Analytical Cytology 
73, 1086-1092, doi:10.1002/cyto.a.20599 (2008).
4 Amanna, I. J. & Slifka, M. K. Quantitation of rare memory B cell populations by two 
independent and complementary approaches. The Journal of Immunological Methods 317, 
175-185, doi:10.1016/j.jim.2006.09.005 (2006).
5 Crotty, S., Aubert, R. D., Glidewell, J. & Ahmed, R. Tracking human antigen-specific memory 
B cells: a sensitive and generalized ELISPOT system. The Journal of Immunological 
Methods 286, 111-122, doi:10.1016/j.jim.2003.12.015 (2004).
6 Weiss, G. E. et al. High efficiency human memory B cell assay and its application to 
studying Plasmodium falciparum-specific memory B cells in natural infections. The Journal 
of Immunological Methods 375, 68-74, doi:10.1016/j.jim.2011.09.006 (2012).
7 Amanna, I. J., Carlson, N. E. & Slifka, M. K. Duration of humoral immunity to common viral 
and vaccine antigens. The New England Journal Medicine 357, 1903-1915, doi:10.1056/
NEJMoa066092 (2007).
8 Esen, M. et al. Effect of IL-15 on IgG versus IgE antibody-secreting cells in vitro. The Journal 
of Immunological Methods 375, 7-13, doi:10.1016/j.jim.2011.08.020 (2012).
9 Jahnmatz, M. et al. Optimization of a human IgG B-cell ELISpot assay for the analysis 
of vaccine-induced B-cell responses. The Journal of Immunological Methods 391, 50-59, 
doi:10.1016/j.jim.2013.02.009 (2013).
10 Moir, S. et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B 
cell compartment in HIV-infected viremic individuals. The Journal of Experimental Medicine 
205, 1797-1805, doi:10.1084/jem.20072683 (2008).
11 Pinna, D., Corti, D., Jarrossay, D., Sallusto, F. & Lanzavecchia, A. Clonal dissection of the 
human memory B-cell repertoire following infection and vaccination. European Journal of 
Immunology 39, 1260-1270, doi:10.1002/eji.200839129 (2009).
12 Weiss, G. E. et al. The Plasmodium falciparum-specific human memory B cell compartment 
expands gradually with repeated malaria infections. PLoS Pathogens 6, e1000912, 
doi:10.1371/journal.ppat.1000912 (2010).
13 Nogaro, S. I. et al. The breadth, but not the magnitude, of circulating memory B cell 
responses to P. falciparum increases with age/exposure in an area of low transmission. 
PloS One 6, e25582, doi:10.1371/journal.pone.0025582 (2011).
14 Morbach, H., Eichhorn, E. M., Liese, J. G. & Girschick, H. J. Reference values for B cell 
subpopulations from infancy to adulthood. Clinical and Experimental Immunology 162, 271-
279, doi:10.1111/j.1365-2249.2010.04206.x (2010).
15 Bijker, E. M. et al. Protection against malaria after immunization by chloroquine prophylaxis 
and sporozoites is mediated by preerythrocytic immunity. Proceedings of the National 
Academy of Sciences of the United States of America 110, 7862-7867, doi:10.1073/
pnas.1220360110 (2013).
16 Bijker, E. M. et al. Cytotoxic Markers Associate With Protection Against Malaria in Human 
Volunteers Immunized With Plasmodium falciparum Sporozoites. The Journal of Infectious 
Diseases, doi:10.1093/infdis/jiu293 (2014).
17 Scholzen, A. et al. BAFF and BAFF receptor levels correlate with B cell subset activation 
and redistribution in controlled human malaria infection. Journal of Immunology 192, 3719-
3729, doi:10.4049/jimmunol.1302960 (2014).
146  l  Chapter 5 Expansion of B cells during mitogen-stimulation for MBC ELISpot assay  l  147
F
I
V
E
S
ub
se
t
G
ro
up
B
as
el
in
e
I(1
)+
28
I(2
)+
28
I(3
)+
28
C
-1
C
+3
5
C
+1
40
To
ta
l B
 c
el
ls
a
Im
m
un
iz
ed
c
7.
3 
[4
.2
-8
.5
]
5.
4 
[3
.9
-7
.0
]
6.
0 
[3
.7
-6
.9
]
5.
2 
[4
.1
-7
.4
]
6.
9 
[4
.6
-9
.2
]
7.
8 
[5
.4
-1
0.
0]
7.
7 
[5
.0
-9
.1
]
C
on
tro
ls
d
7.
1 
[5
.4
-9
.2
]
n.
d.
n.
d.
n.
d.
7.
8 
[5
.0
-8
.6
]
7.
6 
[6
.6
-9
.4
]
6.
9 
[5
.7
-9
.5
]
Ig
G
+ 
B
 c
el
ls
b
Im
m
un
iz
ed
8.
0 
[6
.3
-1
2.
7]
8.
1 
[6
.0
-1
2.
1]
7.
9 
[6
.4
-1
0.
0]
8.
4 
[6
.4
-1
3.
0]
8.
2 
[5
.6
-1
1.
5]
8.
1 
[6
.0
-1
1.
9]
8.
3 
[5
.6
-1
1.
5]
C
on
tro
ls
7.
5 
[5
.2
-1
1.
3]
n.
d.
n.
d.
n.
d.
6.
3 
[5
.0
-1
2.
1]
7.
0 
[4
.6
-1
0.
3]
6.
7 
[5
.7
-1
1.
4]
cM
B
C
b
Im
m
un
iz
ed
13
.8
 [1
0.
1-
18
.6
]
13
.2
 [9
.4
-1
8.
1]
13
.6
 [9
.7
-1
6.
9]
13
.1
 [1
0.
0-
19
.0
]
13
.9
 [1
1.
1-
18
.4
]
12
.7
 [9
.9
-1
6.
6]
13
.1
 [1
0.
2-
17
.4
]
C
on
tro
ls
14
.9
 [1
2.
2-
19
.7
]
n.
d.
n.
d.
n.
d.
16
.2
 [1
1.
1-
20
.0
]
14
.2
 [1
1.
0-
18
.3
]
14
.5
 [1
1.
9-
19
.0
]
C
D
27
- M
B
C
b
Im
m
un
iz
ed
6.
0 
[5
.0
-8
.1
]
5.
7 
[4
.5
-8
.0
]
5.
6 
[4
.6
-7
.5
]
5.
5 
[4
.7
-7
.9
]
5.
6 
[4
.7
-8
.8
]
6.
6 
[5
.1
-8
.6
]
5.
5 
[4
.6
-9
.2
]
C
on
tro
ls
6.
6 
[4
.6
-7
.3
]
n.
d.
n.
d.
n.
d.
6.
7 
[4
.7
-7
.6
]
7.
3 
[4
.6
-8
.3
]
7.
0 
[4
.5
-8
.0
]
ac
tM
B
C
b
Im
m
un
iz
ed
1.
9 
[1
.5
-2
.5
]
2.
2 
[1
.4
-3
.2
]
2.
3 
[1
.6
-3
.6
]
1.
9 
[1
.4
-2
.7
]
1.
6 
[1
.3
-2
.7
]
2.
0 
[1
.4
-2
.4
]
1.
5 
[1
.3
-2
.1
]
C
on
tro
ls
2.
2 
[1
.3
-4
.6
]
n.
d.
n.
d.
n.
d.
2.
3 
[2
.0
-2
.8
]
2.
8 
[2
.2
-2
.9
]
2.
3 
[1
.7
-2
.7
]
at
yp
M
B
C
b
Im
m
un
iz
ed
2.
4 
[1
.7
-3
.2
]
2.
3 
[1
.5
-3
.0
]
2.
0 
[1
.4
-3
.1
]
1.
9 
[1
.5
-3
.1
]
1.
8 
[1
.0
-2
.8
]
1.
9 
[1
.5
-3
.5
]
1.
6 
[1
.4
-3
.4
]
C
on
tro
ls
1.
5 
[1
.3
-2
.1
]
n.
d.
n.
d.
n.
d.
1.
6 
[1
.0
-2
.5
]
2.
0 
[1
.3
-3
.2
]
2.
1 
[1
.5
-2
.3
]
ns
M
B
C
b
Im
m
un
iz
ed
8.
6 
[5
.6
-1
3.
0]
8.
3 
[5
.5
-1
3.
2]
7.
6 
[4
.8
-1
2.
5]
7.
5 
[5
.2
-1
1.
1]
8.
0 
[5
.2
-1
3.
1]
7.
7 
[5
.7
-1
2.
0]
6.
9 
[4
.9
-1
5.
1]
C
on
tro
ls
11
.7
 [9
.0
-1
2.
7]
n.
d.
n.
d.
n.
d.
11
.1
 [6
.6
-1
6.
7]
9.
6 
[6
.9
-1
4.
5]
12
.8
 [7
.7
-1
3.
6]
Ta
bl
e 
S
2 
 | 
 B
 c
el
ls
, I
gG
+ 
B
 c
el
ls
 a
nd
 M
B
C
 s
ub
se
ts
 in
 S
tu
dy
 B
, e
x 
vi
vo
 s
am
pl
es
 o
ve
r 
tim
e
a  A
na
ly
ze
d 
as
 p
er
ce
nt
ag
e 
of
 v
ia
bl
e 
P
B
M
C
s;
 m
ed
ia
n 
w
ith
 in
te
rq
ua
rti
le
 ra
ng
e
b  A
na
ly
ze
d 
as
 p
er
ce
nt
ag
e 
of
 to
ta
l B
 c
el
ls
; m
ed
ia
n 
w
ith
 in
te
rq
ua
rti
le
 ra
ng
e
c 
n=
14
d 
n=
10
n.
d.
 n
ot
 d
on
e
Supporting Information
Table S1  |  B cells, IgG+ B cells and MBC subsets in Study A ex vivo samples over time
Subset Group Baseline C-1 C+35
Total B cellsa Immunizedc 6.0 [3.7-6.6] 5.4 [3.5-8.9] 4.5 [3.8-7.4]
Controlsd 4.8 [3.8-6.0] 4.7 [4.4-5.7] 5.0 [3.6-5.5]
IgG+ B cellsb Immunized 6.6 [4.4-11.6] 5.5 [3.9-10.5] 6.5 [4.5-11.8]
Controls 7.5 [4.7-9.7] 7.1 [4.4-10.3] 6.4 [3.4-11.0]
cMBCb Immunized 13.5 [11.2-19.5] 12.9 [11.2-16.1] 12.4 [11.0-18.2]
Controls 17.3 [7.7-20.6] 19.5 [7.7-22.8] 14.7 [6.1-19.4]
CD27- MBCb Immunized 7.7 [5.9-11.4] 7.2 [5.7-11.3] 8.1 [6.0-11.0]
Controls 6.3 [4.6-7.5] 5.8 [4.9-7.9] 5.3 [4.1-7.7]
actMBCb Immunized 1.5 [0.8-2.0] 1.0 [0.7-1.5] 1.7 [1.1-2.1]
Controls 1.7 [0.7-1.3] 1.2 [1.1-1.8] 1.8 [0.8-3.5]
atypMBCb Immunized 2.4 [1.7-3.1] 1.9 [1.1-4.1] 2.3 [1.5-2.9]
Controls 2.3 [1.5-3.7] 2.1 [1.4-2.8] 2.3 [1.6-3.5]
nsMBCb Immunized 8.0 [4.5-11.2] 8.5 [4.6-11.0] 8.2 [5.3-11.3]
Controls 9.6 [8.8-12.0] 9.0 [7.1-14.0] 8.8 [7.8-13.0]
a Analyzed as percentage of viable PBMCs; median with interquartile range
b Analyzed as percentage of total B cells; median with interquartile range
c n=14
d n=10
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Figure S1  |  Gating strategy of total and IgG+ B cells ex vivo (see previous page)
A) CD19+ B cell were identified following exclusion of debris, doublets, dead cells and CD3/CD56/
CD14- cells. B) shows gating for IgG+ B cells. This IgG+ gate was later applied to individual B cell 
subsets, which were gated as follows: C) CD19+ B cells were first subdivided based on IgD and CD38 
expression. D) CD10+ cells were excluded from all B cell populations except IgD+CD38hi B cells, 
which were specifically subgated based on CD10 expression. E) CD38hi B cells were divided into 
CD10-IgD-CD38highCD27+ plasma blasts (PB, i) and CD10+ IgD+CD38highCD272 transitional B 
cells (TBC, ii). CD38lowCD10- B-cells were subdivided into four pairs of switched/memory (IgD-) and 
non-switched/naive (IgD+) B cell populations: CD21-CD27+ activated MBCs (actMBC, iii) and activated 
naive B cells (actN, iv); CD21+CD27+ classical MBCs (cMBC, v) and non-switched MBCs (nsMBC, vi); 
CD21+CD27- MBC (CD27- MBC, vii) and classical naive B cells (cN, viii); and CD21-CD27- atypical 
MBCs (atypMBC, ix) and double negative naive B cells (dnN, x). F) shows the proportions of the ten B 
cell subsets of the total ex vivo B cell pool and G) the proportion of IgG+ cells within each individual B 
cell subset for the baseline samples of all 62 volunteers.
Figure S2  |  Gating strategy of total and IgG+ B cells after 5 day mitogen-culture.
Following A) exclusion of debris, doublets and dead cells, B cells were identified by B) firstly gating on 
CD19+CD20+ cells and subsequently gating out CD3/CD56/CD14-cells (Boolean gating). C) shows 
gating for IgG+ B cells for two donors.
Figure S1  |  Gating strategy of total and IgG+ B cells ex vivo (for legend see next page)
150  l  Chapter 5
Figure S3  |  CD38 and Ki67 expression on B cells after 5-day mitogen-culture
Ki67 and CD38 gates were based on negative populations (after exclusion of debris, doublets and dead 
cells) in A) total post-culture PBMCs and B) post-culture B cells. C) Grey dots show the percentage of 
Ki67 and CD38 positive cells within post-culture B cells cultures in all 269 stimulated samples, black 
lines indicate the median.
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The novel P. chabaudi mouse model of CPS immunization
We have developed a novel mouse model of CPS immunization using P. chabaudi 
as described in chapter 3. P. chabaudi shares many characteristics with P. 
falciparum12, especially with regard to protection after re-infection. Since timing, 
route of infection62,99 and antigen dose are critical for the initial priming of the 
antimalarial immune response13-17, we employed similar immunizing conditions 
using infected mosquito bites, according to a recently published protocol 
describing the optimal conditions for P. chabaudi mosquito transmission by A. 
stephensi18, as those in human CPS trials. This means that the exact dose of 
sporozoites and subsequently the number of infected hepatocytes will remain 
unknown. Interestingly salivary gland sporozoite numbers were dependent on the 
infecting P. chabaudi line where the AS line harboured a median of 438 (range 43-
956) sporozoites, while the CB line produced 4 times more sporozoites (median 
of 1638, range 175-2576) per mosquito18. These sporozoite numbers are in 
the same order of magnitude as P. falciparum infection rates observed in wild 
mosquitoes19-21, but 50 to 200 times lower than infection rates of experimentally 
infected A. stephensi for human CPS6.
However, injection of sporozoites via mosquito bites is a stochastic process and 
does not necessarily correlate with the salivary gland load of the mosquito22,23. 
Typically few sporozoites (estimated between 1 and 100) are injected during one 
infectious bite23. Based on the number of infected erythrocytes observed directly 
after release from the liver and assuming that 10,000 merozoites are released 
from one infected liver cell, we estimate that approximately 5 hepatocytes (95% 
confidence interval (CI) 1-31) are infected with P. chabaudi AS, whereas in human 
CPS approximately 400 hepatocytes are P. falciparum infected after the first 
immunization (95% CI 137-1250)6. This may be a function of a higher number 
of infectious mosquito bites (usually 155-7) in humans compared to a typical P. 
chabaudi mosquito transmission (Median 9.15 bites18). Therefore, we estimate 
that the number of infected hepatocytes after CPS immunization with mosquito 
bites is approximately 100-fold lower in the P. chabaudi mouse model than in 
human CPS.
It thus appears that the lower number of sporozoites in the salivary glands of 
P. chabaudi versus P. falciparum infected A. stephensi mosquitoes results in a 
lower number of infected hepatocytes in our mouse model compared with those 
in human CPS. This is likely due to a lower number of sporozoites being injected 
during mosquito bite, but low infectivity of P. chabaudi sporozoites in C57BL/6 
mice could also contribute. Differences in infectivity were reported previously 
Discussion
Despite elimination of malaria from temperate areas of Europe and North America, 
global eradication efforts in the 1950s have failed1. In Sub-Saharan Africa, South 
America and parts of Asia malaria is still a major public health concern2. In addition 
to the use of adequate vector-control as well as rapid diagnosis and treatment 
many believe that global eradication will only be possible once an effective 
malaria vaccine3 will become available. A number of subunit and whole parasite 
vaccine strategies are pursued, but their success is hampered by the fact that it 
is still unclear what precisely constitutes protective antimalarial immunity4. It is 
therefore important to study immune responses in human and animal models. 
Chemoprophylaxis and sporozoite (CPS) immunization allows the vertebrate host 
to be exposed to sporozoites, infected hepatocytes and blood-stage parasites, 
while preventing pathogenic blood-stage densities with the antimalarial drug 
chloroquine. Three immunizations with 12-15 P. falciparum infected mosquitoes 
under chloroquine cover can induce sterile protection in human volunteers against 
a standard mosquito challenge with 5 infectious bites5-7. It was suggested that 
protection is mediated by pre-erythrocytic immunity. Evidence for human volunteers 
remains indirect since only peripheral blood-samples and in vitro assays can be 
utilized for validation. As pointed out by Plotkin8 correlates of protection are often 
difficult to determine, especially if multiple correlates act in synergy, and are not 
absolute, meaning that even responses above a nominally protective level can 
lead to breakthrough infections in some individuals. Furthermore vaccine-induced 
responses are not necessarily the same that operate to clear the infection. For 
instance measles vaccination is aimed at inducing high antibody titers that were 
shown to correlate with protection in humans9, but non-human primate models 
established that upon primary infection viremia in organs is largely controlled by 
CD8 T cells, the lack of which leads to measles infection even if immune serum 
from vaccinated animals was transferred10,11. Carefully designed animal models 
can thus be extremely helpful to fill the knowledge gap by addressing fundamental 
questions about the mechanism and not just the correlate of protection. Before 
protective mechanisms can be unraveled key components of immunization and 
the animal models used have to be considered, and where possible matched as 
far as possible to the human system.
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suppression, are responsible for the absence of protection after immunization 
with mosquito bites16. Our data also suggest that specific antibodies present in 
the skin35 or CD8 T cells primed by sporozoites in draining lymph nodes37 do 
not contribute significantly to pre-erythrocytic immunity after CPS immunization 
with a small number of sporozoites. However, if mice were CPS immunized three 
times with 100-times more sporozoites (10,000) injected iv, liver-parasite burden 
was reduced by over 90% following mosquito bite challenge. This is similar to 
reports from other rodent malaria CPS immunization studies using P. berghei25-29 
or P. yoelii30-33, in which sterile pre-erythrocytic immunity is observed after 
immunization with high sporozoite doses (typically 10,000-50,000 sporozoites 
per immunization), while a reduction in sporozoite dose or the number of 
immunizations leads to breakthrough blood-stage infections upon challenge30,32. 
In human CPS immunization using bites of 5 mosquitoes on 3 occasions sterilely 
protected only 50% of volunteers7 compared with almost 100% sterile protection 
after 3 immunizations with 15 infected mosquito bites5-7. After CPS with 5 bites 
only half of the volunteers had blood-stage parasitemia detectable by quantitative 
RealTime (qRT) PCR within the first cycle during the first CPS immunization, 
suggesting that fewer than 60,000 merozoites were released from the liver. This 
would imply that fewer than 6 hepatocytes were parasitized, which may explain 
the lack of protective immunity.
Another possibility is that protection depends on the ratio of immunizing and 
challenging mosquito bites: in the rodent model we use the same minimum 
number of bites (approximately 9) to ensure consistent infection of all mice for 
both immunization and challenge, whereas humans were immunized with 3 
times more bites than required for 100% infection rate, which resulted in close 
to 100% sterile protection5-7. Equalizing the numbers i.e. using 5 bites for CPS 
immunization and challenge, reduced the rate of sterile protection to 50%7. It 
is not possible to increase the number of immunizing bites for mice because of 
animal welfare considerations; we therefore increased the number of immunizing 
sporozoites by iv injection. Keeping the number of mosquitoes constant in the 
challenge infection, we could show strong protection against liver-stage parasites 
can also be acquired with greater doses of sporozoites.
Taken together, evidence from the P. chabaudi mouse model described in chapter 
3 of this thesis, other rodent CPS models25-33 and the human dose de-escalation 
trial7, strongly suggests that the number of infected hepatocytes, which is 
determined by the number of sporozoites infecting the liver, is critical to determine 
whether pre-erythrocytic immunity is acquired.
between P. berghei and P. yoelii, the latter of which is by a factor of 2000 more 
infective to BALB/c mice than P. berghei, which was attributed to more effective 
innate immune responses that eliminate pre-erythrocytic P. berghei parasites24. 
To control the number of sporozoites establishing a liver-stage infection 
unequivocally, sporozoites have to be injected iv. This has been done in all other 
CPS immunization mouse models25-33 but has so far not been attempted on a 
large scale for controlled human malaria infections34. If the number of sporozoites 
inoculated iv would be small (100 or less), whilst still reliably infecting people, 
this approach would model infection dynamics experienced by people in endemic 
areas giving rise to few infected hepatocytes. The smaller number of merozoites 
released would also make it possible to evaluate blood-stage vaccine candidates 
in the context of the whole life-cycle. Iv injection however has the disadvantage 
of bypassing the skin-stage of Plasmodium, where neutralizing antibodies could 
inhibit migration into the circulatory system35,36 and priming of T cell responses 
may occur37.
Another profound difference between human and rodent malaria parasites is 
the duration of liver-stage development. While P. falciparum typically egresses 
from hepatocytes 6.8 days after mosquito bite38, P. chabaudi establishes a 
blood-stage infection after only 52h. Longer exposure to liver-stage parasites, 
as shown by immunization with irradiated sporozoites, is suggested to induce 
a broader repertoire of pre-erythrocytic immune responses39, but this remains 
disputed40. It should be considered that the longer liver stage development in 
human P. falciparum (approximately 6.5 days) compared with those of rodent 
malarias (approximately 2 days) might influence the nature and magnitude of pre-
erythrocytic immunity.
Large numbers of infected hepatocytes during CPS immunization induce 
pre-erythrocytic immunity
It is important to carefully consider the overall load of parasites in the liver, as 
our experiments clearly suggest that it is critical for acquisition of pre-erythrocytic 
immunity. After CPS immunization with P. chabaudi AS by infected mosquito 
bites, parasite burden in the liver was not different from unimmunized controls 
after mosquito-bite challenge. This does not appear to be because of the 
method of sporozoite administration as three iv injections of 100 sporozoites (the 
estimated equivalent number of sporozoites injected during P. chabaudi mosquito 
transmission18), also fail to induce pre-erythrocytic immunity. It therefore seems 
unlikely that sporozoites in the skin, which were suggested to induce immune 
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volunteers7. As for CD8 T cells, the maximum response was already reached and 
maintained after one immunization7, suggesting that the first exposure to parasite 
antigens also determines the magnitude of the CD4 T cell response.
Therefore both CD4 and CD8 T cells have been implicated in mediating pre-
erythrocytic immunity after whole parasite immunization. Their induction seems 
to be crucially dependent on the initial immunization dose53,54. In the P. chabaudi 
CPS model, pre-erythrocytic immunity may hence be absent after immunization 
with low numbers of sporozoites, which are apparently insufficient to give rise to a 
sufficiently large effector memory T cell population.
Does cross-stage immunity contribute to protection after CPS immunization?
CPS immunization not only permits exposure to sporozoites and infected 
hepatocytes, but the use of chloroquine also allows parasites in erythrocytes to 
develop until the late trophozoite-stage58. The load of blood-stage parasites is 
hence another factor that will define generation of protective immunity12,59. Given 
orally, chloroquine treatment cleared blood-stage P. chabaudi parasitemia within 
3 to 4 days in C57BL/6 mice, similar to humans5-7. The number of blood-stage 
parasites was quantified after each immunization by qRT PCR, which is to our 
knowledge the first time this has been determined in a mouse model. Chloroquine 
regimens used in other rodent CPS immunization models were retrospectively 
described to be sub-curative leading to blood-stage parasite persistence30,31,33. Doll 
et al. reported that parasite RNA was detectable in the spleen up to 60 days after 
immunization and chloroquine treatment in 50% of mice infected with P. yoelii33. In 
that case exposure to blood-stage parasites gave rise to T cell-independent blood-
stage immunity33. Thus blood-stage parasite exposure (especially if prolonged) 
can lead to the induction of erythrocytic immunity. However given shared antigenic 
targets between blood- and liver-stage parasites60 it also has the potential to alter 
the development of pre-erythrocytic protection following CPS immunization by 
inducing cross-stage immunity.
We showed that one self-cured infection initiated directly with P. chabaudi 
parasitized erythrocytes reduces liver parasite burden as efficiently (approximately 
90%) as three CPS immunizations with 10,000 sporozoites. Together with 
evidence that immunization with attenuated blood-stage parasites can protect 
against sporozoite challenge15,61,62 (although a reduction in liver-parasite burden 
was not always directly shown) it appears that exposure to blood-stage parasites 
may be a powerful way to induce pre-erythrocytic immunity. It may be that blood-
Are large numbers of immunizing sporozoites required to elicit effective T 
cell-mediated pre-erythrocytic immunity?
A high parasite load in the liver may be necessary to induce large numbers 
of CD8 T cells41, which have been shown to be the main mediators of pre-
erythrocytic immunity42. Hepatocytes, in contrast to erythrocytes, express major 
histocompatibility complex (MHC) class 1 molecules, which allow interaction with 
cytotoxic T cells. One study suggests that antigen-specific CD8 T cells have to 
kill each infected hepatocyte individually by cognate interaction rather than by 
non-specific bystander effects mediated through inflammatory cytokines43. 
Previously however tumor necrosis factor (TNF), possibly acting via the induction 
of interleukin (IL) 645, and interferon (IFN) γ44,45, was demonstrated to be crucial for 
the induction of pre-erythrocytic immunity, while the absence of Fas and Perforin, 
which can destroy cells upon directly contact, was reported to be dispensable for 
protection46. After immunization with irradiated sporozoites, at least 1% of all CD8 T 
cells have to be specific for the pre-erythrocytic parasite antigen circumsporozoite 
protein (CSP) to convey protection47,48. This is 100-1000 times greater than the 
frequencies of CD8 T cells necessary to protect against viral or bacterial agents48, 
possibly because of the small proportion of infected hepatocytes present in the 
whole liver and the requirement to eliminate every single one of them to achieve 
sterile protection.
It seems that the burst size of the responding CD8 T cell population after the initial 
interaction of MHC I with parasite peptide is critical in determining the ultimate 
magnitude of the response49,50. Activation starts as little as 2h after initial contact 
with antigen-presenting cells49,50. Using transgenic mice with CD8 T cell receptors 
specific for P. yoelii CSP51 it was shown that antigen-driven T cell activation occurs 
within the first 48 hours after initial exposure to infected hepatocytes52. Multiple 
subsequent immunizations do not seem to increase the frequency of transgenic 
CD8 T cells52. Immunization with one large dose of irradiated sporozoites 
apparently leads to higher CD8 T cell responses than life-long exposure in endemic 
areas53,54. Since natural exposure may result in a smaller number of sporozoites 
and infected hepatocytes experienced per infection19-21, this may not lead to the 
acquisition of high frequencies of protective CD8 T cells, possibly explaining the 
apparent lack of pre-erythrocytic immunity in naturally-exposed populations55.
Cytotoxic CD4 T cells, utilizing e.g. granzyme or perforin pathways, can also 
contribute to pre-erythrocytic antimalarial immunity in rodent models56,57. It was 
recently shown that the frequency of CD4 T cells expressing the degranulation 
marker CD107a are circulating at high frequencies in protected CPS immunized 
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sporozoites69.
Identification of the protective antigens that are shared between liver and blood-
stage parasites deserve to be a focus for future malaria vaccine development. 
If protection is not stage-specific, a multi-stage malaria vaccine would not only 
reduce the number of pre-erythrocytic parasites substantially while abrogating 
disease caused by blood stage parasites, but exposure to one stage would also 
boost immunity against the other.
Blood-stage immunity following CPS immunization 
We found that CPS induces partial blood-stage protection in our P. chabaudi model. 
Repeated exposure to blood-stage parasites during the immunization is the likely 
source of blood-stage immunity, although we cannot formally rule out that infected 
hepatocytes contributed by inducing cross-stage protective responses. Because 
of their small number after immunization with mosquito bites this seems however 
unlikely. Pre-patent period and parasitemia in the first 5 erythrocytic cycles are 
similar between immunized mice and controls, possibly because memory cells 
first have to be activated and an effective adaptive effector immune response 
has to be mounted. Blood-stage immunity was not strain-specific, since CPS 
immunization with P. chabaudi AS infected mosquito bites also protected against 
the more virulent CB strain.
Similarly, repeated immunizations with 100,000 P. chabaudi AS blood-stage 
parasites under atovaquone cover can elicit protection against blood-stage 
challenge with the more virulent P. chabaudi CB strain in mice14 and protection 
was also observed after repeated immunization of human volunteers with 
approximately 30 erythrocytic parasites and atovaquone-proguanil treatment70. 
The latter findings may have however been confounded by persisting atovaquone 
levels71. Abrogation of blood-stage infections at different times by drug-treatment 
was also found to alter homologous and heterologous immunity to reinfection in 
mice13,72, which was also demonstrated by analysing protection of neurosyphilis 
patients against repeated P. falciparum infection73. In endemic areas repeated 
exposure to malaria during infancy and childhood can also induce immunity 
against blood-stage parasites, which first reduces disease symptoms from severe 
to mild and can eventually control parasite densities, although sterile protection 
is rarely observed4,74,75. Together these data suggest that repeated exposure to 
blood-stage parasites generates protective immunity in a variety of experimental 
models and under field conditions.
stage parasites can induce pre-erythrocytic immunity by boosting expansion of 
protective CD8 T cells as recently shown using a MHC I-restricted T cell receptor 
transgenic mouse line63. Also in humans T cell responses to blood-stage parasite 
antigens were always higher compared to sporozoites 2.5 years after CPS 
immunization, which could represent immunological cross-reactivity64.
In our P. chabaudi CPS immunization model pre-erythrocytic immunity was not 
obtained after immunization with sporozoites by mosquito bite or with small 
numbers of sporozoites injected iv. Early abrogation of blood-stage parasitemia 
by chloroquine in CPS immunization15 hence does not induce cross-stage 
protection, which was only achieved by prolonged blood-stage infection. 
However immunization with 10,000 sporozoites iv reduced liver parasite 
burden after challenge substantially. Since this reduction was less pronounced 
after immunization with irradiated sporozoites, which arrest early in liver-stage 
development, this raises the intriguing possibility that enhanced blood-stage 
parasite load after CPS immunization with 10,000 sporozoites compared to 100 
sporozoites or mosquito bites, could contribute to liver-stage immunity. Similarly, 
induction of sterile protection in humans required only 30 to 45 mosquitoes using 
the CPS immunization regime, whereas 20 times more (over 1000) irradiated 
mosquitoes were needed65,66. Therefore blood-stage exposure during CPS 
immunization may contribute to the observed pre-erythrocytic protection.
The importance of cross-stage immunity for future malaria vaccine design
We consequently advocate in chapter 2 that induction cross-stage protective 
immune responses should be considered, as this could enhance vaccine efficacy. 
Cross-stage immunity is likely facilitated by shared antigens between (late) liver 
and blood-stage parasites60, which could be identified comparing protected and 
unprotected mice or volunteers using immunomics (whole Plasmodium genome 
or proteome-based antibody and T cell screening approaches)67. Immunization 
with fabb/f- genetically attenuated sporozoites that arrest late in liver-stage 
development can protect against direct blood-challenge demonstrating that cross-
stage protective responses can also be elicited by pre-erythrocytic parasites 
targeting blood-stages68. Interventions that arrest parasite development early 
during the liver-stages, when the parasite proteome is less similar to that of the 
blood-stages60, such as irradiation and some genetic modifications, have not been 
shown directly to protect against direct blood challenge. However, blood-stage 
parasites are recognized by T cells from volunteers immunized with irradiated 
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parasites79. Interestingly, despite low blood-stage parasite densities, mice 
infected by mosquito bite still suffered from severe anaemia and their infection 
was even more chronic (up to 90 days) than P. chabaudi infections after serial 
blood-passage79. Importantly attenuation after mosquito transmission was not due 
to low inoculation numbers or influenced by pre-erythrocytic parasite life-cycle 
stages, since the same results were observed after direct injection of mice with 
parasitized erythrocytes derived from a donor mouse infected by mosquito bite79.
How different recently mosquito transmitted and serially blood-passaged parasitized 
erythrocytes are, was revealed by genome-wide RNA sequencing. Vector 
transmission changed 10% of the entire transcriptome, prominently up-regulating 
genes from large multi-gene families implicated in antigenic variation79. While only 
few members of a multigene-family (Plasmodium interspersed repeat genes (pir); 
termed cir in P. chabaudi) are transcribed after serial blood-passage, transcription 
of more than half of all cir genes was increased after mosquito transmission. This 
diversification of cir transcription is associated with a more protective immune 
response in the host in mosquito-transmitted blood-stage parasites, which in turn 
attenuates parasite virulence79. Whether this is a direct effect of cir expression is 
however not known80. Blood-stage parasites from mosquito-transmitted infections 
of P. chabaudi elicited innate and adaptive cellular responses earlier in infection, 
controlled systemic inflammation by reducing plasma levels of cytokines like IFNγ, 
TNF and IFNγ-inducible protein (IP) 10 and induced a stronger antibody response 
during the chronic phase of infection79. Given these profound differences in 
parasite transcriptome, elicited immune response and thus virulence, recently 
mosquito-transmitted blood-stage parasites should be used to evaluate protection 
in rodent protection models.
Evaluation of long-term protective efficacy
Another crucial factor for the evaluation of vaccine-induced protection is 
timing between immunizations and, perhaps more importantly, timing between 
immunization and challenge. Terminally differentiated effector cells are only 
transiently present and only a small proportion of the responding cells survive to 
become memory cells providing long-term protection81,82. In mice we chose 100 
days after the last immunization, while this varied between 565-1337 days up to 2.5 
years64 in human CPS trials.
One hundred days after the last immunization mice immunized with P. chabaudi 
infected mosquito bites are partially protected against direct blood challenge and 
In contrast to CPS-induced protection against the blood-stages of P. chabaudi 
shown in this thesis, no delay in patency or differences in blood-stage multiplication 
rates were observed in human CPS trials6. However, an effect on blood-stage 
parasitemia may have been missed because volunteers have to be treated with 
antimalarial drugs as soon as the first parasite is observed by thick blood film 
(typically around the 3rd erythrocytic replication cycle)6. One volunteer, classified 
as protected by the absence of a positive slide and no clinical symptoms, had 
457 parasites per ml as determined by retrospective qRT PCR at 21 days post 
challenge just prior to presumptive drug treatment6. In addition to a profound 
reduction of liver-stage parasitemia and prolonged liver-stage development, 
erythrocytic immunity may have contributed to this delay. Conversely that this 
volunteer harboured over 1.3 million parasites in total (assuming 3l of blood) may 
also mean that erythrocytic immunity was not acquired.
Data from our new P. chabaudi mouse model reveal that CPS immunization can, 
in addition to pre-erythrocytic immunity induced after infection with high numbers 
of infected hepatocytes, also partially protect against blood-stage parasites, thus 
further enhancing the protective potential of this immunization regimen.
The importance of studying protection against blood-stage parasites in the 
context of mosquito transmission
After CPS immunization with P. chabaudi via infected mosquito bites, protection 
against both homologous and heterologous blood-challenge was only observed 
if blood-stage parasites were used from a donor-mouse infected by mosquito 
bite. Conversely CPS-induced blood-stage immunity was almost overridden 
when the parasites used for challenge had been serially blood passaged 26-32 
times. For many years Plasmodium chabaudi parasites have been maintained in 
the laboratory by serial blood-passage i.e. injection of parasitized erythrocytes 
from one mouse into a naïve recipient. Thus the basic biology and immunology 
of blood-stage infections was studied in isolation from mosquito stages. This 
continuous, unnatural blood-passage, however, significantly increases parasite 
virulence for rodent76,77 and non-human primate78 malaria species. Spence et al.79 
demonstrated that a modification of the parasite itself took place by systematically 
comparing parasite virulence before and after mosquito transmission. Following 
mosquito transmission of P. chabaudi, blood-stage parasite growth is attenuated 
and signs of malaria pathology in mice (severe hypothermia, liver-damage, 
cachexia) are strongly reduced compared to serially blood passaged P. chabaudi 
162  l  Chapter 6 Discussion and conclusion  l  163
S
I
X
Pre-erythrocytic protection in human CPS is not associated with the 
magnitude of the antibody response against CSP, LSA-1, AMA-1 and MSP-1
Protective immunity induced by CPS immunization in humans is considered to be 
directed against infected liver cells6. Pre-erythrocytic immunity after immunization 
with irradiated and genetically attenuated sporozoites is largely CD8 T cell 
mediated42. Similarly T cell frequencies are higher in protected compared to 
unprotected CPS immunized volunteers suggesting that pre-erythrocytic 
immunity is dependent on cellular rather then humoral immune responses in 
this immunization regimen7. However it was recently shown90 that antibodies 
may also have a functional relevance for pre-erythrocytic protection after CPS 
immunization of humans: purified IgG from CPS immunized volunteers can 
inhibit sporozoite traversal in vitro in a dose-dependent manner and reduces P. 
falciparum liver parasite burden in humanized mice90. It is however still unclear 
which property of the antibody response, i.e. inhibition of sporozoite invasion, 
antibody-mediated cellular killing or a different mechanism, is crucial. Furthermore 
not all antibodies specific for different parasite proteins will be equally protective. 
In chapter 4 we therefore analysed in CPS immunized human volunteers the 
association of humoral responses to a set of immunodominant malaria antigens, 
all of which are considered to be potential vaccine candidates91. There was no 
association between protection and the magnitude of antibody responses against 
circumsporozoite protein (CSP), liver-stage antigen (LSA)-1, apical membrane 
antigen (AMA)-1 and merozoite surface protein (MSP)-1.
Monoclonal antibodies targeting the pre-erythrocytic antigen CSP were previously 
shown to confer complete protection against P. berghei sporozoite challenge in 
mice, the degree of which is dependent on the antibody concentration in serum 
and the number of sporozoites used for challenge90. There is of course the 
possibility that antibody responses against novel, less immunodominant antigens 
may be associated with protection92. Analysis of the plasma antibody profile from 
CPS93 and irradiated94 sporozoite-immunized volunteers shows a broad repertoire 
of antigens recognized. A combination of specific responses against multiple 
antigens rather than single antigens may afford protection. In natural transmission 
settings in Kenya a combination of high antibody titers against AMA-1, MSP-2 and 
MSP-3, but not MSP-1 or erythrocyte binding protein (EBA) 175, was predictive 
of protection from clinical malaria episodes95; high antibody responses against 
a combination of 5 out of the 10 top-ranked blood and cross-stage antigens, 
including novel antigens, indicated 100% protection from disease96. Conversely 
in a different study in a holoendemic area of Kenya high levels of IgG specific for 
mice immunized with large numbers of sporozoites injected iv have a strongly 
reduced liver parasite burden. In humans CPS immunized adults with 95% 
protection up to 4 months were re-challenged 2.5 years after initial immunization 
and 4 out of 6 were still sterilely protected against mosquito bite challenge64. 
Therefore CPS-induced immunity appears to be long lived. Any vaccine, but 
perhaps especially malaria, which has to be implemented in developing countries 
with major logistic challenges needs preferably to induce long-lived protection 
after a limited number of booster immunizations.
Blood-stage immunity after P. chabaudi CPS is largely B cell-independent
Antibodies are essential for the clearance of blood-stage parasites83. However in 
the acute phase of infection during the first month blood-stage parasitemia was 
indistinguishable between B cell-deficient mice (μMT)84 and wild-type C57BL/6 
mice. This was equally observed for a primary infection with recently mosquito 
transmitted P. chabaudi blood-stage parasites and after challenge infection of 
CPS immunized mice. Our findings are in line with data from P. chabaudi mouse 
models showing protection against re-infection in B cell-deficient mice using 
serially blood-passaged parasites85,86. It therefore appears that in the acute 
phase of infection cellular CD4 T cell responses control blood-stage parasitemia 
by secretion of cytokines (mainly IFNγ), macrophage activation and priming of 
the B cell response, which can then eliminate persisting parasites in the chronic 
phase87-89.
We demonstrate that B cell-deficient μMT mice were not able to fully clear 
parasitemia during the chronic phase of infection and continuously maintained 
low-level parasitemia from 30 days post challenge until the end of the experiment 
4 months later. Therefore antibodies are important in the chronic phase of 
infection to clear parasitemia83. Antibodies are also only induced in considerable 
quantities from day 30 after P. chabaudi infection79. Interestingly CPS immunized 
μMT mice had significantly lower blood-parasitemias even in the chronic phase 
compared to primary infected μMT mice. Therefore some antibody-independent 
immune mechanism must be triggered by CPS immunization. Since γδ T cells 
producing IFNγ are greatly expanded during chronic infection of μMT mice83, 
the inflammatory environment they provide may be responsible for the observed 
reduction of parasitemia compared to primary infected μMT mice.
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acute infection102,103. Repeated exposure to malaria therefore maintains both the 
antibody and memory B cell response, whereas the absence of exposure can lead 
to a reduction of the antibody response, but not the memory B cell response.
a combination of the pre-erythrocytic antigens CSP, LSA-1 and thrombospondin 
related anonymous protein (TRAP) reduced the risk of infection by 57%, whereas 
AMA-1, EBA175 and MSP-1 antibody levels did not correlate with protection97. 
In our study the combined antibody responses to the pre-erythrocytic and cross-
stage antigens tested (CSP, LSA-1, AMA-1 and MSP-1) were not predictive of 
protection.
The question of which antibody specificities are responsible for the observed 
inhibition of sporozoites by IgG from CPS immunized volunteers90 thus remains 
unanswered. Using new immunomics tools67 both cellular and humoral responses 
should be thus analyzed to find correlates of protection, which can be then verified 
mechanistically in vivo in rodent models.
The magnitude of the antibody response is a sensitive predictor of exposure 
While not predictive of protection, the magnitude of the humoral response against 
a set of 9 immunodominant antigens gave a sensitive indication of cumulative 
parasite exposure i.e. the number and dose of immunization and the life-cycle 
stage experienced. The magnitude of the antibody response increased stepwise 
with repeated exposure, which is in contrast to the reported development of 
the T cell response, where expansion seems to be completed in the first clonal 
burst7. Exposure to few P. falciparum infected erythrocytes for only one day6 was 
accompanied by a strong boost of the MSP-1-specific antibodies. Thus boosting 
of MSP-1 antibody responses after challenge infection may be a sensitive marker 
of blood-stage exposure up to at least 140 days.
Short-lived plasma cells, which secret large amount of antibody in response to 
initial antigen encounter die within 3-5 days after an acute P. chabaudi infection as 
demonstrated by a drop in malaria-specific antibody titres98. Thereafter antibodies 
are secreted by long-lived plasma cells residing in the bone marrow and memory B 
cells, which differentiate into antibody-secreting cells upon antigen re-encounter, 
even in the presence of a chronic malaria infection99. The observed reduction of 
antibody titre against malarial antigens thus reflects the expected contraction of 
short-lived plasma cells in the absence of antigen i.e. parasite exposure. Memory 
B cells on the other hand are stably maintained over the course of several months 
between CPS immunization and challenge in the absence of parasite exposure. 
We can hence not find any indication that humoral immunity in this immunization 
regimen is impaired, as previously suggested in endemic settings100,101 and 
some rodent malaria models as a result of high blood-stage parasitemias during 
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human volunteers after CPS immunization. Strikingly, pre-erythrocytic immunity 
can also be afforded by prolonged exposure to blood-stage parasites in the P. 
chabaudi mouse model. Therefore extending exposure to blood-stage parasites 
elicits cross-protective immune responses targeting pre-erythrocytic parasites, 
which can further enhance protective efficacy of CPS immunization. Our results 
highlight how complex the development of immunity against the different life-cycle 
stages of the malaria parasite is.
CPS immunized B cell-deficient mice showed the same level of protection 
in the acute phase of infection as mice with a normal immune system, clearly 
demonstrating that protective immunity to the early stages of the erythrocytic 
infection generated by this immunization is largely antibody-independent. These 
findings complement data in chapter 4, where we analyse humoral responses 
in peripheral blood samples of human volunteers enrolled in two clinical CPS 
immunization trials. Antibody and memory B cells against well-characterized, 
immunodominant pre-erythrocytic and cross-stage antigens are efficiently acquired 
over the course of CPS immunization. The magnitude of the humoral response 
is dictated by cumulative parasite exposure i.e. the number of immunizations and 
blood-stage parasite densities experienced during immunization. However, the 
magnitude of humoral responses to CSP, LSA-1, MSP-1 and AMA-1 does not 
predict protection from challenge infection. Functionality of these antibodies or 
responses to novel antigens may still account for a humoral component of CPS-
induced protection, while it is equally possible that other immune responses like 
the induction of cytotoxic T cells exclusively mediate protective immunity.
To evaluate human humoral responses after CPS immunization we used the 
memory B cell ELISpot assay. Since this technique relies on a polyclonal pre-
activation step that differentiates quiescent memory B cells into antibody-secreting 
cells, our concern was that antibody-secreting cells measured in ELISpot would 
not reflect memory B cell frequencies ex vivo. Therefore chapter 5 provides a 
comprehensive flow cytometry-based analysis of B cell frequencies before and 
after mitogen stimulation. While the number of antibody-secreting cells detected in 
ELISpot is overall a good estimate of ex vivo memory B cell frequencies, size and 
composition of the ex vivo memory B cell compartment influences its expansion 
during culture. To correct for these differences antigen-specific memory B cell 
frequencies should therefore be expressed as percentage of antibody-secreting 
cells. In doing so the assay allows a good estimate of memory B cell frequencies 
ex vivo, but care should be taken when comparing between age groups or 
intervention strategies that may influence the composition of the memory B cell 
Summary
Malaria continues to be a major global health concern despite interventions 
like vector control, rapid diagnosis and drug-treatment and many believe that 
elimination or eradication measures will only succeed with a highly effective 
malaria vaccine. However even after decades of research such a vaccine 
remains elusive. Vaccines based on individual malarial antigens are moderately 
effective at best and often convey no protective efficacy at all in endemic areas. 
Whole parasite vaccination approaches, which allow exposure to many parasite 
antigens, should hence be used to address precisely what constitutes protective 
antimalarial immunity; a question to which answers remain surprisingly vague. 
Immunity to malaria can be sterile i.e. directed against pre-erythrocytic life-cycle 
stages (sporozoites injected during mosquito bite or liver-stage parasites) or mimic 
naturally acquired immunity controlling blood-stage parasite densities and disease 
severity. Pre-erythrocytic vaccines suffer from the threat of breakthrough blood-
stage infection causing (severe) disease, while blood-stage vaccines are designed 
to control blood-stage parasitemia and therefore disease severity, but allow on-
going transmission to the mosquito vector. In chapter 2 we therefore advocate a 
combination of these two approaches into a multi-stage malaria vaccine in order 
to be optimally safe and effective. Since many antigens are shared between liver 
and blood-stage parasites, immunity to malaria is not necessarily life-cycle stage-
specific. We present evidence of cross-stage immunity from whole parasite pre-
erythrocytic and blood-stage vaccination approaches. We show that functional 
protective cross-stage antigens exist and should be identified in future studies to 
promote multi-stage malaria vaccine development.
Chemoprophylaxis and sporozoite (CPS) immunization, which induces protection 
against malaria in humans with unprecedented efficiency, is one of the most 
powerful tools to investigate cross-stage immunity and to identify cross-stage 
antigens, as prophylactic chloroquine treatment allows exposure to both pre-
erythrocytic and blood-stage parasites. Because obvious ethical constraints 
preclude the investigation of liver parasite burden in humans, chapter 3 
introduces a new mouse model of CPS immunization using Plasmodium chabaudi 
to investigate the stage- and strain-specificity of CPS-induced immunity. This 
model was designed to better mimic conditions of human infections. We found 
that immunization with P. chabaudi by mosquito bite under chloroquine cover 
protects against homologous and heterologous blood-stage parasite challenge. 
In contrast to human CPS studies, however, it does not generate pre-erythrocytic 
immunity. This may relate to the likely higher sporozoite numbers experienced by 
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Zusammenfassung
Malaria ist und bleibt eine globale Gesundheitskatastrophe, obwohl viele 
Anstrengungen, wie die Kontrolle von Mückenpopulationen, schnelle Diagnose 
und Behandlung mit effizienten Medikamenten, unternommen werden. Viele 
Wissenschaftler sind daher der Meinung, dass ein effektiver Impfstoff die 
einzige Chance ist Malaria zu besiegen. Doch obwohl seit Jahrzehnten daran 
geforscht wird, gibt es immer noch keine Impfung, die die Krankheit aufhält. 
Impfstoffe, die auf einzelnen Malaria-Antigenen basieren, induzieren bestenfalls 
moderate Immunität und viele versagen sogar komplett dabei, Menschen in 
endemischen Gebieten zu schützen. Da wir nicht wissen welche Antigene des 
Parasiten von zentraler Bedeutung sind um immun zu werden, ist es sinnvoll 
den ganzen Parasiten für Immunisierungen zu benutzen. Das erlaubt es dem 
Immunsystem in Kontakt zu allen Proteinen, die der Malaria Parasit exprimiert, 
zu gelangen. Erstaunlicherweise wissen wir immer noch nicht wirklich welche 
Immunmechanismen uns gegen Malaria schützen können.
Impfstoff-indizierte Immunität kann steril sein, also gegen die Leberstadien 
des Parasiten gerichtet, was klinische Krankheit verhindert. Alternativ kann sie 
den natürlichen Schutz gegen Parasiten in der Blutbahn imitieren, wie er von 
Erwachsenen in endemischen Gebieten erlangt wird. Beide Herangehensweisen 
haben ihre Nachteile: Impfungen gegen Leberstadien können, falls sie nicht 100% 
effektiv sind, einige Parasiten ins Blut gelangen lassen, die dort zu schwerer 
Erkrankung führen. Impfstoffe gegen Blutparasiten hingegen verhindern zwar 
Symptome, lassen aber gleichzeitig zu, dass infizierte Personen fortlaufend 
Malaria auf Mücken übertragen, welche dann erneut andere Menschen 
infizieren können. Eine Kombination beider Herangehensweisen, wie wir sie in 
Kapitel 2 vorschlagen, wäre daher am sichersten und effektivsten. Da Leber- 
und Blutparasiten viele Antigene gemeinsam haben, muss Immunität nicht 
zwangsläufig spezifisch für ein bestimmtes Stadium sein. Und tatsächlich finden 
wir Hinweise auf stadienübergreifende Immunität nach Impfung mit ganzen 
Parasiten. Zukünftige Studien sollten deshalb diejenigen Antigene identifizieren, 
die für diese stadienübergreifende Immunität verantwortlich sind. Das Ziel dieser 
Herangehensweise ist es, einen Mehrstadien-Impfstoff zu entwickeln, der die 
Vorteile von Leber- und Blutstadien Impfungen vereint.
Chemoprophylaxe mit Sporozoiten (CPS) ist eine experimentelle, 
stadienübergreifende Immunisierungsstrategie, die Menschen mit bisher 
ungeahnter Effizienz gegen Malaria schützt. Da Immunität gegen Leberstadien 
nur indirekt in menschlichen Freiwilligen untersucht werden kann, stellen wir 
compartment.
Taken together the combined findings using samples from both CPS immunized 
human volunteers and from a novel mouse model, show that i) CPS-induced 
immunity induced by relatively low dose of sporozoites is likely to be independent 
of antibody, ii) that pre-erythrocytic protection may rely on higher immunization 
dose sporozoites and iii) that protective cross-stage immunity can be induced. 
In chapter 6 these findings were discussed in a broader context paying special 
attention to the influence of dose, route of administration and timing of immunization 
and challenge on the acquisition of antimalarial immunity after CPS immunization. 
This thesis therefore gives important insights into our understanding of immunity 
to malaria supporting clinical multi-stage malaria vaccine development.
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darstellen, beeinflusst die Größe und Zusammensetzung des ex vivo Gedächtnis-
B-Zellkompartiment die Expansion während der Kultur. Um für diese Unterschiede 
zu korrigieren, sollten antigenspezifische Gedächtnis-B-Zellfrequenzen pro 
Gesamtanzahl der Antikörper-sezernierenden Zellen ausgedrückt werden. Dann 
erlaubt der ELISpot-Test eine gute Schätzung der Gedächtnis-B-Zell-Frequenzen 
ex vivo. Vorsicht ist hingegen geboten beim Vergleich zwischen den Altersgruppen 
oder Interventionsstrategien, die die Zusammensetzung des Gedächtnis-B-
Zellkompartiments beeinflussen.
Die Erkenntnisse, die wir mit CPS-immunisierten Freiwilligen und einem neuen 
Mausmodell erworben haben, zeigen, dass CPS-induzierte Immunität gegen 
die frühen Stadien einer Blutinfektion wahrscheinlich Antikörperunabhängig ist, 
und dass der Schutz nicht spezifisch für ein bestimmtes Parasitenstadium ist. 
In Kapitel 6 diskutieren wir diese Ergebnisse in einem breiteren Kontext mit 
besonderem Augenmerk auf den Einfluss der Dosis sowie Art und Zeitpunkt der 
Verabreichung für den Erwerb von Immunität nach CPS Immunisierung. Diese 
Doktorarbeit gibt daher wichtige Impulse für unser Verständnis wie Immunität 
gegen Malaria erworben wird, was für zukünftige Stadien-übergreifende Malaria 
Impfstoffentwicklung wichtig sein wird.
in Kapitel 3 ein neues Plasmodium chabaudi Mausmodell vor, mit dem wir 
die Stadienspezifität der Immunität nach CPS Immunisierung testen können. 
Dabei war es wichtig dieses Mausmodell so zu konzipieren, dass es klinische 
Studien mit Menschen in wichtigen Punkten repräsentiert. Wir konnten zeigen, 
dass Immunisierung mit P. chabaudi infizierten Mücken, bei gleichzeitiger 
prophylaktischer Behandlung mit dem Medikament Chloroquine, Mäuse vor einer 
Blutparasiteninfektion bewahrt, sie aber nicht gegen Leberparasiten schützt. 
Schutz gegen Leberparasiten war nur gewährleistet, wenn sehr große Mengen 
von Sporozoiten für die Immunisierung benutzt wurden. Darüberhinaus konnte 
eine längere Blutinfektion ebenfalls gegen Leberparasiten erfolgreich sein. Dies 
zeigt ganz klar, dass Immunität nicht stadienspezifisch ist. Eine Verlängerung 
der Dauer der Blutinfektion kann daher stadienübergreifende Immunität gegen 
Leberparasiten induzieren, was CPS Immunisierung noch erfolgreicher machen 
könnte.
CPS-immunisierte B-Zell-defiziente Mäuse zeigten das gleiche Schutzniveau 
in der akuten Phase der Malariainfektion wie Mäuse mit einem normalen 
Immunsystem. Das macht deutlich, dass Immunität im Blutstadium weitgehend 
Antikörper-unabhängig ist. Diese Ergebnisse ergänzen Daten in Kapitel 4, in dem 
wir humorale Reaktionen im peripheren Blut von Probanden von zwei klinischen 
CPS Studien analysierten. Antikörper und Gedächtnis-B-Zellen gegen Leber- und 
Mehrstadienantigene wurden effizient während der CPS Immunisierung erworben. 
Die Stärke der humoralen Antwort wird durch die Anzahl der Immunisierungen, 
die Immunisierungsdosis und die Anzahl der Blutparasiten während der 
Immunisierung, diktiert. Allerdings sagt die Stärke der humoralen Antwort gegen 
CSP, LSA-1, MSP-1 und AMA-1 nicht den Schutz vor einer erneuten Infektion 
voraus. Die Funktionalität dieser Antikörper oder Antikörper gegen andere 
Antigene könnten eine Rolle spielen, während es ebenso möglich, dass andere 
Mechanismen, wie z. B. zytotoxische T-Zellen, schützende Immunität vermitteln.
 Um die menschliche B-Zell Antwort nach CPS Immunisierung zu 
bewerten, verwendeten wir den Gedächtnis-B-Zell ELISpot-Test. Da diese Technik 
auf einer polyklonalen Voraktivierungsstufe beruht, die ruhende Gedächtnis-B-
Zellen in Antikörper-sezernierenden Zellen verwandelt, wollten wir sichergehen, 
dass die in ELISpot gemessenen Antikörper-sezernierenden Zellen Gedächtnis-
B-Zellfrequenzen ex vivo widerspiegeln. Kapitel 5 bietet daher eine umfassende 
Durchflusszytometrie-basierte Analyse der B-Zell-Frequenzen vor und nach 
Mitogenstimulation. Während Antikörper-sezernierenden Zellen im ELISpot-
Test eine gute Schätzung der gesamten ex vivo Gedächtnis-B-Zell-Frequenzen 
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Bescherming tegen de leverfase wordt alleen gegarandeerd als zeer grote 
hoeveelheden sporozoïeten worden gebruikt tijdens de immunisatie. Op deze 
manier kan CPS immunisatie pre-erythrocytaire en heterologe bloedfase immuniteit 
opwekken. Bovendien kan een langere blootstelling aan een bloedinfectie ook 
succesvol zijn tegen de leverfase. Hieruit blijkt weer dat de immuniteit niet fase-
specifiek is, maar verschillende fases elkaar positief beïnvloeden en aanvullen. 
Daarom kan een uitbreiding van het blootstellen aan bloedfase parasieten, fase 
overschrijdende immuniteit tegen lever parasieten opwekken die CPS immunisatie 
nog succesvoller kunnen maken.
CPS geïmmuniseerde B-cel-deficiënte muizen vertoonden hetzelfde 
beschermingsniveau in de acute fase van infectie als muizen met een normaal 
immuunsysteem. Dit toont duidelijk aan dat bloedfase immuniteit opgewekt en 
gehandhaafd wordt door een grotendeels antilichaam-onafhankelijk mechanisme. 
Deze bevindingen werden ondersteund door data in hoofdstuk 4, waar we de 
humorale respons in perifere bloedmonsters van menselijke vrijwilligers, die 
deelnamen aan twee klinische CPS immunisatie proeven, analyseren. Antilichamen 
en geheugen B-cellen tegen goed gekarakteriseerde, immunodominante pre-
erytrocytaire en fase overschrijdende antigenen zijn efficiënt opgewekt in de loop 
van CPS immunisatie. De sterkte van de humorale respons wordt bepaald door de 
cumulatieve parasitaire blootstelling i.e. het aantal immunisaties, de immunisatie 
dosering en de hoeveelheid bloedfase parasieten die zijn ervaren tijdens de 
immunisatie. De sterkte van de humorale respons op CSP, LSA-1, MSP-1 en 
AMA-1 wordt echter niet gecorreleerd met de bescherming tegen herinfectie. 
Functionaliteit van deze antilichamen of reacties tegen nieuwe antigenen kunnen 
een rol spelen in de humorale component van CPS geïnduceerde bescherming, 
terwijl het ook mogelijk is dat andere immuunresponsen, zoals de inductie van 
cytotoxische T-cellen, uitsluitend beschermende immuniteit bemiddelen. 
Om de menselijke humorale respons na CPS immunisatie te evalueren, hebben 
we gebruik gemaakt van de geheugen B-cel ELISpot assay. Deze techniek 
berust op een polyklonale pre-activeringsstap die rustende geheugen B-cellen 
differentieert tot antilichaam afscheidende cellen. Wij maakten ons daarom 
zorgen dat antilichaam afscheidende cellen, gemeten met de ELISpot, geen 
geheugen B celfrequenties ex vivo zouden weerspiegelen. Hoofdstuk 5 bevat 
een uitgebreide flowcytometrische analyse van B-cel frequenties voor en na 
mitogeen stimulatie. Terwijl antilichaam uitscheidende cellen gedetecteerd in 
ELISpot assays een goede schatting van het totale ex vivo geheugen B-cell 
compartiment weergeven, kunnen de omvang en samenstelling van het ex vivo 
Samenvatting
Malaria blijft een wereldwijd gezondheidsprobleem ondanks interventies zoals 
vector controle, snelle diagnose en efficiente medicatie. Veel wetenschappers 
geloven daarom dat een effectief vaccin de enige manier is om malaria te bestrijden. 
Desalniettemin is er na tientallen jaren van onderzoek nog steeds geen werkend 
vaccin. Vaccins op basis van individuele malaria antigenen kunnen op hun best 
matige immuniteit induceren en zijn meestal niet werkzaam in endemische 
gebieden. Vaccinatie met complete parasieten, waarbij het immuunsysteem aan 
vele parasitaire antigenen wordt blootgesteld, moet dus worden gebruikt om een 
precies totaalbeeld van beschermende anti-malaria immuniteit te ontwikkelen. 
Verassend genoeg weet men nog steeds niet welk afweermechanisme ons zou 
kunnen beschermen tegen malaria. Immuniteit tegen malaria kan steriel zijn 
i.e. gericht tegen pre-erythrocytaire parasieten, of de natuurlijke bescherming 
tegen de bloedfase van de parasiet kan worden nagebootst, waardoor de mate 
van infectie beheerst kan worden. Beide benaderingen hebben nadelen: Als 
een vaccinatie tegen de leverfase niet 100% effectief is, kunnen parasieten in 
de bloedbaan terech komen en daar tot ernstige ziekte leiden, terwijl vaccinatie 
tegen de bloedfase de parasiet onderdrukt, maar nog steeds aan malariamuggen 
kan worden doorgegeven. Deze kunnen vervolgens opnieuw mensen infecteren. 
Een combinatie van beide benaderingen, een meerfasig malaria vaccin zoals 
beschreven in hoofdstuk 2, zou volgens ons de meest volledige, optimaal veilige 
en effectieve bescherming geven. Aangezien sommige antigenen worden gedeeld 
tussen de lever- en bloedparasieten, is immuniteit tegen malaria niet noodzakelijk 
fase-specifiek. Wij presenteren bewijs van fase overschrijdende immuniteit na 
complete parasiet pre-erythrocytaire en bloedfase vaccinaties. Toekomstige 
studies moeten antigenen identificeren die verantwoordelijk zijn voor deze fase 
overschrijdende immuniteit om een meerfasig malaria vaccin te ontwikkelen. 
Chemoprofylaxe en sporozoiet (CPS) immunisatie is een experimentele fase 
overschrijdende immunisatie strategie, die bescherming induceert tegen malaria 
bij mensen met ongekende efficiëntie. Sinds leverfases uiteraard niet kunnen 
worden bestudeerd in menselijke vrijwilligers, presenteren we in hoofdstuk 3 
een nieuw Plasmodium chabaudi muismodel waarmee we de specificiteit van de 
immuniteit door CPS immunisatie kunnen onderzoeken. Dit muismodel is uiterst 
belangrijk om de condities voor menselijke klinische proeven zo goed mogelijk te 
weerspiegelen. Immunisatie door muggenbeten van P. chabaudi geïnfecteerde 
muggen onder chloroquine behandeling, beschermt tegen homologe en 
heterologe bloedfase parasieten, maar niet tegen de pre-erytrocytaire immuniteit. 
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geheugen B-cel compartiment van invloed zijn gedurende de celkweek. Om voor 
deze verschillen te corrigeren zijn antigeen-specifieke geheugen B-cel frequenties 
uitgedrukt per antilichaam uitscheidende cellen. De ELISpot assay maakt dus een 
goede schatting van de geheugen B-cel frequenties ex vivo in de geanalyseerde 
CPS immunisatie bij gezonde volwassenen, maar er moet rekening worden 
gehouden met de vergelijking tussen leeftijdsgroepen en interventiestrategieën 
die de samenstelling van het geheugen B-cel compartiment kunnen beïnvloeden. 
Met de resultaten van CPS geïmmuniseerde vrijwilligers en het nieuwe muismodel 
hebben we aangetoond dat CPS-geïnduceerde immuniteit van een vroege 
bloedfase infectie waarschijnlijk antilichaam onafhankelijk is en deze bescherming 
niet fase-specifiek is. In hoofdstuk 6 werden deze bevindingen besproken in een 
bredere context met bijzondere aandacht voor de invloed van de dosis, de wijze 
van toediening en het tijdstip van immunisatie, terwijl het de overname van de 
immuniteit na CPS immunisatie discussieert. Dit proefschrift geeft dus belangrijke 
inzichten in ons begrip van immuniteit tegen malaria, die belangrijk kunnen zijn 
voor de toekomstige meerfasige malariavaccin ontwikkeling.
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